<SEC-DOCUMENT>0001437749-24-008592.txt : 20240320
<SEC-HEADER>0001437749-24-008592.hdr.sgml : 20240320
<ACCEPTANCE-DATETIME>20240320082528
ACCESSION NUMBER:		0001437749-24-008592
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		22
CONFORMED PERIOD OF REPORT:	20240319
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240320
DATE AS OF CHANGE:		20240320

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Genprex, Inc.
		CENTRAL INDEX KEY:			0001595248
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				900772347
		STATE OF INCORPORATION:			TX
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38244
		FILM NUMBER:		24766391

	BUSINESS ADDRESS:	
		STREET 1:		1601 TRINITY STREET, BLDG. B
		STREET 2:		SUITE 3.322
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78712
		BUSINESS PHONE:		512-537-7997

	MAIL ADDRESS:	
		STREET 1:		1601 TRINITY STREET, BLDG. B
		STREET 2:		SUITE 3.322
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78712
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>gnpx20240305_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:rr="http://xbrl.sec.gov/rr/2018-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:gnpx="http://www.gnpx.com/20240319"><head>
	<title>gnpx20240305_8k.htm</title>
	<!-- Created by RDG Portal -->
<meta http-equiv="Content-Type" content="text/html"/></head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-right: 10px; margin-left: 10px; cursor: auto;"><div style="display: none">
<ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="d20248K" name="dei:AmendmentFlag" id="ixv-442">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d20248K" name="dei:EntityCentralIndexKey" id="ixv-443">0001595248</ix:nonNumeric>

</ix:hidden>
<ix:references>
<link:schemaRef xlink:href="gnpx-20240319.xsd" xlink:type="simple"/>
</ix:references>
<ix:resources>
<xbrli:context id="d20248K">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2024-03-19</xbrli:startDate>
<xbrli:endDate>2024-03-19</xbrli:endDate>
</xbrli:period>
</xbrli:context>



</ix:resources>
</ix:header>
</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:12pt;margin:0pt 7.2pt;text-align:center;"><b>UNITED STATES</b></div>

<div style="font-family:'Times New Roman', Times, serif;font-size:12pt;margin:0pt 7.2pt;text-align:center;"><b>SECURITIES AND EXCHANGE COMMISSION</b></div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>Washington, D.C. 20549</b>&#160;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;">&#160; &#160;</div>

<div style="background-color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;line-height:.15;margin:0pt 7.2pt;text-align:center;">&#160;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:12pt;margin:0pt 7.2pt;text-align:center;">&#160;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:12pt;margin:0pt 7.2pt;text-align:center;"><b>FORM <ix:nonNumeric contextRef="d20248K" name="dei:DocumentType" id="ixv-18"><b>8-K</b></ix:nonNumeric></b></div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;">&#160; &#160;&#160;</div>

<div style="background-color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;line-height:.15;margin:0pt 7.2pt;text-align:center;">&#160;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;">&#160;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>CURRENT REPORT</b></div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>PURSUANT TO SECTION 13 OR 15(d)</b></div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>OF THE SECURITIES EXCHANGE ACT OF 1934</b></div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&#160;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><ix:nonNumeric contextRef="d20248K" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="ixv-31"><span style="text-decoration: underline;"><b>March 19,&#160;2024</b></span></ix:nonNumeric></div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;">Date of report (Date of earliest event reported)</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&#160;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:18pt;margin:0pt 7.2pt;text-align:center;"><ix:nonNumeric contextRef="d20248K" name="dei:EntityRegistrantName" id="ixv-37"><span style="text-decoration: underline;"><b>GENPREX, INC.</b></span></ix:nonNumeric></div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>(Exact name of registrant as specified in its charter)</b></div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>&#160;</b></div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tbody><tr>
			<td style="vertical-align:middle;width:35%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><ix:nonNumeric contextRef="d20248K" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="ixv-49"><span style="text-decoration: underline;"><b>Delaware</b></span></ix:nonNumeric></div>
			</td>
			<td style="vertical-align:top;width:29.9%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><ix:nonNumeric contextRef="d20248K" name="dei:EntityFileNumber" id="ixv-54"><span style="text-decoration: underline;"><b>001-38244</b></span></ix:nonNumeric></div>
			</td>
			<td style="vertical-align:middle;width:35%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><ix:nonNumeric contextRef="d20248K" name="dei:EntityTaxIdentificationNumber" id="ixv-59"><span style="text-decoration: underline;"><b>90-0772347</b></span></ix:nonNumeric></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:35%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(State or other jurisdiction of</div>

			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">incorporation or organization)</div>
			</td>
			<td style="vertical-align:top;width:29.9%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(Commission File Number)</div>
			</td>
			<td style="vertical-align:middle;width:35%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(I.R.S. Employer</div>

			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Identification Number)</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:35%;">&#160;</td>
			<td style="vertical-align:top;width:29.9%;">&#160;</td>
			<td style="vertical-align:middle;width:35%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:35%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><ix:nonNumeric contextRef="d20248K" name="dei:EntityAddressAddressLine1" id="ixv-78"><span style="text-decoration: underline;"><b><span style="text-decoration: underline;"><b>3300 Bee Cave Road</b></span></b></span></ix:nonNumeric><span style="text-decoration: underline;"><b><span style="text-decoration: underline;"><b>, <ix:nonNumeric contextRef="d20248K" name="dei:EntityAddressAddressLine2" id="ixv-87"><span style="text-decoration: underline;"><b><span style="text-decoration: underline;"><b><span style="text-decoration: underline;"><b><span style="text-decoration: underline;"><b>#650-227</b></span></b></span></b></span></b></span></ix:nonNumeric></b></span>, <ix:nonNumeric contextRef="d20248K" name="dei:EntityAddressCityOrTown" id="ixv-96"><span style="text-decoration: underline;"><b><span style="text-decoration: underline;"><b><span style="text-decoration: underline;"><b>Austin</b></span></b></span></b></span></ix:nonNumeric>, <ix:nonNumeric contextRef="d20248K" name="dei:EntityAddressStateOrProvince" id="ixv-103"><span style="text-decoration: underline;"><b><span style="text-decoration: underline;"><b><span style="text-decoration: underline;"><b><span style="text-decoration: underline;"><b>TX</b></span></b></span></b></span></b></span></ix:nonNumeric></b></span></div>
			</td>
			<td style="vertical-align:top;width:29.9%;">&#160;</td>
			<td style="vertical-align:middle;width:35%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><ix:nonNumeric contextRef="d20248K" name="dei:EntityAddressPostalZipCode" id="ixv-115"><span style="text-decoration: underline;"><b>78746</b></span></ix:nonNumeric></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:35%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(Address of principal executive offices)</div>
			</td>
			<td style="vertical-align:top;width:29.9%;">&#160;</td>
			<td style="vertical-align:middle;width:35%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(Zip Code)</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&#160;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;">Registrant&#8217;s telephone number, including area code: <span style="text-decoration: underline;"><b>(<ix:nonNumeric contextRef="d20248K" name="dei:CityAreaCode" id="ixv-128"><span style="text-decoration: underline;"><b><span style="text-decoration: underline;"><b><span style="text-decoration: underline;"><b>512</b></span></b></span></b></span></ix:nonNumeric>) <ix:nonNumeric contextRef="d20248K" name="dei:LocalPhoneNumber" id="ixv-135"><span style="text-decoration: underline;"><b><span style="text-decoration: underline;"><b><span style="text-decoration: underline;"><b>537-7997</b></span></b></span></b></span></ix:nonNumeric></b></span></div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;">&#160;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tbody><tr>
			<td style="vertical-align:top;width:5.7%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><ix:nonNumeric contextRef="d20248K" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="ixv-453">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="vertical-align:top;width:94.3%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tbody><tr>
			<td style="vertical-align:top;width:5.7%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><ix:nonNumeric contextRef="d20248K" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="ixv-454">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="vertical-align:top;width:94.3%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tbody><tr>
			<td style="vertical-align:top;width:5.7%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><ix:nonNumeric contextRef="d20248K" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="ixv-455">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="vertical-align:top;width:94.3%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tbody><tr>
			<td style="vertical-align:top;width:5.7%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><ix:nonNumeric contextRef="d20248K" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="ixv-456">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="vertical-align:top;width:94.3%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&#160;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">Securities registered pursuant to Section&#160;12(b) of the Act:</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tbody><tr>
			<td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:37.8%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Title of each class</b></div>
			</td>
			<td style="vertical-align:bottom;border-bottom: 1px #000000;;width:1.3%;">&#160;</td>
			<td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:15%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Trading</b></div>

			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Symbol(s)</b></div>
			</td>
			<td style="vertical-align:bottom;border-bottom: 1px #000000;;width:1.3%;">&#160;</td>
			<td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:44.7%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Name of each exchange on which registered</b></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;border-bottom:solid 1px #000000;;width:37.8%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><ix:nonNumeric contextRef="d20248K" name="dei:Security12bTitle" id="ixv-457">Common Stock</ix:nonNumeric>, par value $0.001 per share</div>
			</td>
			<td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:1.3%;">&#160;</td>
			<td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:15%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><ix:nonNumeric contextRef="d20248K" name="dei:TradingSymbol" id="ixv-458">GNPX</ix:nonNumeric></div>
			</td>
			<td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:1.3%;">&#160;</td>
			<td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:44.7%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">The <ix:nonNumeric contextRef="d20248K" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="ixv-459">Nasdaq</ix:nonNumeric> Capital Market</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&#160;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b&#8211;2 of the Securities Exchange Act of 1934 (&#167; 240.12b&#8211;2 of this chapter).</div>

<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-align: justify;">Emerging growth company&#160;<ix:nonNumeric contextRef="d20248K" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="ixv-460">&#9744;</ix:nonNumeric></div>

<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-align: justify;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-align: justify;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#9744;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&#160;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><b>Item 1.01. Entry into a Material Definitive Agreement.</b></div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><i>The Offering</i></div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">On March 19, 2024, Genprex, Inc. (the &#8220;Company&#8221;) entered into a securities purchase agreement (the &#8220;Purchase Agreement&#8221;) with an institutional investor pursuant to which the Company agreed to sell, in a registered direct offering (the &#8220;Offering&#8221;) priced at the market under Nasdaq rules, an aggregate of (i) 165,000 shares (the &#8220;Shares&#8221;) of its common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;), (ii)&#160;pre-funded&#160;warrants (the&#160;&#8220;Pre-Funded&#160;Warrants&#8221;) exercisable for up to an aggregate of 1,377,112 shares of Common Stock, (iii) warrants (the &#8220;Warrants&#8221;) exercisable for up to an aggregate of 1,542,112 shares of Common Stock. The offering price for each share of Common Stock and accompanying Warrant is $4.215 and the offering price for each&#160;Pre-Funded&#160;Warrant and accompanying Warrant is $4.2149.</div>

<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">The Offering is expected to close on or about March 21, 2024, subject to the satisfaction of customary closing conditions.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The net proceeds of the Offering, after deducting the placement agent&#8217;s fees and expenses and other estimated Offering expenses payable by the Company and excluding the net proceeds, if any, from the exercise of the Warrants, are expected to be approximately $5.8&#160;million. The Company intends to use the net proceeds from the Offering for working capital and general corporate purposes.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">In the Purchase Agreement, the Company has agreed not to issue, enter into any agreement to issue or announce the issuance or proposed issuance of, any shares of Common Stock or any securities convertible into or exercisable or exchangeable for shares of Common Stock or file any registration statement or prospectus, or any amendment or supplement thereto for 60 days after the closing date of the Offering, subject to certain exceptions, including an exception for the sale an issuance of shares in an &#8220;at-the-market&#8221; (ATM) offering with the placement agent after any trading day on which the closing price of our common stock exceeds $8.00 per share, provided that any such sales be at a per shar price at or above $8.00. In addition, the Company has agreed not to effect or enter into an agreement to effect any issuance of Common Stock or any securities convertible into or exercisable or exchangeable for shares of Common Stock involving a variable rate transaction (as defined in the Purchase Agreement) until the&#160;one-year&#160;anniversary of the closing date of the Offering, subject to certain exceptions, including the exception for certain ATM offerings as contemplated by the immediately preceding sentence.</div>

<div style="text-align: justify; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">The Purchase Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the purchaser, including for liabilities arising under the Securities Act (as defined below), other obligations of the parties and termination provisions. The representations, warranties and covenants contained in the Purchase Agreement were made only for the purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement, and may be subject to limitations agreed upon by the contracting parties.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The form of Purchase Agreement is filed as Exhibit 10.1 to this Current Report on Form&#160;8-K.&#160;The foregoing summary of the terms of the Purchase Agreement is subject to, and qualified in its entirety by the form of such document, which is incorporated herein by reference.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Terms of the</i>&#160;<i>Pre-Funded</i>&#160;<i>Warrants</i></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Each&#160;Pre-Funded&#160;Warrant is exercisable for one share of Common Stock at an exercise price of $0.0001 per share and will expire when exercised in full. The Company is prohibited from effecting an exercise of any&#160;Pre-Funded&#160;Warrants to the extent that such exercise would result in the number of shares of Common Stock beneficially owned by such holder and its affiliates exceeding 9.99% of the total number of shares of Common Stock outstanding immediately after giving effect to the exercise, which percentage may be increased or decreased at the holder&#8217;s election not to exceed 9.99%.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The form of&#160;Pre-Funded&#160;Warrant is filed as Exhibit 4.1 to this Current Report on Form&#160;8-K.&#160;The foregoing summary of the terms of the&#160;Pre-Funded&#160;Warrants is subject to, and qualified in its entirety by, the form of such document, which is incorporated herein by reference.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Terms of the Warrants</i></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Each Warrant is exercisable for one share of Common Stock at an exercise price of $4.09 per share. The Warrants will expire five years from the date of issuance. The Warrants may only be exercised on a cashless basis if there is no registration statement registering, or the prospectus contained therein in not available for, the issuance or resale of shares of Common Stock underlying the Warrants to or by the holder. The Company is prohibited from effecting an exercise of any Warrants to the extent that such exercise would result in the number of shares of Common Stock beneficially owned by such holder and its affiliates exceeding 4.99% of the total number of shares of Common Stock outstanding immediately after giving effect to the exercise, which percentage may be increased or decreased at the holder&#8217;s election not to exceed 9.99%. In the event of certain fundamental transactions, the holder of the Warrants will have the right to receive the Black Scholes Value of its Warrants calculated pursuant to a formula set forth in the Warrants, payable in the form of consideration as described in the Warrants.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The form of Warrant is filed as Exhibit 4.2 to this Current Report on Form&#160;8-K.&#160;The foregoing summary of the terms of the Warrants is subject to, and qualified in its entirety by, the form of such document, which is incorporated herein by reference.</div>

<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><i>Placement Agent Compensation</i></div>

<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Pursuant to an Engagement Letter (the &#8220;Engagement Letter&#8221;) with H.C. Wainwright&#160;&amp; Co., LLC (the &#8220;Placement Agent&#8221;), the Company agreed to pay the Placement Agent a cash fee equal to 7.0% of the gross proceeds received in the Offering and a management fee equal to 1.0% of the gross proceeds received in the Offering. The Company also agreed to reimburse certain expenses of the Placement Agent, including (iii) up to $50,000 for fees and expenses of the Placement Agent&#8217;s counsel and other out-of-pocket expenses, (iv)&#160;a&#160;non-accountable&#160;expense allowance of $25,000 and (v)&#160;$15,950 for the clearing expenses. The Company has also agreed to pay the Placement Agent, subject to certain exceptions, a tail fee equal to the cash and warrant compensation in the Offering, if any investor, who was contacted or introduced to the Company by the Placement Agent during the term of its engagement or introduced to the Company by the Placement Agent during the term of its engagement, provides the Company with capital in any public or private offering or other financing or capital raising transaction during&#160;the&#160;12-month&#160;period&#160;following the termination or expiration of the Engagement Letter. In addition, the Company has granted a right of first refusal to the Placement Agent, subject to certain exceptions, pursuant to which it has the right to act as the sole book-running manager, sole underwriter or sole placement agent, as applicable, if the Company or its subsidiaries raise capital through certain public or private offerings of equity or debt securities at any time until the&#160;9-month&#160;anniversary&#160;of the consummation date of the Offering.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Also pursuant to the Engagement Letter, the Company, in connection with the Offering, agreed to issue the Placement Agent or its designees warrants (the &#8220;Placement Agent Warrants&#8221;) to purchase up to an aggregate of 92,527 shares of Common Stock (which represents 6.0% of the Shares and&#160;Pre-Funded&#160;Warrants sold in the Offering). The Placement Agent Warrants will have substantially the same terms as the Warrants described above, except that the Placement Agent Warrants will have an exercise price of $5.2688 per share and will expire on March 19, 2029.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The form of Placement Agent Warrant is filed as Exhibit 4.3 to this Current Report on Form&#160;8-K.&#160;The foregoing summary of the terms of the Placement Agent Warrants is subject to, and qualified in its entirety by, the form of such document, which is incorporated herein by reference.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Offering of the securities described above was made pursuant to the Company&#8217;s effective Registration Statement on Form&#160;S-3&#160;(Registration&#160;No.&#160;333-271386),&#160;including a prospectus contained therein dated June 9, 2023, as supplemented by a prospectus supplement, dated as of March 19, 2024, relating to the Offering.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The opinion of Lowenstein Sandler LLP regarding the validity of the securities issued in the Offering is attached as Exhibit 5.1 hereto.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Warrant Amendment</i></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">In connection with the Offering, on March 19, 2024, the Company entered into a warrant amendment agreement (the &#8220;Warrant Amendment Agreement&#8221;) with the purchaser party to the Purchase Agreement pursuant to which the Company agreed to amend the purchaser&#8217;s existing warrants to purchase up to 95,238 shares of Common Stock at an exercise price of $44.00 per share issued in March 2023 and warrants to purchase up to 99,010 shares of Common stock at an exercise price of $35.40 per share issued in July 2023 (the &#8220;Existing Warrants&#8221;), in consideration for such investor&#8217;s participation and purchase of $6.5&#160;million of securities in the Offering (the &#8220;Purchase Commitment&#8221;) and the payment of $24,281 (the &#8220;Cash Consideration&#8221;) to (i)&#160;lower the exercise price of the Existing Warrants to $4.09 per share and (ii)&#160;amend the expiration date of the Existing Warrants to five years following the closing of the Offering, effective upon the closing of the Offering.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The form of Warrant Amendment Agreement is filed as Exhibit 4.4 to this Current Report on Form&#160;8-K.&#160;The foregoing summary of the terms of the Warrant Amendment Agreement is subject to, and qualified in its entirety by, the form of such document, which is incorporated herein by reference.</div>

<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">This Current Report on Form 8-K does not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.</div>

<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&#160;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><i>Forward-Looking Statements</i></div>

<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">This Current Report on Form 8-K contains forward-looking statements that involve risks and uncertainties, such as statements related to the amount of proceeds expected from the Offering. The risks and uncertainties involved include the Company's financial position, market conditions and other risks detailed from time to time in the Company's periodic reports and other filings with the Commission. You are cautioned not to place undue reliance on forward-looking statements, which are based on the Company's current expectations and assumptions and speak only as of the date of this Current Report on Form 8-K. The Company does not intend to revise or update any forward-looking statement in this Current Report on Form 8-K as a result of new information, future events or otherwise, except as required by law.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Item 8.01. Other Events.</b></div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">On March 19, 2024, the Company issued a press release announcing the Offering. A copy of this press release is attached as Exhibit 99.1 hereto.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Item 9.01.&#160;Financial Statements and Exhibits.</b></div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(d) <i>Exhibits</i>.</div>

<div style="text-align: justify; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tbody><tr>
			<td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:8.9%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Exhibit</b></div>

			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Number</b></div>
			</td>
			<td style="vertical-align:bottom;width:4.8%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>&#160;</b></div>
			</td>
			<td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:86.2%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>&#160;Description</b></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:8.9%;">&#160;</td>
			<td style="vertical-align:middle;width:4.8%;">&#160;</td>
			<td style="vertical-align:middle;width:86.2%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 8.9%; text-align: center;">4.1</td>
			<td style="vertical-align:middle;width:4.8%;">&#160;</td>
			<td style="vertical-align:middle;width:86.2%;"><a href="ex_641797.htm" style="-sec-extract:exhibit;">Form of Pre-Funded Warrant</a></td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 8.9%; text-align: center;">&#160;</td>
			<td style="vertical-align:middle;width:4.8%;">&#160;</td>
			<td style="vertical-align:middle;width:86.2%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 8.9%; text-align: center;">4.2</td>
			<td style="vertical-align:middle;width:4.8%;">&#160;</td>
			<td style="vertical-align:middle;width:86.2%;"><a href="ex_635389.htm" style="-sec-extract:exhibit;">Form of Warrant</a></td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 8.9%; text-align: center;">&#160;</td>
			<td style="vertical-align:middle;width:4.8%;">&#160;</td>
			<td style="vertical-align:middle;width:86.2%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 8.9%; text-align: center;">4.3</td>
			<td style="vertical-align:middle;width:4.8%;">&#160;</td>
			<td style="vertical-align:middle;width:86.2%;"><a href="ex_635390.htm" style="-sec-extract:exhibit;">Form of Placement Agent Warrant</a></td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 8.9%; text-align: center;">&#160;</td>
			<td style="vertical-align:middle;width:4.8%;">&#160;</td>
			<td style="vertical-align:middle;width:86.2%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 8.9%; text-align: center;">4.4</td>
			<td style="vertical-align:middle;width:4.8%;">&#160;</td>
			<td style="vertical-align:middle;width:86.2%;"><a href="ex_641798.htm" style="-sec-extract:exhibit;">Form of Warrant Amendment Agreement</a></td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 8.9%; text-align: center;">&#160;</td>
			<td style="vertical-align:middle;width:4.8%;">&#160;</td>
			<td style="vertical-align:middle;width:86.2%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 8.9%; text-align: center;">5.1</td>
			<td style="vertical-align:middle;width:4.8%;">&#160;</td>
			<td style="vertical-align:middle;width:86.2%;"><a href="ex_635391.htm" style="-sec-extract:exhibit;">Opinion of Lowenstein Sandler LLP</a></td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 8.9%; text-align: center;">&#160;</td>
			<td style="vertical-align:middle;width:4.8%;">&#160;</td>
			<td style="vertical-align:middle;width:86.2%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 8.9%; text-align: center;">10.1</td>
			<td style="vertical-align:middle;width:4.8%;">&#160;</td>
			<td style="vertical-align:middle;width:86.2%;"><a href="ex_635392.htm" style="-sec-extract:exhibit;">Form of Purchase Agreement</a></td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 8.9%; text-align: center;">&#160;</td>
			<td style="vertical-align:middle;width:4.8%;">&#160;</td>
			<td style="vertical-align:middle;width:86.2%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 8.9%; text-align: center;">23.1</td>
			<td style="vertical-align:middle;width:4.8%;">&#160;</td>
			<td style="vertical-align:middle;width:86.2%;"><a href="ex_635391.htm" style="-sec-extract:exhibit;">Consent of Lowenstein Sandler LLP (contained in Exhibit 5.1)</a></td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 8.9%; text-align: center;">&#160;</td>
			<td style="vertical-align:middle;width:4.8%;">&#160;</td>
			<td style="vertical-align:middle;width:86.2%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 8.9%; text-align: center;">99.1</td>
			<td style="vertical-align:middle;width:4.8%;">&#160;</td>
			<td style="vertical-align:middle;width:86.2%;"><a href="ex_635393.htm" style="-sec-extract:exhibit;">Press Release dated March 19, 2024</a></td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 8.9%; text-align: center;">&#160;</td>
			<td style="vertical-align:middle;width:4.8%;">&#160;</td>
			<td style="vertical-align:middle;width:86.2%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 8.9%; text-align: center;">104</td>
			<td style="vertical-align:middle;width:4.8%;">&#160;</td>
			<td style="vertical-align:middle;width:86.2%;">Cover Page Interactive Data File (embedded within the Inline XBRL document).</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&#160;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>SIGNATURES</b></div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">Pursuant to the requirements of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tbody><tr>
			<td style="vertical-align:top;border-bottom: 1px #000000;;width:55.1%;">&#160;</td>
			<td colspan="2" style="vertical-align:top;border-bottom: 1px #000000;;width:33.1%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>GENPREX, INC.</b></div>
			</td>
			<td style="vertical-align:top;border-bottom: 1px #000000;;width:11.8%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;border-bottom: 1px #000000;;width:55.1%;">&#160;</td>
			<td style="vertical-align:top;width:3.5%;">&#160;</td>
			<td style="vertical-align:top;width:29.6%;">&#160;</td>
			<td style="vertical-align:top;width:11.8%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;border-bottom: 1px #000000;;width:55.1%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Date: March 20, 2024</div>
			</td>
			<td style="vertical-align:top;width:3.5%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">By:</div>
			</td>
			<td style="vertical-align:top;border-bottom:solid 1px #000000;;width:29.6%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>/s/ Ryan Confer</i></div>
			</td>
			<td style="vertical-align:top;width:11.8%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;border-bottom: 1px #000000;;width:55.1%;">&#160;</td>
			<td style="vertical-align:top;width:3.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:29.6%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Ryan Confer</div>
			</td>
			<td style="vertical-align:top;width:11.8%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 55.1%;">&#160;</td>
			<td style="vertical-align: top; width: 3.5%;">&#160;</td>
			<td style="vertical-align: top; width: 29.6%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Chief Financial Officer</div>

			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">(Principal Financial Officer)</div>
			</td>
			<td style="vertical-align: top; width: 11.8%;">&#160;</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&#160;</div>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&#160;</div>
</div>
</div>
</div>


</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>ex_641797.htm
<DESCRIPTION>EXHIBIT 4.1
<TEXT>
<html><head>
	<title>ex_641797.htm</title>
	<!-- Generated by ThunderDome Portal - 3/19/2024 9:03:05 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><b>Exhibit 4.1</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div contenteditable="false" data-applyto="t" data-auto-pgnum="start" data-displaynum="1" data-fontname="Times New Roman" data-fontsize="10pt" data-numstyle="a" data-prefix="" data-startnum="1" data-suffix="" data-textalign="center">&nbsp;</div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>PRE-FUNDED COMMON STOCK PURCHASE WARRANT</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>GENPREX, INC.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 50%;">Warrant Shares: _______</td>
			<td style="width: 50%; text-align: right;">Initial Exercise Date: March ____, 2024</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the &#8220;<u>Warrant</u>&#8221;) certifies that, for value received, _____________ or its assigns (the &#8220;<u>Holder</u>&#8221;) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the &#8220;<u>Initial Exercise Date</u>&#8221;) and until this Warrant is exercised in full (the &#8220;<u>Termination Date</u>&#8221;) but not thereafter, to subscribe for and purchase from Genprex, Inc., a Delaware corporation (the &#8220;<u>Company</u>&#8221;), up to ______ shares (as subject to adjustment hereunder, the &#8220;<u>Warrant Shares</u>&#8221;) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><u>Section 1</u>.&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<u>Definitions</u>. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities Purchase Agreement (the &#8220;<u>Purchase Agreement</u>&#8221;), dated March ____, 2024, among the Company and the purchasers signatory thereto.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><u>Section 2</u>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Exercise</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">a)&nbsp; &nbsp; &nbsp;&nbsp;<u>Exercise of Warrant</u>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &#8220;<u>Notice of Exercise</u>&#8221;). Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the Warrant Shares specified in the applicable Notice of Exercise by wire transfer or cashier&#8217;s check drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise.<b> </b>No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Business Day of receipt of such notice. <b>The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="1" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">1</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-align: justify;">For the avoidance of doubt, there is no circumstance that would require the Company to net cash settle the Warrants.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">b)&nbsp; &nbsp; &nbsp;<u>Exercise Price</u>. The aggregate exercise price of this Warrant, except for a nominal exercise price of $0.0001 per Warrant Share, was pre-funded to the Company on or prior to the Initial Exercise Date and, consequently, no additional consideration (other than the nominal exercise price of $0.0001 per Warrant Share) shall be required to be paid by the Holder to any Person to effect any exercise of this Warrant. The Holder shall not be entitled to the return or refund of all, or any portion, of such pre-paid aggregate exercise price under any circumstance or for any reason whatsoever. The remaining unpaid exercise price per share of Common Stock under this Warrant shall be $0.0001, subject to adjustment hereunder (the &#8220;<u>Exercise Price</u>&#8221;).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">c)&nbsp; &nbsp; &nbsp; &nbsp;<u>Cashless Exercise</u>. This Warrant may also be exercised, in whole or in part, at such time by means of a &#8220;cashless exercise&#8221; in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-align: justify; text-indent: -27pt;">(A) =&nbsp; as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &#8220;regular trading hours&#8221; (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. (&#8220;<u>Bloomberg</u>&#8221;) as of the time of the Holder&#8217;s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &#8220;regular trading hours&#8221; on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of &#8220;regular trading hours&#8221; on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of &#8220;regular trading hours&#8221; on such Trading Day;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="2" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">2</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: -27pt; text-align: justify;">(B) =&nbsp; the Exercise Price of this Warrant, as adjusted hereunder; and</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: -27pt; text-align: justify;">(X) =&nbsp; the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">If Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised.&nbsp;&nbsp;The Company agrees not to take any position contrary to this Section 2(c).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;"><u>&#8220;Bid Price</u>&#8221; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading Market, the VWAP of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of Common Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;"><u>&#8220;VWAP</u>&#8221; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of Common Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="3" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">3</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 18pt; text-align: justify;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">d)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><u>Mechanics of Exercise</u>.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 36pt; text-align: justify;">i.&nbsp;&nbsp;&nbsp;&nbsp;<u>Delivery of Warrant Shares Upon Exercise</u>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted to the Holder by crediting the account of the Holder&#8217;s or its designee&#8217;s balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (&#8220;<u>DWAC</u>&#8221;) if the Company is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by the Holder or (B) this Warrant is being exercised via cashless exercise, and otherwise by physical delivery of the Warrant Shares registered in the Company&#8217;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earliest of (i) two (2) Trading Days after the delivery to the Company of the Notice of Exercise, (ii) one (1) Trading Day after delivery of the aggregate Exercise Price to the Company and (iii) the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the &#8220;<u>Warrant Share Delivery Date</u>&#8221;). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the third Trading Day after the Warrant Share Delivery Date) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a registrar (which may be the Transfer Agent) that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, &#8220;<u>Standard Settlement Period</u>&#8221; means the standard settlement period, expressed in a number of Trading Days, on the Company&#8217;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise. Notwithstanding the foregoing, with respect to any Notice(s) of Exercise delivered on or prior to 12:00 p.m. (New York City time) on the Initial Exercise Date, which may be delivered at any time after the time of execution of the Purchase Agreement, the Company agrees to deliver, or cause to be delivered, the Warrant Shares subject to such notice(s) by 4:00 p.m. (New York City time) on the Initial Exercise Date and the Initial Exercise Date shall be the Warrant Share Delivery Date for purposes hereunder, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received by such Warrant Share Delivery Date.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="4" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">4</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 36pt; text-align: justify;">ii.&nbsp;&nbsp;&nbsp;<u>Delivery of New Warrants Upon Exercise</u>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 36pt; text-align: justify;">iii.&nbsp;&nbsp;<u>Rescission Rights</u>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 36pt; text-align: justify;">iv.&nbsp;&nbsp;<u>Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</u>. In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&#8217;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &#8220;<u>Buy-In</u>&#8221;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&#8217;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases shares of Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of Warrants with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder&#8217;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&#8217;s failure to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="5" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">5</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 36pt; text-align: justify;">v.&nbsp;&nbsp;&nbsp;&nbsp;<u>No Fractional Shares or Scrip</u>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 36pt; text-align: justify;">vi.&nbsp;&nbsp;<u>Charges, Taxes and Expenses</u>. The issuance and delivery of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <u>provided</u>, <u>however</u>, that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 36pt; text-align: justify;">vii.&nbsp;&nbsp;<u>Closing of Books</u>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="6" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">6</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 18pt; text-align: justify;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">e)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><u>Holder</u><u>&#8217;</u><u>s Exercise Limitations</u>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with (i) the Holder&#8217;s Affiliates, (ii) any other Persons acting as a group together with the Holder or any of the Holder&#8217;s Affiliates and (iii) any other Persons whose beneficial ownership of the shares of Common Stock would or could be aggregated with the Holder&#8217;s for the purposes of Section 13(d) of the Exchange Act (such Persons, &#8220;<u>Attribution Parties</u>&#8221;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).&nbsp;&nbsp;For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number of Warrant Shares issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of Warrant Shares which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties.&nbsp;&nbsp;Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&#8217;s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder and the Company shall have no obligation to verify or confirm the accuracy of such determination. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&#8217;s most recent periodic or annual report filed with the Securities and Exchange Commission (the &#8220;Commission&#8221;), as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.&nbsp;&nbsp;Upon the written or oral request of a Holder, the Company shall within one Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding.&nbsp;&nbsp;In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The &#8220;<u>Beneficial Ownership Limitation</u>&#8221;&nbsp;shall be [4.99%][9.99%] of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of the Warrant Shares issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of Warrant Shares upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61<sup style="vertical-align:top;line-height:120%;">st</sup>&nbsp;day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant. If the Warrant is unexercisable as a result of the Holder&#8217;s Beneficial Ownership Limitation, no alternate consideration is owing to the Holder.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="7" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">7</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><u>Section 3</u>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Certain Adjustments</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">a)&nbsp; &nbsp; &nbsp;&nbsp;<u>Stock Dividends and Splits</u>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any Warrant Shares issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant remains unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or reclassification.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">b)&nbsp; &nbsp; &nbsp; &nbsp;<u>Subsequent Rights Offerings</u>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of Common Stock (the &#8220;<u>Purchase Rights</u>&#8221;), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (<u>provided</u>, <u>however</u>, that, to the extent that the Holder&#8217;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="8" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">8</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">c)&nbsp; &nbsp; &nbsp; &nbsp;<u>Pro Rata Distributions</u>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &#8220;<u>Distribution</u>&#8221;), at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<u>provided</u>, <u>however</u>, that, to the extent that the Holder's right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation). To the extent that this Warrant has not been partially or completely exercised at the time of such Distribution, such portion of the Distribution shall be held in abeyance for the benefit of the Holder until the Holder has exercised this Warrant.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="9" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">9</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">d)&nbsp; &nbsp; &nbsp; &nbsp;<u>Fundamental Transaction</u>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company (or any Subsidiary), directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of the Company&#8217;s assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common Stock or 50% or more of the voting power of the common equity of the Company, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of shares of Common Stock or any compulsory share exchange pursuant to which the shares of Common Stock are effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires 50% or more of the outstanding Common Stock or 50% or more of the voting power of the common equity of the Company (each a &#8220;Fundamental Transaction&#8221;), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &#8220;<u>Alternate Consideration</u>&#8221;) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the &#8220;Successor Entity&#8221;) to assume in writing all of the obligations of the Company under this Warrant and the other Transaction Documents in accordance with the provisions of this Section 3(d) pursuant to written agreements in form and substance reasonably satisfactory to the Holder prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant and the other Transaction Documents referring to the &#8220;Company&#8221; shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant and the other Transaction Documents with the same effect as if such Successor Entity had been named as the Company herein.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="10" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">10</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">e)&nbsp; &nbsp; &nbsp; &nbsp;<u>Calculations</u>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share of Common Stock, as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">f)&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<u>Notice to Holder</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 36pt; text-align: justify;">i.&nbsp;&nbsp;&nbsp;&nbsp;<u>Adjustment to Exercise Price</u>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 36pt; text-align: justify;">ii.&nbsp;&nbsp;&nbsp;&nbsp;<u>Notice to Allow Exercise by Holder</u>. If (A) the Company declares a dividend (or any other distribution in whatever form) on the shares of Common Stock, (B) the Company declares a special nonrecurring cash dividend on or a redemption of the shares of Common Stock, (C) the Company authorizes the granting to all holders of the shares of Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholder of the Company is required in connection with any Fundamental Transaction, or (E) the Company authorizes the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the shares of Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the shares of Common Stock of record shall be entitled to exchange their shares of Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice and provided, further that no notice shall be required if the information is disseminated in a press release or document filed with the Securities and Exchange Commission within such time period. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="11" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">11</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><u>Section 4</u>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Transfer of Warrant</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">a)&nbsp; &nbsp; &nbsp; &nbsp;<u>Transferability</u>. This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">b)&nbsp; &nbsp; &nbsp;&nbsp;<u>New Warrants</u>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">c)&nbsp; &nbsp; &nbsp; &nbsp;<u>Warrant Register</u>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &#8220;<u>Warrant Register</u>&#8221;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="12" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">12</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><u>Section 5</u>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Miscellaneous</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">a)&nbsp; &nbsp; &nbsp; &nbsp;<u>Currency</u>. All dollar amounts referred to in this Warrant are in United States Dollars (&#8220;<u>U.S. Dollars</u>&#8221;). All amounts owing under this Warrant shall be paid in U.S. Dollars. All amounts denominated in other currencies shall be converted in the U.S. Dollar equivalent amount in accordance with the Exchange Rate on the date of calculation. &#8220;<u>Exchange Rate</u>&#8221; means, in relation to any amount of currency to be converted into U.S. Dollars pursuant to this Warrant, the U.S. Dollar exchange rate as published in the Wall Street Journal (NY edition) on the relevant date of calculation.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">b)&nbsp; &nbsp; &nbsp; &nbsp;<u>No Rights as Stockholder Until Exercise; No Settlement in Cash</u>. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &#8220;cashless exercise&#8221; pursuant to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be required to net cash settle an exercise of this Warrant.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">c)&nbsp; &nbsp; &nbsp; &nbsp;<u>Loss, Theft, Destruction or Mutilation of Warrant</u>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">d)&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<u>Saturdays, Sundays, Holidays, etc</u>. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Trading Day, then such action may be taken or such right may be exercised on the next succeeding Trading Day.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">e)&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<u>Authorized Shares</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 63pt; text-align: justify;">The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued shares of Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares underlying this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued and delivered as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares underlying this Warrant which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="13" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">13</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 27pt; text-align: justify;">Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any shares of Common Stock above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable shares of Common Stock upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 27pt; text-align: justify;">Before taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">f)&nbsp; &nbsp;&nbsp; &nbsp;&nbsp;<u>Jurisdiction</u>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance with the provisions of the Purchase Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">g)&nbsp; &nbsp; &nbsp; &nbsp;<u>Restrictions</u>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and if the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state, federal or foreign securities laws.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">h)&nbsp; &nbsp; &nbsp;<u>Nonwaiver and Expenses</u>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice the Holder&#8217;s rights, powers or remedies. Without limiting any other provision of this Warrant or the Purchase Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys&#8217; fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="14" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">14</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">i)&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<u>Notices</u>. Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered in accordance with the notice provisions of the Purchase Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">j)&nbsp; &nbsp; &nbsp; &nbsp;<u>Limitation of Liability</u>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any share of Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">k)&nbsp; &nbsp;&nbsp; &nbsp;<u>Remedies</u>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">l)&nbsp; &nbsp; &nbsp; &nbsp;<u>Successors and Assigns</u>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">m)&nbsp; &nbsp; &nbsp;&nbsp;<u>Amendment</u>. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">n)&nbsp; &nbsp; &nbsp;&nbsp;<u>Severability</u>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">o)&nbsp; &nbsp; &nbsp; &nbsp;<u>Headings</u>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">********************</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>(Signature Page Follows)</i></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" data-number="15" data-prefix="" data-suffix="" style="text-align: center; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">15</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:72pt;">IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="text-indent: 0; width: 100%;font-family: 'Times New Roman', Times, serif; font-size: 10pt">

		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td colspan="2" valign="top" width="38%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><b>GENPREX, INC.</b><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td align="left" nowrap="nowrap" valign="bottom" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td align="left" style="text-align: left;" valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="text-align: left" valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">By: </font></p>
			</td>
			<td align="left" nowrap="nowrap" style="BORDER-BOTTOM: #000000 1px solid" valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&nbsp;</p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Name:<font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Title:<font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="16" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">16</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;&nbsp;</p>

<div contenteditable="false" data-auto-pgnum="end">&nbsp;</div>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>NOTICE OF EXERCISE</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">TO:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;GENPREX, INC.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(1)&nbsp;&nbsp;&nbsp;&nbsp;The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(2)&nbsp;&nbsp;&nbsp;&nbsp;Payment shall take the form of (check applicable box):</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 108pt;">[&nbsp; ] in lawful money of the United States; or</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 108pt;">[&nbsp; ] the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(3)&nbsp;&nbsp;&nbsp;&nbsp;Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;text-indent:27pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Warrant Shares shall be delivered to the following DWAC Account Number:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 63pt; text-indent: 27pt;">_______________________________</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;text-indent:27pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 63pt; text-indent: 27pt;">_______________________________</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;text-indent:27pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 63pt; text-indent: 27pt;">_______________________________</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">[SIGNATURE OF HOLDER]</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td nowrap="true" style="width: 5%; padding: 0px;">Name of Investing Entity:&nbsp;</td>
			<td style="width: 95%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td nowrap="true" style="width: 5%; padding: 0px;"><i>Signature of Authorized Signatory of Investing Entity</i>:&nbsp;</td>
			<td style="width: 95%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td nowrap="true" style="width: 5%; padding: 0px;">Name of Authorized Signatory:&nbsp;</td>
			<td style="width: 95%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td nowrap="true" style="width: 5%; padding: 0px;">Title of Authorized Signatory:&nbsp;</td>
			<td style="width: 95%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td nowrap="true" style="width: 5%; padding: 0px;">Date:</td>
			<td style="width: 95%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><b>EXHIBIT B</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">ASSIGNMENT FORM</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:11pt;"><i>(To assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:11pt;">FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 100%;">

		<tr>
			<td colspan="2" style="vertical-align: top; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Name:</p>
			</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
			<td style="vertical-align: top; width: 40%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align: top; width: 13%;">&nbsp;</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
			<td style="vertical-align: top; width: 40%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">(Please Print)</p>
			</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align: top; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
			<td style="vertical-align: top; width: 40%;">&nbsp;</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align: top; width: 13%;">Address:</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
			<td style="vertical-align: top; width: 40%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align: top; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;">&nbsp;</p>
			</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
			<td style="vertical-align: top; width: 40%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(Please Print)</p>
			</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align: top; width: 13%;">&nbsp;</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
			<td style="vertical-align: top; width: 40%;">&nbsp;</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align: top; width: 13%;">Phone Number:</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
			<td style="vertical-align: top; width: 40%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align: top; width: 13%;">&nbsp;</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
			<td style="vertical-align: top; width: 40%;">&nbsp;</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align: top; width: 13%;">Email Address:</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
			<td style="vertical-align: top; width: 40%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align: top; width: 13%;">&nbsp;</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
			<td style="vertical-align: top; width: 40%;">&nbsp;</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align: top; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Dated: _______________ __, ______</p>
			</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
			<td style="vertical-align: top; width: 40%;">&nbsp;</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 13%;">&nbsp;</td>
			<td style="vertical-align: top; width: 27%;">&nbsp;</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
			<td style="vertical-align: top; width: 40%;">&nbsp;</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Holder&#8217;s Signature:</p>
			</td>
			<td style="vertical-align: top; width: 27%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
			<td style="vertical-align: top; width: 40%;">&nbsp;</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 13%;">&nbsp;</td>
			<td style="vertical-align: top; width: 27%;">&nbsp;</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
			<td style="vertical-align: top; width: 40%;">&nbsp;</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Holder&#8217;s Address:</p>
			</td>
			<td style="vertical-align: top; width: 27%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
			<td style="vertical-align: top; width: 40%;">&nbsp;</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>3
<FILENAME>ex_635389.htm
<DESCRIPTION>EXHIBIT 4.2
<TEXT>
<html><head>
	<title>ex_635389.htm</title>
	<!-- Generated by ThunderDome Portal - 3/19/2024 8:56:56 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><b>Exhibit 4.2</b></p>

<div contenteditable="false" data-applyto="t" data-auto-pgnum="start" data-displaynum="1" data-fontname="Times New Roman" data-fontsize="10pt" data-numstyle="a" data-prefix="" data-startnum="1" data-suffix="" data-textalign="center">&nbsp;</div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>COMMON STOCK PURCHASE WARRANT</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>GENPREX, INC.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 50%;">Warrant Shares:<u>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</u>&nbsp;</td>
			<td style="width: 50%; text-align: right;">Initial Exercise Date: March ___, 2024</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">THIS COMMON STOCK PURCHASE WARRANT (the &#8220;<u>Warrant</u>&#8221;) certifies that, for value received, _____________ or its assigns (the &#8220;<u>Holder</u>&#8221;) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the &#8220;<u>Initial Exercise Date</u>&#8221;) and on or prior to 5:00 p.m. (New York City time) on _____, 2029 (the &#8220;<u>Termination Date</u>&#8221;) but not thereafter, to subscribe for and purchase from Genprex, Inc., a Delaware corporation (the &#8220;<u>Company</u>&#8221;), up to ______ shares (as subject to adjustment hereunder, the &#8220;<u>Warrant Shares</u>&#8221;) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><u>Section 1</u>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Definitions</u>. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities Purchase Agreement (the &#8220;<u>Purchase Agreement</u>&#8221;), dated March ___, 2024, among the Company and the purchasers signatory thereto.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><u>Section 2</u>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Exercise</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">a)&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<u>Exercise of Warrant</u>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &#8220;<u>Notice of Exercise</u>&#8221;). Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the Warrant Shares specified in the applicable Notice of Exercise by wire transfer or cashier&#8217;s check drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise.<b> </b>No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Business Day of receipt of such notice. <b>The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<hr style="text-align: left; height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt 0">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><sup style="vertical-align:top;line-height:120%;">1</sup>&nbsp;Insert the date that is the five (5) year anniversary of the Initial Exercise Date, provided that, if such date is not a Trading Day, insert the immediately following Trading Day.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="1" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">1</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-align: justify;">For the avoidance of doubt, there is no circumstance that would require the Company to net cash settle the Warrants.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">b)&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<u>Exercise Price</u>. The exercise price per share of Common Stock under this Warrant shall be <b>$4.09</b>, subject to adjustment hereunder (the &#8220;<u>Exercise Price</u>&#8221;).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">c)&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<u>Cashless Exercise</u>. Notwithstanding anything to the contrary set forth herein, if at the time of exercise hereof there is no effective registration statement registering , or the prospectus contained therein is not available for, the issuance of the Warrant Shares to, or the resale by, the Holder, then this Warrant may also be exercised, in whole or in part, at such time by means of a &#8220;cashless exercise&#8221; in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 90pt; text-align: justify; text-indent: -27pt;">(A) =&nbsp; as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &#8220;regular trading hours&#8221; (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. (&#8220;<u>Bloomberg</u>&#8221;) as of the time of the Holder&#8217;s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &#8220;regular trading hours&#8221; on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of &#8220;regular trading hours&#8221; on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of &#8220;regular trading hours&#8221; on such Trading Day;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 90pt; text-indent: -27pt; text-align: justify;">(B) =&nbsp; the Exercise Price of this Warrant, as adjusted hereunder; and</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="2" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">2</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 90pt; text-indent: -27pt; text-align: justify;">(X) =&nbsp; the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">If Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised.&nbsp;&nbsp;The Company agrees not to take any position contrary to this Section 2(c).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;"><u>&#8220;Bid Price</u>&#8221; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading Market, the VWAP of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of Common Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;"><u>&#8220;VWAP</u>&#8221; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of Common Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="3" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">3</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">d)&nbsp;&nbsp;<u>Mechanics of Exercise</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 36pt; text-align: justify;">i.&nbsp; &nbsp; &nbsp;<u>Delivery of Warrant Shares Upon Exercise</u>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted to the Holder by crediting the account of the Holder&#8217;s or its designee&#8217;s balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (&#8220;<u>DWAC</u>&#8221;) if the Company is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by the Holder or (B) this Warrant is being exercised via cashless exercise, and otherwise by physical delivery of the Warrant Shares registered in the Company&#8217;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earliest of (i) two (2) Trading Days after the delivery to the Company of the Notice of Exercise, (ii) one (1) Trading Day after delivery of the aggregate Exercise Price to the Company and (iii) the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the &#8220;<u>Warrant Share Delivery Date</u>&#8221;). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the third Trading Day after the Warrant Share Delivery Date) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a registrar (which may be the Transfer Agent) that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, &#8220;<u>Standard Settlement Period</u>&#8221; means the standard settlement period, expressed in a number of Trading Days, on the Company&#8217;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise. Notwithstanding the foregoing, with respect to any Notice(s) of Exercise delivered on or prior to 12:00 p.m. (New York City time) on the Initial Exercise Date, which may be delivered at any time after the time of execution of the Purchase Agreement, the Company agrees to deliver, or cause to be delivered, the Warrant Shares subject to such notice(s) by 4:00 p.m. (New York City time) on the Initial Exercise Date and the Initial Exercise Date shall be the Warrant Share Delivery Date for purposes hereunder, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received by such Warrant Share Delivery Date.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="4" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">4</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 36pt; text-align: justify;">ii.&nbsp; &nbsp;&nbsp;<u>Delivery of New Warrants Upon Exercise</u>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 36pt; text-align: justify;">iii.&nbsp; &nbsp;<u>Rescission Rights</u>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 36pt; text-align: justify;">iv&nbsp; &nbsp;&nbsp;<u>Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</u>. In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&#8217;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &#8220;<u>Buy-In</u>&#8221;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&#8217;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases shares of Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of Warrants with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder&#8217;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&#8217;s failure to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 36pt; text-align: justify;">v.&nbsp;&nbsp;&nbsp;&nbsp;<u>No Fractional Shares or Scrip</u>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 36pt; text-align: justify;">vi.&nbsp;&nbsp;&nbsp;<u>Charges, Taxes and Expenses</u>. The issuance and delivery of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <u>provided</u>, <u>however</u>, that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 36pt; text-align: justify;">vii.&nbsp;&nbsp;<u>Closing of Books</u>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="5" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">5</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-align: justify;">e)&nbsp;&nbsp;<u>Holder</u><u>&#8217;</u><u>s Exercise Limitations</u>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with (i) the Holder&#8217;s Affiliates, (ii) any other Persons acting as a group together with the Holder or any of the Holder&#8217;s Affiliates and (iii) any other Persons whose beneficial ownership of the shares of Common Stock would or could be aggregated with the Holder&#8217;s for the purposes of Section 13(d) of the Exchange Act (such Persons, &#8220;<u>Attribution Parties</u>&#8221;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).&nbsp;&nbsp;For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number of Warrant Shares issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of Warrant Shares which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties.&nbsp;&nbsp;Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&#8217;s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder and the Company shall have no obligation to verify or confirm the accuracy of such determination. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&#8217;s most recent periodic or annual report filed with the Securities and Exchange Commission (the &#8220;Commission&#8221;), as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.&nbsp;&nbsp;Upon the written or oral request of a Holder, the Company shall within one Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding.&nbsp;&nbsp;In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The &#8220;<u>Beneficial Ownership Limitation</u>&#8221;&nbsp;shall be [4.99%][9.99%] of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of the Warrant Shares issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of Warrant Shares upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61<sup style="vertical-align:top;line-height:120%;">st</sup>&nbsp;day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant. If the Warrant is unexercisable as a result of the Holder&#8217;s Beneficial Ownership Limitation, no alternate consideration is owing to the Holder.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="6" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">6</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><u>Section 3</u>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Certain Adjustments</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">a)&nbsp; &nbsp; &nbsp;&nbsp;<u>Stock Dividends and Splits</u>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any Warrant Shares issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant remains unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or reclassification.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">b)&nbsp; &nbsp; &nbsp; &nbsp;<u>Subsequent Rights Offerings</u>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of Common Stock (the &#8220;<u>Purchase Rights</u>&#8221;), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (<u>provided</u>, <u>however</u>, that, to the extent that the Holder&#8217;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="7" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">7</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">c)&nbsp; &nbsp; &nbsp;&nbsp;<u>Pro Rata Distributions</u>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &#8220;<u>Distribution</u>&#8221;), at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<u>provided</u>, <u>however</u>, that, to the extent that the Holder's right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation). To the extent that this Warrant has not been partially or completely exercised at the time of such Distribution, such portion of the Distribution shall be held in abeyance for the benefit of the Holder until the Holder has exercised this Warrant.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="8" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">8</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">d)&nbsp; &nbsp; &nbsp;&nbsp;<u>Fundamental Transaction</u>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company (or any Subsidiary), directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of the Company&#8217;s assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common Stock or 50% or more of the voting power of the common equity of the Company, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of shares of Common Stock or any compulsory share exchange pursuant to which the shares of Common Stock are effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires 50% or more of the outstanding Common Stock or 50% or more of the voting power of the common equity of the Company (each a &#8220;Fundamental Transaction&#8221;), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &#8220;<u>Alternate Consideration</u>&#8221;) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary, in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder&#8217;s option, exercisable at any time concurrently with, or within thirty (30) days after, the consummation of the Fundamental Transaction (or, if later, the date of the public announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the Holder, as described below, an amount of cash consideration equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this Warrant on the date of the consummation of such Fundamental Transaction, <u>provided</u>, <u>however</u>, that, if the Fundamental Transaction is not within the Company&#8217;s control, including not approved by the Company&#8217;s Board of Directors, Holder shall only be entitled to receive from the Company or any Successor Entity, as of the date of the consummation of such Fundamental Transaction the same type or form of consideration (and in the same proportion), valued at the Black Scholes Value of the unexercised portion of this Warrant, that is being offered and paid to the holders of Common Stock of the Company in connection with the Fundamental Transaction, whether that consideration be in the form of cash, stock or any combination thereof, or whether the holders of Common Stock are given the choice to receive from among alternative forms of consideration in connection with the Fundamental Transaction; provided further, that if holders of Common Stock of the Company are not offered or paid any consideration in such Fundamental Transaction, such holders of Common Stock will be deemed to have received shares of the Successor Entity (which Successor Entity may be the Company following such Fundamental Transaction) in such Fundamental Transaction. &#8220;<u>Black Scholes Value</u>&#8221; means the value of this Warrant based on the Black-Scholes Option Pricing Model obtained from the &#8220;OV&#8221; function on Bloomberg determined as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the applicable contemplated Fundamental Transaction and the Termination Date, (B) an expected volatility equal to 100 day volatility obtained from the HVT function on Bloomberg (determined utilizing a 365-day annualization factor) as of the Trading Day immediately following the public announcement of the applicable Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the greater of (i) the sum of the price per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental Transaction and (ii) the highest VWAP during the period beginning on the Trading Day immediately preceding the announcement of the applicable Fundamental Transaction (or the consummation of the applicable Fundamental Transaction, if earlier) and ending on the Trading Day of the Holder&#8217;s request pursuant to this Section 3(d) and (D) a remaining option time equal to the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date and (E) a zero cost of borrow. The payment of the Black Scholes Value will be made by wire transfer of immediately available funds within five Business Days of the Holder&#8217;s election (or, if later, on the effective date of the Fundamental Transaction). The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the &#8220;Successor Entity&#8221;) to assume in writing all of the obligations of the Company under this Warrant and the other Transaction Documents in accordance with the provisions of this Section 3(d) pursuant to written agreements in form and substance reasonably satisfactory to the Holder prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant and the other Transaction Documents referring to the &#8220;Company&#8221; shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant and the other Transaction Documents with the same effect as if such Successor Entity had been named as the Company herein.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="9" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">9</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">e)&nbsp; &nbsp; &nbsp; &nbsp;<u>Calculations</u>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share of Common Stock, as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">f)&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<u>Notice to Holder</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 36pt; text-align: justify;">i.&nbsp;&nbsp;&nbsp;&nbsp;<u>Adjustment to Exercise Price</u>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 36pt; text-align: justify;">ii.&nbsp;&nbsp;&nbsp;&nbsp;<u>Notice to Allow Exercise by Holder</u>. If (A) the Company declares a dividend (or any other distribution in whatever form) on the shares of Common Stock, (B) the Company declares a special nonrecurring cash dividend on or a redemption of the shares of Common Stock, (C) the Company authorizes the granting to all holders of the shares of Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholder of the Company is required in connection with any Fundamental Transaction, or (E) the Company authorizes the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the shares of Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the shares of Common Stock of record shall be entitled to exchange their shares of Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice and provided, further that no notice shall be required if the information is disseminated in a press release or document filed with the Securities and Exchange Commission within such time period. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="10" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">10</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><u>Section 4</u>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Transfer of Warrant</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">a)&nbsp; &nbsp; &nbsp; &nbsp;<u>Transferability</u>. This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">b)&nbsp; &nbsp; &nbsp;&nbsp;<u>New Warrants</u>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">c)&nbsp; &nbsp; &nbsp; &nbsp;<u>Warrant Register</u>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &#8220;<u>Warrant Register</u>&#8221;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="11" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">11</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><u>Section 5</u>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Miscellaneous</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">a)&nbsp; &nbsp; &nbsp; &nbsp;<u>Currency</u>. All dollar amounts referred to in this Warrant are in United States Dollars (&#8220;<u>U.S. Dollars</u>&#8221;). All amounts owing under this Warrant shall be paid in U.S. Dollars. All amounts denominated in other currencies shall be converted in the U.S. Dollar equivalent amount in accordance with the Exchange Rate on the date of calculation. &#8220;<u>Exchange Rate</u>&#8221; means, in relation to any amount of currency to be converted into U.S. Dollars pursuant to this Warrant, the U.S. Dollar exchange rate as published in the Wall Street Journal (NY edition) on the relevant date of calculation.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">b)&nbsp; &nbsp; &nbsp; &nbsp;<u>No Rights as Stockholder Until Exercise; No Settlement in Cash</u>. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &#8220;cashless exercise&#8221; pursuant to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be required to net cash settle an exercise of this Warrant.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">c)&nbsp; &nbsp; &nbsp; &nbsp;<u>Loss, Theft, Destruction or Mutilation of Warrant</u>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">d)&nbsp; &nbsp; &nbsp; &nbsp;<u>Saturdays, Sundays, Holidays, etc</u>. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Trading Day, then such action may be taken or such right may be exercised on the next succeeding Trading Day.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">e)&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<u>Authorized Shares</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 72pt; text-align: justify;">The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued shares of Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares underlying this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued and delivered as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares underlying this Warrant which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="12" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">12</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 27pt; text-align: justify;">Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any shares of Common Stock above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable shares of Common Stock upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 27pt; text-align: justify;">Before taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">f)&nbsp; &nbsp; &nbsp; <u>Jurisdiction</u>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance with the provisions of the Purchase Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">g)&nbsp; &nbsp; &nbsp;&nbsp;&nbsp;<u>Restrictions</u>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and if the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state, federal or foreign securities laws.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">h)&nbsp;&nbsp;&nbsp; &nbsp;<u>Nonwaiver and Expenses</u>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice the Holder&#8217;s rights, powers or remedies. Without limiting any other provision of this Warrant or the Purchase Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys&#8217; fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">i)&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<u>Notices</u>. Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered in accordance with the notice provisions of the Purchase Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="13" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">13</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">j)&nbsp; &nbsp; &nbsp; &nbsp;<u>Limitation of Liability</u>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any share of Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">k)&nbsp; &nbsp; &nbsp;&nbsp;<u>Remedies</u>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">l)&nbsp; &nbsp; &nbsp; &nbsp;<u>Successors and Assigns</u>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">m)&nbsp; &nbsp; <u>Amendment</u>. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">n)&nbsp; &nbsp; &nbsp;&nbsp;<u>Severability</u>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">o)&nbsp; &nbsp; &nbsp; &nbsp;<u>Headings</u>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">********************</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>(Signature Page Follows)</i></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" data-number="14" data-prefix="" data-suffix="" style="text-align: center; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">14</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:72pt;">IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="text-indent: 0; width: 100%;font-family: 'Times New Roman', Times, serif; font-size: 10pt">

		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td colspan="2" valign="top" width="38%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><b>GENPREX, INC.</b><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td align="left" nowrap="nowrap" valign="bottom" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td align="left" style="text-align: left;" valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="text-align: left" valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">By: </font></p>
			</td>
			<td align="left" nowrap="nowrap" style="BORDER-BOTTOM: #000000 1px solid" valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&nbsp;</p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Name:<font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Title:<font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="15" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">15</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;&nbsp;</p>

<div contenteditable="false" data-auto-pgnum="end">&nbsp;</div>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>NOTICE OF EXERCISE</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">TO:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;GENPREX, INC.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(1)&nbsp;&nbsp;&nbsp;&nbsp;The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(2)&nbsp;&nbsp;&nbsp;&nbsp;Payment shall take the form of (check applicable box):</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 108pt;">[&nbsp; ] in lawful money of the United States; or</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 108pt;">[&nbsp; ] if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(3)&nbsp;&nbsp;&nbsp;&nbsp;Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;text-indent:27pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Warrant Shares shall be delivered to the following DWAC Account Number:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 63pt; text-indent: 27pt;">_______________________________</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;text-indent:27pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 63pt; text-indent: 27pt;">_______________________________</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;text-indent:27pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 63pt; text-indent: 27pt;">_______________________________</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">[SIGNATURE OF HOLDER]</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td nowrap="true" style="width: 5%; padding: 0px;">Name of Investing Entity:&nbsp;</td>
			<td style="width: 95%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td nowrap="true" style="width: 5%; padding: 0px;"><i>Signature of Authorized Signatory of Investing Entity</i>:&nbsp;</td>
			<td style="width: 95%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td nowrap="true" style="width: 5%; padding: 0px;">Name of Authorized Signatory:&nbsp;</td>
			<td style="width: 95%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td nowrap="true" style="width: 5%; padding: 0px;">Title of Authorized Signatory:&nbsp;</td>
			<td style="width: 95%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td nowrap="true" style="width: 5%; padding: 0px;">Date:</td>
			<td style="width: 95%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><b>EXHIBIT B</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">ASSIGNMENT FORM</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:11pt;"><i>(To assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:11pt;">FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 100%;">

		<tr>
			<td colspan="2" style="vertical-align: top; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Name:</p>
			</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
			<td style="vertical-align: top; width: 40%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align: top; width: 13%;">&nbsp;</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
			<td style="vertical-align: top; width: 40%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">(Please Print)</p>
			</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align: top; width: 13%;">&nbsp;</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
			<td style="vertical-align: top; width: 40%;">&nbsp;</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align: top; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Address:</p>
			</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
			<td style="vertical-align: top; width: 40%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align: top; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;">&nbsp;</p>
			</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
			<td style="vertical-align: top; width: 40%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(Please Print)</p>
			</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align: top; width: 13%;">&nbsp;</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
			<td style="vertical-align: top; width: 40%;">&nbsp;</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align: top; width: 13%;">Phone Number:</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
			<td style="vertical-align: top; width: 40%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align: top; width: 13%;">&nbsp;</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
			<td style="vertical-align: top; width: 40%;">&nbsp;</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align: top; width: 13%;">Email Address:</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
			<td style="vertical-align: top; width: 40%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align: top; width: 13%;">&nbsp;</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
			<td style="vertical-align: top; width: 40%;">&nbsp;</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align: top; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Dated: _______________ __, ______</p>
			</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
			<td style="vertical-align: top; width: 40%;">&nbsp;</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align: top; width: 13%;">&nbsp;</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
			<td style="vertical-align: top; width: 40%;">&nbsp;</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Holder&#8217;s Signature:</p>
			</td>
			<td style="vertical-align: top; width: 27%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
			<td style="vertical-align: top; width: 40%;">&nbsp;</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align: top; width: 13%;">&nbsp;</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
			<td style="vertical-align: top; width: 40%;">&nbsp;</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Holder&#8217;s Address:</p>
			</td>
			<td style="vertical-align: top; width: 27%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
			<td style="vertical-align: top; width: 40%;">&nbsp;</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>4
<FILENAME>ex_635390.htm
<DESCRIPTION>EXHIBIT 4.3
<TEXT>
<html><head>
	<title>ex_635390.htm</title>
	<!-- Generated by ThunderDome Portal - 3/19/2024 9:07:08 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>Exhibit 4.3</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div contenteditable="false" data-applyto="t" data-auto-pgnum="start" data-displaynum="1" data-fontname="Times New Roman" data-fontsize="10pt" data-numstyle="a" data-prefix="" data-startnum="1" data-suffix="" data-textalign="center">&nbsp;</div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>GENPREX, INC.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 50%;">Warrant Shares: _______</td>
			<td style="width: 50%; text-align: right;">Initial Exercise Date: March 21, 2024</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:72pt;">THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the &#8220;<u>Warrant</u>&#8221;) certifies that, for value received, _____________ or its assigns (the &#8220;<u>Holder</u>&#8221;) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the &#8220;<u>Initial Exercise Date</u>&#8221;) and on or prior to 5:00 p.m. (New York City time) on March 19, 2029 (the &#8220;<u>Termination Date</u>&#8221;) but not thereafter, to subscribe for and purchase from Genprex, Inc., a Delaware corporation (the &#8220;<u>Company</u>&#8221;), up to ______ shares (as subject to adjustment hereunder, the &#8220;<u>Warrant Shares</u>&#8221;) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant is issued pursuant to that certain Engagement Agreement, by and between the Company and H.C. Wainwright &amp; Co., LLC, dated as of February 1, 2024.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><u>Section 1</u>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Definitions</u>. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities Purchase Agreement (the &#8220;<u>Purchase Agreement</u>&#8221;), dated March 19, 2024, among the Company and the purchasers signatory thereto.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><u>Section 2</u>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Exercise</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">a)&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;<u>Exercise of Warrant</u>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &#8220;<u>Notice of Exercise</u>&#8221;). Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the Warrant Shares specified in the applicable Notice of Exercise by wire transfer or cashier&#8217;s check drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise.<b> </b>No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Business Day of receipt of such notice. <b>The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="1" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">1</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">For the avoidance of doubt, there is no circumstance that would require the Company to net cash settle the Warrants.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;text-indent:36pt;">b)&nbsp; &nbsp; &nbsp; &nbsp;<u>Exercise Price</u>. The exercise price per share of Common Stock under this Warrant shall be <b>$5.2688</b>, subject to adjustment hereunder (the &#8220;<u>Exercise Price</u>&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;text-indent:36pt;">c)&nbsp; &nbsp; &nbsp; &nbsp;<u>Cashless Exercise</u>. Notwithstanding anything to the contrary set forth herein, if at the time of exercise hereof there is no effective registration statement registering , or the prospectus contained therein is not available for, the issuance of the Warrant Shares to, or the resale by, the Holder, then this Warrant may also be exercised, in whole or in part, at such time by means of a &#8220;cashless exercise&#8221; in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 99pt; text-indent: -27pt;">(A) =&nbsp; as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &#8220;regular trading hours&#8221; (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. (&#8220;<u>Bloomberg</u>&#8221;) as of the time of the Holder&#8217;s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &#8220;regular trading hours&#8221; on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of &#8220;regular trading hours&#8221; on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of &#8220;regular trading hours&#8221; on such Trading Day;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 99pt; text-indent: -27pt;">(B) =&nbsp; the Exercise Price of this Warrant, as adjusted hereunder; and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="2" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">2</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 99pt; text-indent: -27pt;">(X) =&nbsp; the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">If Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised.&nbsp;&nbsp;The Company agrees not to take any position contrary to this Section 2(c).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Bid Price</u>&#8221; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading Market, the VWAP of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of Common Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;VWAP</u>&#8221; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of Common Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="3" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">3</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">d)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>Mechanics of Exercise</u>.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 36pt; text-align: justify;">i.&nbsp;&nbsp;&nbsp;&nbsp;<u>Delivery of Warrant Shares Upon Exercise</u>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted to the Holder by crediting the account of the Holder&#8217;s or its designee&#8217;s balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (&#8220;<u>DWAC</u>&#8221;) if the Company is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by the Holder or (B) this Warrant is being exercised via cashless exercise, and otherwise by physical delivery of the Warrant Shares registered in the Company&#8217;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earliest of (i) two (2) Trading Days after the delivery to the Company of the Notice of Exercise, (ii) one (1) Trading Day after delivery of the aggregate Exercise Price to the Company and (iii) the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the &#8220;<u>Warrant Share Delivery Date</u>&#8221;). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the third Trading Day after the Warrant Share Delivery Date) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a registrar (which may be the Transfer Agent) that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, &#8220;<u>Standard Settlement Period</u>&#8221; means the standard settlement period, expressed in a number of Trading Days, on the Company&#8217;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise. Notwithstanding the foregoing, with respect to any Notice(s) of Exercise delivered on or prior to 12:00 p.m. (New York City time) on the Initial Exercise Date, which may be delivered at any time after the time of execution of the Purchase Agreement, the Company agrees to deliver, or cause to be delivered, the Warrant Shares subject to such notice(s) by 4:00 p.m. (New York City time) on the Initial Exercise Date and the Initial Exercise Date shall be the Warrant Share Delivery Date for purposes hereunder, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received by such Warrant Share Delivery Date.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="4" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">4</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 36pt; text-align: justify;">ii.&nbsp;&nbsp;&nbsp;&nbsp;<u>Delivery of New Warrants Upon Exercise</u>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 36pt; text-align: justify;">iii.&nbsp;&nbsp;&nbsp;&nbsp;<u>Rescission Rights</u>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 36pt; text-align: justify;">iv.&nbsp;&nbsp;&nbsp;&nbsp;<u>Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</u>. In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&#8217;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &#8220;<u>Buy-In</u>&#8221;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&#8217;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases shares of Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of Warrants with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder&#8217;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&#8217;s failure to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="5" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">5</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 36pt; text-align: justify;">v.&nbsp;&nbsp;&nbsp;&nbsp;<u>No Fractional Shares or Scrip</u>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 36pt; text-align: justify;">vi.&nbsp;&nbsp;&nbsp;&nbsp;<u>Charges, Taxes and Expenses</u>. The issuance and delivery of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <u>provided</u>, <u>however</u>, that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 36pt; text-align: justify;">vii.&nbsp;&nbsp;&nbsp;&nbsp;<u>Closing of Books</u>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="6" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">6</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 18pt; text-align: justify;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">e)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><u>Holder</u><u>&#8217;</u><u>s Exercise Limitations</u>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with (i) the Holder&#8217;s Affiliates, (ii) any other Persons acting as a group together with the Holder or any of the Holder&#8217;s Affiliates and (iii) any other Persons whose beneficial ownership of the shares of Common Stock would or could be aggregated with the Holder&#8217;s for the purposes of Section 13(d) of the Exchange Act (such Persons, &#8220;<u>Attribution Parties</u>&#8221;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).&nbsp;&nbsp;For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number of Warrant Shares issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of Warrant Shares which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties.&nbsp;&nbsp;Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&#8217;s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder and the Company shall have no obligation to verify or confirm the accuracy of such determination. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&#8217;s most recent periodic or annual report filed with the Securities and Exchange Commission (the &#8220;Commission&#8221;), as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.&nbsp;&nbsp;Upon the written or oral request of a Holder, the Company shall within one Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding.&nbsp;&nbsp;In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The &#8220;<u>Beneficial Ownership Limitation</u>&#8221;&nbsp;shall be 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of the Warrant Shares issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of Warrant Shares upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61<sup style="vertical-align:top;line-height:120%;">st</sup>&nbsp;day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant. If the Warrant is unexercisable as a result of the Holder&#8217;s Beneficial Ownership Limitation, no alternate consideration is owing to the Holder.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="7" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">7</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><u>Section 3</u>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Certain Adjustments</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">a)&nbsp; &nbsp;&nbsp; &nbsp;<u>Stock Dividends and Splits</u>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any Warrant Shares issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant remains unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or reclassification.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">b)&nbsp; &nbsp; &nbsp; &nbsp;<u>Subsequent Rights Offerings</u>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of Common Stock (the &#8220;<u>Purchase Rights</u>&#8221;), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (<u>provided</u>, <u>however</u>, that, to the extent that the Holder&#8217;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="8" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">8</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">c)&nbsp; &nbsp; &nbsp; &nbsp;<u>Pro Rata Distributions</u>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise, other than cash (including, without limitation, any distribution of stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &#8220;<u>Distribution</u>&#8221;), at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<u>provided</u>, <u>however</u>, that, to the extent that the Holder's right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation). To the extent that this Warrant has not been partially or completely exercised at the time of such Distribution, such portion of the Distribution shall be held in abeyance for the benefit of the Holder until the Holder has exercised this Warrant.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="9" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">9</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">d)&nbsp; &nbsp; &nbsp;&nbsp;<u>Fundamental Transaction</u>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company (or any Subsidiary), directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of the Company&#8217;s assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common Stock or 50% or more of the voting power of the common equity of the Company, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of shares of Common Stock or any compulsory share exchange pursuant to which the shares of Common Stock are effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires 50% or more of the outstanding Common Stock or 50% or more of the voting power of the common equity of the Company (each a &#8220;Fundamental Transaction&#8221;), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &#8220;<u>Alternate Consideration</u>&#8221;) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary, in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder&#8217;s option, exercisable at any time concurrently with, or within thirty (30) days after, the consummation of the Fundamental Transaction (or, if later, the date of the public announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the Holder, as described below, an amount of cash consideration equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this Warrant on the date of the consummation of such Fundamental Transaction, <u>provided</u>, <u>however</u>, that, if the Fundamental Transaction is not within the Company&#8217;s control, including not approved by the Company&#8217;s Board of Directors, Holder shall only be entitled to receive from the Company or any Successor Entity, as of the date of the consummation of such Fundamental Transaction the same type or form of consideration (and in the same proportion), valued at the Black Scholes Value of the unexercised portion of this Warrant, that is being offered and paid to the holders of Common Stock of the Company in connection with the Fundamental Transaction, whether that consideration be in the form of cash, stock or any combination thereof, or whether the holders of Common Stock are given the choice to receive from among alternative forms of consideration in connection with the Fundamental Transaction; provided further, that if holders of Common Stock of the Company are not offered or paid any consideration in such Fundamental Transaction, such holders of Common Stock will be deemed to have received shares of the Successor Entity (which Successor Entity may be the Company following such Fundamental Transaction) in such Fundamental Transaction. &#8220;<u>Black Scholes Value</u>&#8221; means the value of this Warrant based on the Black-Scholes Option Pricing Model obtained from the &#8220;OV&#8221; function on Bloomberg determined as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the applicable contemplated Fundamental Transaction and the Termination Date, (B) an expected volatility equal to 100 day volatility obtained from the HVT function on Bloomberg (determined utilizing a 365-day annualization factor) as of the Trading Day immediately following the public announcement of the applicable Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the greater of (i) the sum of the price per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental Transaction and (ii) the highest VWAP during the period beginning on the Trading Day immediately preceding the announcement of the applicable Fundamental Transaction (or the consummation of the applicable Fundamental Transaction, if earlier) and ending on the Trading Day of the Holder&#8217;s request pursuant to this Section 3(d) and (D) a remaining option time equal to the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date and (E) a zero cost of borrow. The payment of the Black Scholes Value will be made by wire transfer of immediately available funds within five Business Days of the Holder&#8217;s election (or, if later, on the effective date of the Fundamental Transaction). The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the &#8220;Successor Entity&#8221;) to assume in writing all of the obligations of the Company under this Warrant and the other Transaction Documents in accordance with the provisions of this Section 3(d) pursuant to written agreements in form and substance reasonably satisfactory to the Holder prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant and the other Transaction Documents referring to the &#8220;Company&#8221; shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant and the other Transaction Documents with the same effect as if such Successor Entity had been named as the Company herein.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="10" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">10</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">e)&nbsp; &nbsp; &nbsp; &nbsp;<u>Calculations</u>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share of Common Stock, as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">f)&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<u>Notice to Holder</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 36pt; text-align: justify;">i.&nbsp;&nbsp;&nbsp;&nbsp;<u>Adjustment to Exercise Price</u>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 36pt; text-align: justify;">ii.&nbsp;&nbsp;&nbsp;&nbsp;<u>Notice to Allow Exercise by Holder</u>. If (A) the Company declares a dividend (or any other distribution in whatever form) on the shares of Common Stock, (B) the Company declares a special nonrecurring cash dividend on or a redemption of the shares of Common Stock, (C) the Company authorizes the granting to all holders of the shares of Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholder of the Company is required in connection with any Fundamental Transaction, or (E) the Company authorizes the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the shares of Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the shares of Common Stock of record shall be entitled to exchange their shares of Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice and provided, further that no notice shall be required if the information is disseminated in a press release or document filed with the Securities and Exchange Commission within such time period. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="11" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">11</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><u>Section 4</u>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Transfer of Warrant</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">a)&nbsp; &nbsp; &nbsp; &nbsp;<u>Transferability</u>. This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">b)&nbsp; &nbsp;&nbsp; &nbsp;<u>New Warrants</u>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">c)&nbsp; &nbsp; &nbsp; &nbsp;<u>Warrant Register</u>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &#8220;<u>Warrant Register</u>&#8221;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="12" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">12</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><u>Section 5</u>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Miscellaneous</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">a)&nbsp; &nbsp; &nbsp; &nbsp;<u>Currency</u>. All dollar amounts referred to in this Warrant are in United States Dollars (&#8220;<u>U.S. Dollars</u>&#8221;). All amounts owing under this Warrant shall be paid in U.S. Dollars. All amounts denominated in other currencies shall be converted in the U.S. Dollar equivalent amount in accordance with the Exchange Rate on the date of calculation. &#8220;<u>Exchange Rate</u>&#8221; means, in relation to any amount of currency to be converted into U.S. Dollars pursuant to this Warrant, the U.S. Dollar exchange rate as published in the Wall Street Journal (NY edition) on the relevant date of calculation.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">b)&nbsp; &nbsp; &nbsp; &nbsp;<u>No Rights as Stockholder Until Exercise; No Settlement in Cash</u>. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &#8220;cashless exercise&#8221; pursuant to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be required to net cash settle an exercise of this Warrant.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">c)&nbsp; &nbsp; &nbsp;&nbsp;&nbsp;<u>Loss, Theft, Destruction or Mutilation of Warrant</u>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">d)&nbsp; &nbsp; &nbsp; &nbsp;<u>Saturdays, Sundays, Holidays, etc</u>. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Trading Day, then such action may be taken or such right may be exercised on the next succeeding Trading Day.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">e)&nbsp; &nbsp; &nbsp; &nbsp;<u>Authorized Shares</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 63pt; text-align: justify;">The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued shares of Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares underlying this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued and delivered as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares underlying this Warrant which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="13" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">13</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 27pt; text-align: justify;">Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any shares of Common Stock above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable shares of Common Stock upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 27pt; text-align: justify;">Before taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">f)&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<u>Jurisdiction</u>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance with the provisions of the Purchase Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">g)&nbsp; &nbsp; &nbsp;&nbsp;&nbsp;<u>Restrictions</u>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and if the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state, federal or foreign securities laws.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">h)&nbsp;&nbsp; &nbsp;&nbsp;<u>Nonwaiver and Expenses</u>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice the Holder&#8217;s rights, powers or remedies. Without limiting any other provision of this Warrant or the Purchase Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys&#8217; fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">i)&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<u>Notices</u>. Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered to the address of the Holder in the Warrant Register.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="14" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">14</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">j)&nbsp; &nbsp; &nbsp; &nbsp;<u>Limitation of Liability</u>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any share of Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">k)&nbsp; &nbsp; &nbsp;&nbsp;<u>Remedies</u>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">l)&nbsp; &nbsp; &nbsp; &nbsp;<u>Successors and Assigns</u>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">m)&nbsp; &nbsp; &nbsp;&nbsp;<u>Amendment</u>. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">n)&nbsp; &nbsp; &nbsp; <u>Severability</u>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">o)&nbsp; &nbsp; &nbsp; &nbsp;<u>Headings</u>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">********************</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>(Signature Page Follows)</i></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" data-number="15" data-prefix="" data-suffix="" style="text-align: center; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">15</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:72pt;">IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="text-indent: 0; width: 100%;font-family: 'Times New Roman', Times, serif; font-size: 10pt">

		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td colspan="2" valign="top" width="38%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><b>GENPREX, INC.</b><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td align="left" nowrap="nowrap" valign="bottom" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td align="left" style="text-align: left;" valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="text-align: left" valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">By: </font></p>
			</td>
			<td align="left" nowrap="nowrap" style="BORDER-BOTTOM: #000000 1px solid" valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&nbsp;</p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Name:<font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Title:<font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="16" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">16</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;&nbsp;</p>

<div contenteditable="false" data-auto-pgnum="end">&nbsp;</div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>NOTICE OF EXERCISE</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">TO:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;GENPREX, INC.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(1)&nbsp;&nbsp;&nbsp;&nbsp;The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(2)&nbsp;&nbsp;&nbsp;&nbsp;Payment shall take the form of (check applicable box):</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 108pt;">[&nbsp; ] in lawful money of the United States; or</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 108pt;">[&nbsp; ] if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(3)&nbsp;&nbsp;&nbsp;&nbsp;Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Warrant Shares shall be delivered to the following DWAC Account Number:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 63pt; text-indent: 27pt;">_______________________________</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;text-indent:27pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 63pt; text-indent: 27pt;">_______________________________</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;text-indent:27pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 63pt; text-indent: 27pt;">_______________________________</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">[SIGNATURE OF HOLDER]</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td nowrap="true" style="width: 5%; padding: 0px;">Name of Investing Entity:&nbsp;</td>
			<td style="width: 95%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td nowrap="true" style="width: 5%; padding: 0px;"><i>Signature of Authorized Signatory of Investing Entity</i>:&nbsp;</td>
			<td style="width: 95%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td nowrap="true" style="width: 5%; padding: 0px;">Name of Authorized Signatory:&nbsp;</td>
			<td style="width: 95%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td nowrap="true" style="width: 5%; padding: 0px;">Title of Authorized Signatory:&nbsp;</td>
			<td style="width: 95%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td nowrap="true" style="width: 5%; padding: 0px;">Date:</td>
			<td style="width: 95%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><b>EXHIBIT B</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">ASSIGNMENT FORM</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:11pt;"><i>(To assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:11pt;">FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 100%;">

		<tr>
			<td colspan="2" style="vertical-align: top; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Name:</p>
			</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
			<td style="vertical-align: top; width: 40%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align: top; width: 13%;">&nbsp;</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
			<td style="vertical-align: top; width: 40%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">(Please Print)</p>
			</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align: top; width: 13%;">&nbsp;</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
			<td style="vertical-align: top; width: 40%;">&nbsp;</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align: top; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Address:</p>
			</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
			<td style="vertical-align: top; width: 40%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align: top; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;">&nbsp;</p>
			</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
			<td style="vertical-align: top; width: 40%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(Please Print)</p>
			</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align: top; width: 13%;">&nbsp;</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
			<td style="vertical-align: top; width: 40%;">&nbsp;</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align: top; width: 13%;">Phone Number:</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
			<td style="vertical-align: top; width: 40%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align: top; width: 13%;">&nbsp;</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
			<td style="vertical-align: top; width: 40%;">&nbsp;</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align: top; width: 13%;">Email Address:</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
			<td style="vertical-align: top; width: 40%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align: top; width: 13%;">&nbsp;</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
			<td style="vertical-align: top; width: 40%;">&nbsp;</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align: top; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Dated: _______________ __, ______</p>
			</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
			<td style="vertical-align: top; width: 40%;">&nbsp;</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align: top; width: 13%;">&nbsp;</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
			<td style="vertical-align: top; width: 40%;">&nbsp;</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Holder&#8217;s Signature:</p>
			</td>
			<td style="vertical-align: top; width: 27%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
			<td style="vertical-align: top; width: 40%;">&nbsp;</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 13%;">&nbsp;</td>
			<td style="vertical-align: top; width: 27%;">&nbsp;</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
			<td style="vertical-align: top; width: 40%;">&nbsp;</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Holder&#8217;s Address:</p>
			</td>
			<td style="vertical-align: top; width: 27%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
			<td style="vertical-align: top; width: 40%;">&nbsp;</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.4
<SEQUENCE>5
<FILENAME>ex_641798.htm
<DESCRIPTION>EXHIBIT 4.4
<TEXT>
<html><head>
	<title>HTML Editor</title>
	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; padding:0in .1in;">
<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><b>Exhibit 4.4</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt;">March 19, 2024</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">Holder of Warrants to Purchase Common Stock set forth on <u>Exhibit A</u> attached hereto</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">Re: <u>Amendment to Existing Warrants</u></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">Dear Holder:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:36pt;">Reference is hereby made to the registered direct offering on or about the date hereof (the &#8220;<u>Offering</u>&#8221;) by Genprex, Inc. (the &#8220;<u>Company</u>&#8221;) of its common stock, par value $0.001 per share (&#8220;<u>Common Stock</u>&#8221;), and/or other securities of the Company (collectively, the &#8220;<u>Securities</u>&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:36pt;">This letter confirms that, in consideration for the Holder&#8217;s participation in the Offering and purchase of Securities in the Offering (the &#8220;<u>Purchase Commitment</u>&#8221;) and the payment of $24,281 (the &#8220;<u>Cash Consideration</u>&#8221;), the Company hereby amends, effective as of the closing of the Offering, the Common Stock purchase warrants set forth on <u>Exhibit A</u> hereto (the &#8220;<u>Existing Warrants</u>&#8221;) by (i) reducing the Exercise Price (as defined therein) of the Existing Warrants to $4.09 per share and (ii) amending the expiration date of the Existing Warrants to five years following the closing of the Offering (the &#8220;<u>Warrant Amendment</u>&#8221;). The Warrant Amendment shall be effective upon the closing the Offering and the satisfaction of the other terms and conditions referenced below.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:36pt;">The Warrant Amendment is subject to the consummation of the Offering, the payment of the Cash Consideration by the Holder and the Holder&#8217;s satisfaction of the Purchase Commitment. In the event that either (i) the Offering is not consummated, or (ii) the Holder does not satisfy the Purchase Commitment or pay the Cash Consideration, the Warrant Amendment shall be null and void and the provisions of the Existing Warrants in effect prior to the date hereof shall remain in effect.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-indent: 36pt; text-align: justify;">Except as expressly set forth herein, the terms and provisions of the Existing Warrants shall remain in full force and effect after the execution of this letter and shall not be in any way changed, modified or superseded except by the terms set forth herein.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:36pt;">From and after the effectiveness of the Warrant Amendment, the Company agrees to promptly deliver to the Holder, upon request, amended Existing Warrants that reflect the Warrant Amendments in exchange for the surrender for cancellation of the Holder&#8217;s Existing Warrants to be amended as provided herein.&nbsp; For any registered Existing Warrants or if the shares of Common Stock underlying the Existing Warrants are registered for resale on a registration statement, the Company shall file a prospectus supplement to the applicable registration statement in connection with the amendments hereunder by the closing of the Offering.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><i>[Signature Page Follows]</i></p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-indent: 36pt; text-align: justify;">IN WITNESS WHEREOF, the parties hereto have caused this agreement to be duly executed by their respective authorized signatories as of the date first indicated above.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><b>GENPREX, INC.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">By: _____________________</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Name:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Title:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">Name of Holder: ________________________________________________________</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">Signature of Authorized Signatory of Holder: __________________________________</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">Name of Authorized Signatory: ____________________________________________________</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;">EXHIBIT A</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;">EXISTING WARRANTS</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;">Common Stock purchase warrants to purchase up to 95,238 shares of Common Stock with a current exercise price of $44.00 per share and an expiration date of March 1, 2028, issued on March 1, 2023</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;">Common Stock purchase warrants to purchase up to 99,010 shares of Common Stock with an exercise price of $35.40 per share and expiration date of July 21, 2028, issued on July 21, 2023</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>6
<FILENAME>ex_635391.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<html><head>
	<title>ex_635391.htm</title>
	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; padding:0in .1in;">
<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><b>Exhibit 5.1</b></p>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div><img alt="a01.jpg" src="a01.jpg"></div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">March 19, 2024&nbsp;&nbsp;&nbsp;&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">Genprex, Inc.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">3300 Bee Cave Road, #650-227</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Austin, TX 78746</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">Ladies and Gentlemen:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">We have acted as counsel to Genprex, Inc., a Delaware corporation (the &#8220;Company&#8221;), in connection with (i)&nbsp;the preparation and filing of the Registration Statement on Form&nbsp;S-3&nbsp;(Registration No.&nbsp;333-271386) filed with the Securities and Exchange Commission (the &#8220;Commission&#8221;) under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), (as so filed and as amended, the &#8220;Registration Statement&#8221;) and the related prospectus contained in the Registration Statement (the &#8220;Base Prospectus&#8221;) and (ii)&nbsp;the preparation and filing of the prospectus supplement, dated March 19, 2024 (the &#8220;Prospectus Supplement&#8221; and, together with the Base Prospectus, the &#8220;Prospectus&#8221;) relating to the issuance and sale by the Company (the &#8220;Offering&#8221;) of (i) 165,000 shares of common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;), of the Company (the &#8220;Shares&#8221;) (ii)&nbsp;pre-funded&nbsp;warrants to purchase up to 1,377,112 shares of Common Stock (each a&nbsp;&#8220;Pre-Funded&nbsp;Warrant,&#8221; and each share of Common Stock underlying a&nbsp;Pre-Funded&nbsp;Warrant, a&nbsp;&#8220;Pre-Funded&nbsp;Warrant Share&#8221;), and (iii) warrants to purchase up to 1,542,112 shares of Common Stock (each a &#8220;Warrant,&#8221; and each share of Common Stock underlying a Warrant, a &#8220;Warrant Share&#8221;).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">The Shares,&nbsp;Pre-Funded&nbsp;Warrants,&nbsp;Pre-Funded&nbsp;Warrant Shares, Warrants and Warrant Shares are to be issued and sold by the Company pursuant to the Securities Purchase Agreement, dated as of March 19, 2024 (the &#8220;Purchase Agreement&#8221;), between the Company and the purchaser signatory thereto.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">In connection with the Offering, the Company will issue to the placement agent, or its designees, warrants (the &#8220;Placement Agent Warrants&#8221;) to purchase up to 92,527 shares of Common Stock (the &#8220;Placement Agent Warrant Shares&#8221;).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">The form of Purchase Agreement,&nbsp;Pre-Funded&nbsp;Warrant, Warrant and Placement Agent Warrants will be filed with the Commission as exhibits to the Company&#8217;s Current Report on Form&nbsp;8-K&nbsp;to be filed in connection with the transactions effected by the Purchase Agreement (the &#8220;Form&nbsp;8-K&#8221;).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">In connection with this opinion, we have (i)&nbsp;investigated such questions of law, (ii)&nbsp;examined originals or certified, conformed or reproduction copies of such agreements, instruments, documents and records of the Company, such certificates of public officials and such other documents and (iii)&nbsp;received such information from officers and representatives of the Company as we have deemed necessary or appropriate for the purposes of this opinion.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">In all such examinations, we have assumed the legal capacity of all natural persons, the genuineness of all signatures, the authenticity of original and certified documents and the conformity to original or certified documents of all copies submitted to us as conformed or reproduction copies. As to various questions of fact relevant to the opinion expressed herein, we have relied upon, and assume the accuracy of, the representations and warranties set forth in the Purchase Agreement, and certificates and oral or written statements and other information of or from public officials and officers and representatives of the Company.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">Based on the foregoing, and subject to the assumptions, limitations and qualifications stated herein, we are of the opinion that (i)&nbsp;the Shares have been duly authorized and, when issued and paid for in accordance with the terms of the Purchase Agreement, will be validly issued, fully paid and&nbsp;non-assessable,&nbsp;(ii)&nbsp;the&nbsp;Pre-Funded&nbsp;Warrants, the Warrants and the Placement Agent Warrants have been duly authorized and, when executed and delivered by the Company will constitute the legal, valid and binding obligation of the Company, enforceable against the Company in accordance with their terms, subject to bankruptcy, insolvency or other similar laws affecting creditors&#8217; rights and to general equitable principles and (iii)&nbsp;the&nbsp;Pre-Funded&nbsp;Warrant Shares, the Warrant Shares and the Placement Agent Warrant Shares have been duly authorized and, when issued and paid for upon the due exercise of the&nbsp;Pre-Funded&nbsp;Warrants, the Warrants or the Placement Agent Warrants, as applicable, in accordance with the terms thereof, will be validly issued, fully paid and&nbsp;non-assessable.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt; text-align: justify;">The opinion expressed herein is limited to the General Corporation Law of the State of Delaware (including reported judicial decisions interpreting the General Corporation Law of the State of Delaware) and the applicable laws of the State of New York.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">The opinion expressed herein is limited to the matters stated herein and no opinion is implied or may be inferred beyond the matters expressly stated herein. We undertake no obligation to supplement this letter if any applicable laws change after the date hereof or if we become aware of any facts that might change the opinion expressed herein after that date or for any other reason.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">We hereby consent to the inclusion of this opinion as an exhibit to the Form&nbsp;8-K,&nbsp;which will be incorporated by reference into the Registration Statement, and to the references to our firm under the caption &#8220;Legal Matters&#8221; in the Prospectus Supplement. In giving our consent, we do not admit that we are in the category of persons whose consent is required under Section&nbsp;7 of the Securities Act or the rules and regulations thereunder.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%; margin-left: 9pt; margin-right: auto;">

		<tr>
			<td style="vertical-align: middle; width: auto; text-indent: 9pt;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 0pt;">Very truly yours,</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>/s/ Lowenstein Sandler LLP</i></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Lowenstein Sandler LLP</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>7
<FILENAME>ex_635392.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<html><head>
	<title>ex_635392.htm</title>
	<!-- Generated by ThunderDome Portal - 3/19/2024 9:25:42 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt 0pt 0pt 36pt;text-indent:-36pt;"><b>Exhibit 10.1</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>SECURITIES PURCHASE AGREEMENT</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">This Securities Purchase Agreement (this &#8220;<u>Agreement</u>&#8221;) is dated as of March 19, 2024, between Genprex, Inc., a Delaware corporation (the &#8220;<u>Company</u>&#8221;), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a &#8220;<u>Purchaser</u>&#8221; and collectively the &#8220;<u>Purchasers</u>&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act (as defined below), the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>ARTICLE I.</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">DEFINITIONS</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">1.1&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<u>Definitions</u>. In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms have the meanings set forth in this Section 1.1:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt;"><u>&#8220;Acquiring Person</u>&#8221; shall have the meaning ascribed to such term in Section 4.5.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Action</u>&#8221; shall have the meaning ascribed to such term in Section 3.1(j).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Affiliate</u>&#8221; means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person as such terms are used in and construed under Rule 405 under the Securities Act.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Applicable Laws</u>&#8221; shall have the meaning ascribed to such term in Section 3.1(hh).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Authorizations</u>&#8221; shall have the meaning ascribed to such term in Section 3.1(hh).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Beneficial Ownership Limitation</u>&#8221; shall have the meaning ascribed to such term in Section 2.1.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;BHCA</u>&#8221; shall have the meaning ascribed to such term in Section 3.1(pp).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Board of Directors</u>&#8221; means the board of directors of the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Business Day</u>&#8221; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized or required by law to remain closed; <u>provided</u>, <u>however</u>, for clarification, commercial banks shall not be deemed to be authorized or required by law to remain closed due to &#8220;stay at home&#8221;, &#8220;shelter-in-place&#8221;, &#8220;non-essential employee&#8221;&nbsp; or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York are generally open for use by customers on such day.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Closing</u>&#8221; means the closing of the purchase and sale of the Securities pursuant to Section 2.1.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Closing Date</u>&#8221; means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable parties thereto, and all conditions precedent to (i) the Purchasers&#8217; obligations to pay the Subscription Amount and (ii) the Company&#8217;s obligations to deliver the Securities, in each case, have been satisfied or waived, but in no event later than the second (2<sup style="vertical-align:top;line-height:120%;">nd</sup>) Trading Day following the date hereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Closing Price</u>&#8221; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the closing price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading Market, the closing price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported in The Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of Common Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holders of a majority in interest of the Securities purchased hereunder, the fees and expenses of which shall be paid by the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Commission</u>&#8221; means the United States Securities and Exchange Commission.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Common Stock</u>&#8221; means the common stock of the Company, par value $0.001 per share, and any other class of securities into which such securities may hereafter be reclassified or changed.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Common Stock Equivalents</u>&#8221; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Common Warrants</u>&#8221; means, collectively, the Common Stock purchase warrants delivered to the Purchasers at the Closing in accordance with Section 2.2(a) hereof, which Common Warrants shall be exercisable immediately and have a term of exercise equal to five (5) years, in the form of <u>Exhibit A-1</u> attached hereto.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Common Warrant Shares</u>&#8221; means the shares of Common Stock issuable upon exercise of the Common Warrants.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Company Counsel</u>&#8221; means Lowenstein Sandler LLP with offices located at 1251 Avenue of the Americas, New York, New York 10020.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Disclosure Schedules</u>&#8221; means the Disclosure Schedules of the Company delivered concurrently herewith.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Disclosure Time</u>&#8221; means, (i) if this Agreement is signed on a day that is not a Trading Day or after 9:00 a.m. (New York City time) and before midnight (New York City time) on any Trading Day, 9:01 a.m. (New York City time) on the Trading Day immediately following the date hereof, unless otherwise instructed as to an earlier time by the Placement Agent, and (ii) if this Agreement is signed between midnight (New York City time) and 9:00 a.m. (New York City time) on any Trading Day, no later than 9:01 a.m. (New York City time) on the date hereof, unless otherwise instructed as to an earlier time by the Placement Agent.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;EGS</u>&#8221; means Ellenoff Grossman &amp; Schole LLP, with offices located at 1345 Avenue of the Americas, New York, New York 10105-0302.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Environmental Laws</u>&#8221; shall have the meaning assigned to such term in Section 3.1(m).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Evaluation Date</u>&#8221; shall have the meaning ascribed to such term in Section 3.1(s).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Exchange Act</u>&#8221; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Exempt Issuance</u>&#8221; means the issuance of (a) shares of Common Stock, restricted stock units, options or other equity awards to employees, officers or directors of the Company pursuant to any stock or option plan duly adopted for such purpose, by a majority of the non-employee members of the Board of Directors or a majority of the members of a committee of non-employee directors established for such purpose for services rendered to the Company, (b) securities upon the exercise or exchange of or conversion of any Securities issued hereunder, warrants to the Placement Agent in connection with the transactions pursuant to this Agreement and any securities upon exercise of warrants to the Placement Agent and/or other securities exercisable or exchangeable for or convertible into shares of Common Stock issued and outstanding on the date of this Agreement, provided that (other than with respect to the Warrant Amendment (as such term is defined below)) such securities have not been amended since the date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities (other than in connection with stock splits or combinations) or to extend the term of such securities, (c) securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, provided that such securities are issued as &#8220;restricted securities&#8221; (as defined in Rule 144) and carry no registration rights that require or permit the filing of any registration statement in connection therewith during the prohibition period in Section 4.11(a) herein, and provided that any such issuance shall only be to a Person (or to the equityholders of a Person) which is, itself or through its subsidiaries, an operating company or an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities, (d) securities to consultants, advisors or vendors of the Company, provided that such securities are issued as &#8220;restricted securities&#8221; (as defined in Rule 144) and carry no registration rights that require or permit the filing of any registration statement in connection therewith during the prohibition period in Section 4.11(a) herein and (e) securities issued pursuant to an amendment to certain existing warrants held by one or more Purchasers (the &#8220;<u>Warrant Amendment</u>&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;FCPA</u>&#8221; means the Foreign Corrupt Practices Act of 1977, as amended.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;FDA</u>&#8221; shall have the meaning ascribed to such term in Section 3.1(hh).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Federal Reserve</u>&#8221; shall have the meaning ascribed to such term in Section 3.1(pp).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;GAAP</u>&#8221; means generally accepted accounting principles in the United States.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Hazardous Materials</u>&#8221; shall have the meaning assigned to such term in Section 3.1(m).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Healthcare Laws</u>&#8221; shall have the meaning ascribed to such term in Section 3.1(jj).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Indebtedness</u>&#8221; shall have the meaning ascribed to such term in Section 3.1(aa).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Intellectual Property Rights</u>&#8221; shall have the meaning ascribed to such term in Section 3.1(p).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;IT Systems</u>&#8221; shall have the meaning ascribed to such term in Section 3.1(rr).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;IT Systems and Data</u>&#8221; shall have the meaning ascribed to such term in Section 3.1(mm).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Liens</u>&#8221; means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Material Adverse Effect</u>&#8221; shall have the meaning assigned to such term in Section 3.1(b).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Material Permits</u>&#8221; shall have the meaning ascribed to such term in Section 3.1(n).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Money Laundering Laws</u>&#8221; shall have the meaning ascribed to such term in Section 3.1(qq).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;OFAC</u>&#8221; shall have the meaning ascribed to such term in Section 3.1(nn).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Per Share Purchase Price</u>&#8221; equals $4.215, subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this Agreement, provided that the purchase price per Pre-Funded Warrant shall be the Per Share Purchase Price minus $0.0001.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Person</u>&#8221; means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Personal Data</u>&#8221; shall have the meaning ascribed to such term in Section 3.1(rr).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Placement Agent</u>&#8221; means H.C. Wainwright &amp; Co., LLC.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Pre-Funded Warrant</u>&#8221; means, collectively, the Pre-Funded Common Stock purchase warrants delivered to the Purchasers at the Closing in accordance with Section 2.2(a) hereof, which Pre-Funded Warrants shall be exercisable immediately and shall expire when exercised in full, in the form of <u>Exhibit A-2</u> attached hereto.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Pre-Funded Warrant Shares</u>&#8221; means the shares of Common Stock issuable upon exercise of the Pre-Funded Warrants.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Proceeding</u>&#8221; means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding, such as a deposition), whether commenced or threatened in writing against the Company before any court, governmental agency or regulatory authority.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Prospectus</u>&#8221; means the final prospectus filed for the Registration Statement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Prospectus Supplement</u>&#8221; means the supplement to the Prospectus complying with Rule 424(b) of the Securities Act that is filed with the Commission and delivered by the Company to each Purchaser at the Closing.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Purchaser Party</u>&#8221; shall have the meaning ascribed to such term in Section 4.8.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Registration Statement</u>&#8221; means the effective registration statement with Commission file No. 333-271386 which registers the sale of the Shares, the Warrants and the Warrant Shares to the Purchasers, and includes any Rule 462(b) Registration Statement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Required Approvals</u>&#8221; shall have the meaning ascribed to such term in Section 3.1(e).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Rule 144</u>&#8221; means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Rule 424</u>&#8221; means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Rule 462(b) Registration Statement</u>&#8221; means any registration statement prepared by the Company registering additional Securities, which was filed with the Commission on or prior to the date hereof and became automatically effective pursuant to Rule 462(b) promulgated by the Commission pursuant to the Securities Act.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>SEC Reports</u>&#8221; shall have the meaning ascribed to such term in Section 3.1(h).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Securities</u>&#8221; means the Shares, the Warrants and the Warrant Shares.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Securities Act</u>&#8221; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Shares</u>&#8221; means the shares of Common Stock issued or issuable to each Purchaser pursuant to this Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Short Sales</u>&#8221; means all &#8220;short sales&#8221; as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall not be deemed to include locating and/or borrowing shares of Common Stock).&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Subscription Amount</u>&#8221; means, as to each Purchaser, the aggregate amount to be paid for Shares and Warrants purchased hereunder as specified below such Purchaser&#8217;s name on the signature page of this Agreement and next to the heading &#8220;Subscription Amount,&#8221; in United States dollars and in immediately available funds (minus, if applicable, a Purchaser&#8217;s aggregate exercise price of the Pre-Funded Warrants, which amounts shall be paid as and when such Pre-Funded Warrants are exercised).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Subsidiary</u>&#8221; means any subsidiary of the Company as set forth on <u>Schedule 3.1(a)</u>, and shall, where applicable, also include any direct or indirect subsidiary of the Company formed or acquired after the date hereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Trading Day</u>&#8221; means a day on which the principal Trading Market is open for trading.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Trading Market</u>&#8221; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York Stock Exchange (or any successors to any of the foregoing).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Transaction Documents</u>&#8221; means this Agreement, the Warrants, all exhibits and schedules thereto and hereto and any other documents or agreements executed in connection with the transactions contemplated hereunder.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Transfer Agent</u>&#8221; means VStock Transfer, LLC, the current transfer agent of the Company, at its principal office located at 18 Lafayette Place, Woodmere, New York 11598, and any successor transfer agent of the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Variable Rate Transaction</u>&#8221; shall have the meaning ascribed to such term in Section 4.11(b).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Warrants</u>&#8221; means, collectively, the Common Warrants and the Pre-Funded Warrants.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Warrant Shares</u>&#8221; means, collectively, the Common Warrant Shares and the Pre-Funded Warrant Shares.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>ARTICLE II.</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">PURCHASE AND SALE</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">2.1&nbsp; &nbsp; &nbsp; &nbsp;<u>Closing</u>. On the Closing Date, upon the terms and subject to the conditions set forth herein, the Company agrees to sell, and the Purchasers, severally and not jointly, agree to purchase, up to an aggregate of $6,500,003 of Shares and Common Warrants; <u>provided</u>, <u>howeve</u>r, that, to the extent that a Purchaser determines, in its sole discretion, that such Purchaser (together with such Purchaser&#8217;s Affiliates, and any Person acting as a group together with such Purchaser or any of such Purchaser&#8217;s Affiliates) would beneficially own in excess of the Beneficial Ownership Limitation, or as such Purchaser may otherwise choose, in lieu of purchasing Shares such Purchaser may elect to purchase Pre-Funded Warrants in lieu of Shares in such manner to result in the same aggregate purchase price being paid by such Purchaser to the Company, less $0.0001 per Pre-Funded Warrant purchased. The &#8220;<u>Beneficial Ownership Limitation</u>&#8221; shall be 4.99% (or, at the election of the Purchaser at Closing, 9.99%) of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of the Securities on the Closing Date. Each Purchaser&#8217;s Subscription Amount as set forth on the signature page hereto executed by such Purchaser shall be made available for &#8220;Delivery Versus Payment&#8221; (&#8220;<u>DVP</u>&#8221;)<i> </i>settlement with the Company or its designee. The Company shall deliver to each Purchaser its respective Shares and Warrants as determined pursuant to Section 2.2(a), and the Company and each Purchaser shall deliver the other items set forth in Section 2.2 deliverable at the Closing. Upon satisfaction of the covenants and conditions set forth in Sections 2.2 and 2.3, the Closing shall take place remotely by electronic transfer of the Closing documentation. Unless otherwise directed by the Placement Agent, settlement of the Shares shall occur via DVP<i> </i>(i.e., on the Closing Date, the Company shall issue the Shares registered in the Purchasers&#8217; names and addresses and released by the Transfer Agent directly to the account(s) at the Placement Agent identified by each Purchaser; upon receipt of such Shares, the Placement Agent shall promptly electronically deliver such Shares to the applicable Purchaser, and payment therefor shall be made by the Placement Agent (or its clearing firm) by wire transfer to the Company). Notwithstanding anything herein to the contrary, if at any time on or after the time of execution of this Agreement by the Company and an applicable Purchaser, through, and including the time immediately prior to the Closing (the &#8220;<u>Pre-Settlement Period</u>&#8221;), such Purchaser sells to any Person all, or any portion, of the Shares to be issued hereunder to such Purchaser at the Closing (collectively, the &#8220;<u>Pre-Settlement Shares</u>&#8221;), such Purchaser shall, automatically hereunder (without any additional required actions by such Purchaser or the Company), be deemed to be unconditionally bound to purchase, such Pre-Settlement Shares at the Closing; provided, that the Company shall not be required to deliver any Pre-Settlement Shares to such Purchaser prior to the Company&#8217;s receipt of the purchase price of such Pre-Settlement Shares hereunder; and provided further that the Company hereby acknowledges and agrees that the forgoing shall not constitute a representation or covenant by such Purchaser as to whether or not during the Pre-Settlement Period such Purchaser shall sell any shares of Common Stock to any Person and that any such decision to sell any shares of Common Stock by such Purchaser shall solely be made at the time such Purchaser elects to effect any such sale, if any. Notwithstanding the foregoing, with respect to any Notice(s) of Exercise (as defined in the Warrants) delivered on or prior to 12:00 p.m. (New York City time) on the Closing Date, which may be delivered at any time after the time of execution of this Agreement, the Company agrees to deliver the Warrant Shares subject to such notice(s) by 4:00 p.m. (New York City time) on the Closing Date and the Closing Date shall be the Warrant Share Delivery Date (as defined in the Warrants) for purposes hereunder.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="text-align: justify; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: justify;">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="text-align: justify;">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">2.2&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<u>Deliveries</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp;On or prior to the Closing Date (except as indicated below), the Company shall deliver or cause to be delivered to each Purchaser the following:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">(i)&nbsp; &nbsp; &nbsp; this Agreement duly executed by the Company;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">(ii)&nbsp; &nbsp; &nbsp;a legal opinion of Company Counsel, in form and substance reasonably satisfactory to the Placement Agent;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;subject to Section 2.1, the Company shall have provided each Purchaser with the Company&#8217;s wire instructions, on Company letterhead and executed by the Chief Executive Officer or Chief Financial Officer;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">(iv)&nbsp;&nbsp;&nbsp;&nbsp;subject to Section 2.1, a copy of the irrevocable instructions to the Transfer Agent instructing the Transfer Agent to deliver on an expedited basis via The Depository Trust Company Deposit or Withdrawal at Custodian system (&#8220;<u>DWAC</u>&#8221;) Shares equal to such Purchaser&#8217;s Subscription Amount divided by the Per Share Purchase Price (minus the number of shares of Common Stock issuable upon exercise of such Purchaser&#8217;s Pre-Funded Warrant, if applicable), registered in the name of such Purchaser;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">(v)&nbsp; &nbsp; &nbsp;a Common Warrant registered in the name of such Purchaser to purchase up to a number of shares of Common Stock equal to 100% of the sum of such Purchaser&#8217;s Shares and Pre-Funded Warrants, with an exercise price equal to $4.09, subject to adjustment therein;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">(vi)&nbsp;&nbsp;&nbsp;&nbsp;for each Purchaser of Pre-Funded Warrants pursuant to Section 2.1, a Pre-Funded Warrant registered in the name of such Purchaser to purchase up to a number of shares of Common Stock equal to the portion of such Purchaser&#8217;s Subscription Amount applicable to Pre-Funded Warrant divided by the Per Share Purchase Price minus $0.0001, with an exercise price equal to $0.0001, subject to adjustment therein; and</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="text-align: justify; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: justify;">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="text-align: justify;">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">(vii)&nbsp;&nbsp;&nbsp;the Prospectus and Prospectus Supplement (which may be delivered in accordance with Rule 172 under the Securities Act).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp;On or prior to the Closing Date, each Purchaser shall deliver or cause to be delivered to the Company the following:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">(i)&nbsp; &nbsp; &nbsp; this Agreement duly executed by such Purchaser; and</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">(ii)&nbsp; &nbsp; &nbsp;such Purchaser&#8217;s Subscription Amount, which shall be made available for DVP settlement with the Company or its designee.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">2.3&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<u>Closing Conditions</u>.<u> </u></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">(i)&nbsp; &nbsp; &nbsp; the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect, in all respects) on the Closing Date of the representations and warranties of the Purchasers contained herein (unless as of a specific date therein in which case they shall be accurate in all material respects (or, to the extent representations or warranties are qualified by materiality, in all respects) as of such date);</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">(ii)&nbsp; &nbsp; &nbsp;all obligations, covenants and agreements of each Purchaser required to be performed at or prior to the Closing Date shall have been performed; and</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;the delivery by each Purchaser of the items set forth in Section 2.2(b) of this Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp;The respective obligations of the Purchasers hereunder in connection with the Closing are subject to the following conditions being met:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">(i)&nbsp; &nbsp; &nbsp; the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect, in all respects) when made and on the Closing Date of the representations and warranties of the Company contained herein (unless as of a specific date therein in which case they shall be accurate in all material respects or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect, in all respects) as of such date);</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="text-align: justify; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: justify;">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="text-align: justify;">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">(ii)&nbsp; &nbsp; &nbsp;all obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been performed;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;the delivery by the Company of the items set forth in Section 2.2(a) of this Agreement;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">(iv)&nbsp;&nbsp;&nbsp;&nbsp;there shall have been no Material Adverse Effect with respect to the Company; and</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">(v)&nbsp; &nbsp; &nbsp;from the date hereof to the Closing Date, trading in the Common Stock shall not have been suspended by the Commission or the Company&#8217;s principal Trading Market, and, at any time prior to the Closing Date, trading in securities generally as reported by Bloomberg L.P. shall not have been suspended or limited, or minimum prices shall not have been established on securities whose trades are reported by such service, or on any Trading Market, nor shall a banking moratorium have been declared either by the United States or New York State authorities nor shall there have occurred any material outbreak or escalation of hostilities or other national or international calamity of such magnitude in its effect on, or any material adverse change in, any financial market which, in each case, in the reasonable judgment of such Purchaser, makes it impracticable or inadvisable to purchase the Securities at the Closing.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>ARTICLE III.</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">REPRESENTATIONS AND WARRANTIES</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">3.1&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Representations and Warranties of the Company</u>. Except as set forth in the Disclosure Schedules, which Disclosure Schedules shall be deemed a part hereof and shall qualify any representation or otherwise made herein to the extent of the disclosure contained in the corresponding section of the Disclosure Schedules, the Company hereby makes the following representations and warranties to each Purchaser:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Subsidiaries</u>. All of the direct and indirect subsidiaries of the Company are set forth on <u>Schedule 3.1(a)</u>. The Company owns, directly or indirectly, all of the capital stock or other equity interests of each Subsidiary free and clear of any Liens, and all of the issued and outstanding shares of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable and free of preemptive and similar rights to subscribe for or purchase securities. If the Company has no subsidiaries, all other references to the Subsidiaries or any of them in the Transaction Documents shall be disregarded.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Organization and Qualification</u>. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized, validly existing, and, if applicable under the laws of the jurisdiction in which they are formed, in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power and authority to own and use its properties and assets and to carry on its business as currently conducted. Neither the Company nor any Subsidiary is in violation nor default of any of the provisions of its respective memorandum of association, articles of association, certificate or articles of incorporation, bylaws, operating agreement, or other organizational or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business and is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, could not have or reasonably be expected to result in: (i) a material adverse effect on the legality, validity or enforceability of any Transaction Document, (ii) a material adverse effect on the results of operations, assets, business, prospects or condition (financial or otherwise) of the Company and the Subsidiaries, taken as a whole, or (iii) a material adverse effect on the Company&#8217;s ability to perform in any material respect on a timely basis its obligations under any Transaction Document (any of (i), (ii) or (iii), a &#8220;<u>Material Adverse Effect</u>&#8221;) and no Proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority or qualification.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Authorization; Enforcement</u>. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of this Agreement and each of the other Transaction Documents by the Company and the consummation by it of the transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company and no further action is required by the Company, the Board of Directors or the Company&#8217;s stockholders in connection herewith or therewith other than in connection with the Required Approvals. This Agreement and each other Transaction Document to which it is a party has been (or upon delivery will have been) duly executed by the Company and, when delivered in accordance with the terms hereof and thereof, will constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors&#8217; rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(d)&nbsp;&nbsp;&nbsp;&nbsp;<u>No Conflicts</u>. Except as set forth on <u>Schedule 3.1(d)</u>, the execution, delivery and performance by the Company of this Agreement and the other Transaction Documents to which it is a party, the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby and thereby do not and will not (i) conflict with or violate any provision of the Company&#8217;s or any Subsidiary&#8217;s memorandum of association, articles of association, certificate or articles of incorporation, bylaws, operating agreement, or other organizational or charter documents, or (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties or assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, anti-dilution or similar adjustments acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by which any property or asset of the Company or any Subsidiary is bound or affected, or (iii) subject to the Required Approvals, conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations), or by which any property or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii) and (iii), such as could not have or reasonably be expected to result in a Material Adverse Effect.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(e)&nbsp;&nbsp;&nbsp;&nbsp;<u>Filings, Consents and Approvals</u>. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other Person in connection with the execution, delivery and performance by the Company of the Transaction Documents, other than: (i) the filings required pursuant to Section 4.4 of this Agreement, (ii) the filing with the Commission of the Prospectus Supplement, (iii) notices and/or application(s) to and approvals by each applicable Trading Market for the listing of the applicable Securities for trading thereon in the time and manner required thereby, and (iv) such filings as are required to be made under applicable state securities laws, if any, and the rules and regulations of the Financial Industry Regulatory Authority, Inc. (collectively, the &#8220;<u>Required Approvals</u>&#8221;).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(f)&nbsp;&nbsp;&nbsp;&nbsp;<u>Issuance of the Securities; Registration</u>. The Shares and Warrant Shares are duly authorized and, when issued and paid for in accordance with the applicable Transaction Documents, will be duly and validly issued, fully paid and non-assessable, free and clear of all Liens imposed by the Company. The Warrants are duly authorized and, when issued in accordance with this Agreement, will constitute valid and binding obligations of the Company, and be free and clear of all Liens imposed by the Company. The Company has reserved from its duly authorized capital stock the maximum number of shares of Common Stock issuable pursuant to this Agreement and the Warrants. The Company has prepared and filed the Registration Statement in conformity with the requirements of the Securities Act, which Registration Statement became effective on June 9, 2023, including the Prospectus, and such amendments and supplements thereto as may have been required to the date of this Agreement. The Registration Statement is effective under the Securities Act and no stop order preventing or suspending the effectiveness of the Registration Statement or suspending or preventing the use of the Prospectus has been issued by the Commission and no proceedings for that purpose have been instituted or, to the knowledge of the Company, are threatened by the Commission. The Company, if required by the rules and regulations of the Commission, shall file the Prospectus Supplement with the Commission pursuant to Rule 424(b). At the time the Registration Statement and any amendments thereto became effective as determined under the Securities Act, at the date of this Agreement and at the Closing Date, the Registration Statement and any amendments thereto conformed and will conform in all material respects to the requirements of the Securities Act and did not and will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading; and the Prospectus and any amendments or supplements thereto, at the time the Prospectus or any amendment or supplement thereto was issued and at the Closing Date, conformed and will conform in all material respects to the requirements of the Securities Act and did not and will not contain an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. The Company was at the time of the filing of the Registration Statement eligible to use Form S-3. The Company is eligible to use Form S-3 under the Securities Act pursuant to General Instruction I.B.1 of Form S-3.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(g)&nbsp;&nbsp;&nbsp;&nbsp;<u>Capitalization</u>. The capitalization of the Company as of the date hereof is as set forth on <u>Schedule 3.1(g)</u>, which <u>Schedule 3.1(g)</u> shall also include the number of shares of Common Stock owned beneficially, and of record, by Affiliates of the Company as of the date hereof. Except as set forth on <u>Schedule 3.1(g)</u>, the Company has not issued any shares since its most recently filed periodic report under the Exchange Act other than Shares issued hereunder, securities included in the capitalization reflected on <u>Schedule 3.1(g)</u> or pursuant to the exercise of stock options or vesting of restricted stock units under the Company&#8217;s stock incentive plans, the issuance of shares of Common Stock to consultants or to employees under the Company&#8217;s employee stock purchase plan, the issuance of shares of Common Stock to employees, directors and consultants pursuant to the Company&#8217;s stock incentive plan, and pursuant to the conversion and/or exercise of Common Stock Equivalents outstanding as of the date of the Company&#8217;s most recently filed periodic report under the Exchange Act. No Person has any right of first refusal, preemptive right, right of participation, or any similar right to participate in the transactions contemplated by the Transaction Documents. Except as set forth on <u>Schedule 3.1(g)</u>, and as a result of the purchase and sale of the Securities, there are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire, any shares of Common Stock, or contracts, commitments, understandings or arrangements by which the Company is or may become bound to issue additional shares of Common Stock or Common Stock Equivalents. The issuance and sale of the Securities will not obligate the Company to issue shares of Common Stock or other securities to any Person (other than the Purchasers). There are no outstanding securities or instruments of the Company with any provision that adjusts the exercise, conversion, exchange or reset price under any of such securities. There are no outstanding securities or instruments of the Company that contain any redemption or similar provisions, and there are no contracts, commitments, understandings or arrangements by which the Company is or may become bound to redeem a security of the Company. The Company does not have any share appreciation rights or &#8220;phantom share&#8221; plans or agreements or any similar plan or agreement. All of the outstanding shares of the Company are duly authorized, validly issued, fully paid and non-assessable, have been issued in compliance with all federal and state securities laws where applicable, and none of such outstanding shares was issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities. Except for the Required Approvals, no further approval or authorization of any stockholder, the Board of Directors or others is required for the issuance and sale of the Securities. There are no stockholders agreements, voting agreements or other similar agreements with respect to the Company&#8217;s share capital to which the Company is a party or, to the knowledge of the Company, between or among any of the Company&#8217;s stockholders.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(h)&nbsp;&nbsp;&nbsp;&nbsp;<u>SEC Reports; Financial Statements</u>. The Company has filed all reports, schedules, forms, statements and other documents required to be filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the one year preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such materials) (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, together with the Prospectus and the Prospectus Supplement, being collectively referred to herein as the &#8220;<u>SEC Reports</u>&#8221;) on a timely basis or has received a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration of any such extension. As of their respective dates, the SEC Reports complied in all material respects with the requirements of the Securities Act and the Exchange Act, as applicable, and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. In addition, any further documents so filed and incorporated by reference to the Prospectus and Prospectus Supplement, when such documents are filed with the Commission, will conform in all material respects to the requirements of the Exchange Act and the applicable rules and regulations, as applicable, and will not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in light of the circumstances under which they were made not misleading. The financial statements of the Company included in the SEC Reports comply in all material respects with applicable accounting requirements and the rules and regulations of the Commission with respect thereto as in effect at the time of filing. Such financial statements have been prepared in accordance with GAAP, except as may be otherwise specified in such financial statements or the notes thereto and except that unaudited financial statements may not contain all footnotes required by GAAP, and fairly present in all material respects the financial position of the Company and its consolidated Subsidiaries as of and for the dates thereof and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(i)&nbsp;&nbsp;&nbsp;&nbsp;<u>Material Changes; Undisclosed Events, Liabilities or Developments</u>. Since the date of the latest audited financial statements included within the SEC Reports, except as set forth on <u>Schedule 3.1(i)</u>, (i) there has been no event, occurrence or development that has had or that could reasonably be expected to result in a Material Adverse Effect, (ii) the Company has not incurred any liabilities (contingent or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice and strategic acquisitions or otherwise incurred in connection with strategic transactions and (B) liabilities not required to be reflected in the Company&#8217;s financial statements pursuant to GAAP or disclosed in filings made with the Commission, (iii) the Company has not altered its method of accounting, (iv) the Company has not declared or made any dividend or distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any of its shares and (v) the Company has not issued any equity securities to any officer, director or Affiliate, except pursuant to existing Company equity incentive plans. Except for the issuance of the Securities contemplated by this Agreement or as set forth on <u>Schedule 3.1(i)</u>, no event, liability, fact, circumstance, occurrence or development has occurred or exists with respect to the Company or its Subsidiaries or their respective businesses, properties, operations, assets or financial condition that would be required to be disclosed by the Company under applicable securities laws at the time this representation is made or deemed made that has not been publicly disclosed in accordance with the federal securities laws at least one (1) Trading Day prior to the date that this representation is made.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(j)&nbsp;&nbsp;&nbsp;&nbsp;<u>Litigation</u>. Except as set forth on <u>Schedule 3.1(j)</u>, there is no action, suit, inquiry, notice of violation, proceeding or investigation pending or, to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary or any of their respective properties before or by any court, arbitrator, governmental or administrative agency or regulatory authority (federal, state, county, local or foreign) (collectively, an &#8220;<u>Action</u>&#8221;) which (i) adversely affects or challenges the legality, validity or enforceability of any of the Transaction Documents, the Shares or the Warrant Shares (ii) could, if there were an unfavorable decision, have or reasonably be expected to result in a Material Adverse Effect. Except as set forth on <u>Schedule 3.1(j)</u>, neither the Company nor any Subsidiary, nor any director or officer thereof, is or has been the subject of any Action involving a claim of violation of or liability under federal or state securities laws or a claim of breach of fiduciary duty, which could result in a Material Adverse Effect. There has not been, and to the knowledge of the Company, there is not pending or contemplated, any investigation by the Commission involving the Company or any current or former director or officer of the Company. The Commission has not issued any stop order or other order suspending the effectiveness of any registration statement filed by the Company or any Subsidiary under the Exchange Act or the Securities Act.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(k)&nbsp;&nbsp;&nbsp;&nbsp;<u>Labor Relations</u>. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees of the Company, which could reasonably be expected to result in a Material Adverse Effect. None of the Company&#8217;s or its Subsidiaries&#8217; employees is a member of a union that relates to such employee&#8217;s relationship with the Company or such Subsidiary, and neither the Company nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe that their relationships with their employees are good. To the knowledge of the Company, no executive officer of the Company or any Subsidiary, is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary information agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant in favor of any third party, and the continued employment of each such executive officer does not subject the Company or any of its Subsidiaries to any liability with respect to any of the foregoing matters. The Company and its Subsidiaries are in compliance with all applicable U.S. federal, state, local and foreign laws and regulations relating to employment and employment practices, terms and conditions of employment and wages and hours, except where the failure to be in compliance could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(l)&nbsp;&nbsp;&nbsp;&nbsp;<u>Compliance</u>. Except as set forth on <u>Schedule 3.1(l)</u>, neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred that has not been waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor has the Company or any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture, loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is bound (whether or not such default or violation has been waived), (ii) is in violation of any judgment, decree or order of any court, arbitrator or other governmental authority or (iii) is or has been in violation of any statute, rule, ordinance or regulation of any governmental authority, including without limitation all foreign, federal, state and local laws relating to taxes, environmental protection, occupational health and safety, product quality and safety and employment and labor matters, except in each case of (i), (ii) and (iii) as could not have or reasonably be expected to result in a Material Adverse Effect.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(m)&nbsp;&nbsp;&nbsp;&nbsp;<u>Environmental Laws</u>. The Company and its Subsidiaries (i) are in compliance with all federal, state, local and foreign laws relating to pollution or protection of human health or the environment (including ambient air, surface water, groundwater, land surface or subsurface strata), including laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants, or toxic or hazardous substances or wastes (collectively, &#8220;<u>Hazardous Materials</u>&#8221;) into the environment, or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials, as well as all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments, licenses, notices or notice letters, orders, permits, plans or regulations, issued, entered, promulgated or approved thereunder (&#8220;<u>Environmental Laws</u>&#8221;); (ii) have received all permits licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses; and (iii) are in compliance with all terms and conditions of any such permit, license or approval where in each clause (i), (ii) and (iii), the failure to so comply could be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(n)&nbsp;&nbsp;&nbsp;&nbsp;<u>Regulatory Permits</u>. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate federal, state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the SEC Reports, except where the failure to possess such certificates, authorizations or permits could not reasonably be expected to result in a Material Adverse Effect (&#8220;<u>Material Permits</u>&#8221;), and neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation or modification of any Material Permit.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(o)&nbsp;&nbsp;&nbsp;&nbsp;<u>Title to Assets</u>. The Company and the Subsidiaries have good and marketable title in fee simple to all real property owned by them and good and marketable title in all personal property owned by them that is material to the business of the Company and the Subsidiaries, in each case free and clear of all Liens, except for (i) Liens as do not materially affect the value of such property and do not materially interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries and (ii) Liens for the payment of federal, state or other taxes, for which appropriate reserves have been made therefor in accordance with GAAP and, the payment of which is neither delinquent nor subject to penalties. Any real property and facilities held under lease by the Company and the Subsidiaries are held by them under valid, subsisting and enforceable leases with which the Company and the Subsidiaries are in compliance in all material respects.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(p)&nbsp;&nbsp;&nbsp;&nbsp;<u>Intellectual Property</u>. To the knowledge of the Company and the Subsidiaries, the Company and the Subsidiaries have, or have rights to use, all patents, patent applications, trademarks, trademark applications, service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights necessary or required for use in connection with their respective businesses as described in the SEC Reports and which the failure to so have could have a Material Adverse Effect (collectively, the &#8220;<u>Intellectual Property Rights</u>&#8221;). None of, and neither the Company nor any Subsidiary has received a notice (written or otherwise) that any of, the Intellectual Property Rights has expired, terminated or been abandoned, or is expected to expire or terminate or be abandoned, within two (2) years from the date of this Agreement except as would not reasonably be expected to have a Material Adverse Effect. Neither the Company nor any Subsidiary has received, since the date of the latest audited financial statements included within the SEC Reports, a written notice of a claim or otherwise has any knowledge that the Intellectual Property Rights violate or infringe upon the rights of any Person, except as could not have or reasonably be expected to not have a Material Adverse Effect. To the knowledge of the Company, all such Intellectual Property Rights are enforceable and, to the knowledge of the Company, there is no existing infringement by another Person of any of the Intellectual Property Rights. The Company and its Subsidiaries have taken reasonable security measures to protect the secrecy, confidentiality and value of all of their intellectual properties, except where failure to do so could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. The Company has no knowledge of any facts that would preclude it from having valid license rights or clear title to the Intellectual Property Rights. The Company has no knowledge that it lacks or will be unable to obtain any rights or licenses to use all Intellectual Property Rights that are necessary to conduct its business.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(q)&nbsp;&nbsp;&nbsp;&nbsp;<u>Insurance</u>. The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged, including, but not limited to, directors and officers insurance coverage at least equal to the aggregate Subscription Amount. Neither the Company nor any Subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business without a significant increase in cost.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(r)&nbsp;&nbsp;&nbsp;&nbsp;<u>Transactions With Affiliates and Employees</u>. Except as set forth on <u>Schedule 3.1(r)</u>, none of the officers or directors of the Company or any Subsidiary and, to the knowledge of the Company, none of the employees of the Company or any Subsidiary is presently a party to any transaction with the Company or any Subsidiary (other than for services as employees, officers and directors), including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or from, providing for the borrowing of money from or lending of money to or otherwise requiring payments to or from any officer, director or such employee or, to the knowledge of the Company, any entity in which any officer, director, or any such employee has a substantial interest or is an officer, director, trustee, stockholder, member or partner, in each case in excess of $120,000 other than for (i) payment of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred on behalf of the Company or a Subsidiary and (iii) other employee benefits, including equity incentive agreements under any equity incentive plan of the Company.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(s)&nbsp; &nbsp; <u>Sarbanes-Oxley; Internal Accounting Controls</u>. The Company and the Subsidiaries are in material compliance with any and all applicable requirements of the Sarbanes-Oxley Act of 2002 that are effective as of the date hereof, and any and all applicable rules and regulations promulgated by the Commission thereunder that are effective as of the date hereof and as of the Closing Date. The Company and the Subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable assurance that: (i) transactions are executed in accordance with management&#8217;s general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability, (iii) access to assets is permitted only in accordance with management&#8217;s general or specific authorization, and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. The Company and the Subsidiaries have established disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company and the Subsidiaries and designed such disclosure controls and procedures to ensure that information required to be disclosed by the Company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission&#8217;s rules and forms. The Company&#8217;s certifying officers have evaluated the effectiveness of the disclosure controls and procedures of the Company and the Subsidiaries as of the end of the period covered by the most recently filed Form 10-K under the Exchange Act (such date, the &#8220;<u>Evaluation Date</u>&#8221;). The Company presented in its most recently filed Form 10-K under the Exchange Act the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations as of the Evaluation Date. Except as set forth on <u>Schedule 3.1(s)</u>, since the Evaluation Date, there have been no changes in the internal control over financial reporting (as such term is defined in the Exchange Act) that have materially affected, or are reasonably likely to materially affect, the internal control over financial reporting of the Company and its Subsidiaries.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(t)&nbsp;&nbsp;&nbsp;&nbsp;<u>Certain Fees</u>. Except as set forth in the Prospectus Supplement, no brokerage or finder&#8217;s fees or commissions are or will be payable by the Company or any Subsidiary to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other Person with respect to the transactions contemplated by the Transaction Documents (for the avoidance of doubt, the foregoing shall not include any fees and/or commissions owed to the Transfer Agent). Other than for Persons engaged by any Purchaser, if any, the Purchasers shall have no obligation with respect to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated in this Section that may be due in connection with the transactions contemplated by the Transaction Documents.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(u)&nbsp;&nbsp;&nbsp;&nbsp;<u>Investment Company</u>. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities, will not be or be an Affiliate of, an &#8220;investment company&#8221; within the meaning of the Investment Company Act of 1940, as amended. The Company shall conduct its business in a manner so that it will not become an &#8220;investment company&#8221; subject to registration under the Investment Company Act of 1940, as amended.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(v)&nbsp;&nbsp;&nbsp;&nbsp;<u>Registration Rights</u>. Except as set forth on <u>Schedule 3.1(v)</u>, no Person has any right to cause the Company to effect the registration under the Securities Act of any securities of the Company or any Subsidiary.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(w)&nbsp;&nbsp;&nbsp;&nbsp;<u>Listing and Maintenance Requirements</u>. The shares of Common Stock are registered pursuant to Section 12(b) or 12(g) of the Exchange Act, and the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration of the Common Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating such registration. Except as set forth on <u>Schedule 3.1(w)</u>, the Company has not, in the 12 months preceding the date hereof, received notice from any Trading Market on which the Common Stock is or has been listed or quoted to the effect that the Company is not in compliance with the listing or maintenance requirements of such Trading Market. Except as set forth on <u>Schedule 3.1(w)</u>, the Company is, and has no reason to believe that it will not in the foreseeable future continue to be, in compliance with all such listing and maintenance requirements. The Common Stock is currently eligible for electronic transfer through The Depository Trust Company or another established clearing corporation and the Company is current in payment of the fees to The Depository Trust Company (or such other established clearing corporation) in connection with such electronic transfer.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(x)&nbsp;&nbsp;&nbsp;&nbsp;<u>Application of Takeover Protections</u>. The Company and the Board of Directors have taken all necessary action, if any, in order to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or other similar anti-takeover provision under the Company&#8217;s certificate of incorporation or the laws of its state of incorporation that is or could become applicable to the Purchasers as a result of the Purchasers and the Company fulfilling their obligations or exercising their rights under the Transaction Documents, including without limitation as a result of the Company&#8217;s issuance of the Securities and the Purchasers&#8217; ownership of the Securities.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(y)&nbsp;&nbsp;&nbsp;&nbsp;<u>Disclosure</u>. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, the Company confirms that neither it nor any other Person acting on its behalf has provided any of the Purchasers or their agents or counsel with any information that it believes constitutes or might constitute material, non-public information which is not otherwise disclosed in the Prospectus or Prospectus Supplement. The Company understands and confirms that the Purchasers will rely on the foregoing representation in effecting transactions in securities of the Company. All of the disclosure furnished by or on behalf of the Company to the Purchasers regarding the Company and its Subsidiaries, their respective businesses and the transactions contemplated hereby, including the Disclosure Schedules to this Agreement, is true and correct in all material respects and does not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements made therein, in the light of the circumstances under which they were made, not misleading. The press releases disseminated by the Company during the twelve (12) months preceding the date of this Agreement taken as a whole do not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made and when made, not misleading. The Company acknowledges and believes, to its best knowledge, that no Purchaser makes or has made any representations or warranties with respect to the transactions contemplated hereby other than those specifically set forth in Section 3.2 hereof.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(z)&nbsp; &nbsp; &nbsp;<u>No Integrated Offering</u>. Assuming the accuracy of the Purchasers&#8217; representations and warranties set forth in Section 3.2, neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering of the Securities to be integrated with prior offerings by the Company for purposes of any applicable shareholder approval provisions of any Trading Market on which any of the securities of the Company are listed or designated.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(aa)&nbsp;&nbsp;&nbsp;&nbsp;<u>Solvency</u>. Except as set forth on <u>Schedule 3.1(aa)</u>, based on the consolidated financial condition of the Company as of the Closing Date, after giving effect to the receipt by the Company of the proceeds from the sale of the Securities hereunder, (i) the fair saleable value of the Company&#8217;s assets exceeds the amount that will be required to be paid on or in respect of the Company&#8217;s existing debts and other liabilities (including known contingent liabilities) as they mature, (ii) the Company&#8217;s assets do not constitute unreasonably small capital to carry on its business as now conducted and as proposed to be conducted including its capital needs taking into account the particular capital requirements of the business conducted by the Company, consolidated and projected capital requirements and capital availability thereof, and (iii) the current cash flow of the Company, together with the proceeds the Company would receive, were it to liquidate all of its assets, after taking into account all anticipated uses of the cash, would be sufficient to pay all amounts on or in respect of its liabilities when such amounts are required to be paid. Except as set forth on <u>Schedule 3.1(aa)</u>, the Company does not intend to incur debts beyond its ability to pay such debts as they mature (taking into account the timing and amounts of cash to be payable on or in respect of its debt) within one year from the date hereof. The Company has no knowledge of any facts or circumstances which lead it to believe that it will file for reorganization or liquidation under the bankruptcy or reorganization laws of any jurisdiction within one year from the Closing Date. <u>Schedule 3.1(aa)</u> sets forth as of the date hereof all outstanding secured and unsecured Indebtedness of the Company or any Subsidiary, or for which the Company or any Subsidiary has commitments. For the purposes of this Agreement, &#8220;<u>Indebtedness</u>&#8221; means (x) any liabilities for borrowed money or amounts owed by the Company in excess of $250,000 (other than trade accounts payable incurred in the ordinary course of business), (y) all guaranties, endorsements and other contingent obligations in respect of indebtedness of others to third parties, whether or not the same are or should be reflected in the Company&#8217;s consolidated balance sheet (or the notes thereto), except guaranties by endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of business; and (z) the present value of any lease payments in excess of $250,000 due under leases required to be capitalized in accordance with GAAP. Neither the Company nor any Subsidiary is in default with respect to any Indebtedness.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(bb)&nbsp;&nbsp;&nbsp;&nbsp;<u>Tax Compliance</u>. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a Material Adverse Effect, or as set forth on <u>Schedule 3.1(bb)</u>, the Company and its Subsidiaries each (i) has made or filed all United States federal, state and local income and all foreign income and franchise tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii) has paid all taxes and other governmental assessments and charges, fines or penalties that are material in amount, shown or determined to be due on such returns, reports and declarations and (iii) to the extent required under GAAP, has set aside on its financial statements provision reasonably adequate for the payment of all material tax liability of which has not been finally determined and all material taxes for periods subsequent to the periods to which such returns, reports or declarations apply. There are no unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company or of any Subsidiary know of no basis for any such claim.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(cc)&nbsp;&nbsp;&nbsp;&nbsp;<u>Foreign Corrupt Practices</u>. Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any agent or other person acting on behalf of the Company or any Subsidiary, has (i) directly or indirectly, used any funds for unlawful contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate funds, (iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any person acting on its behalf of which the Company is aware) which is in violation of law, or (iv) violated in any material respect any provision of FCPA.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(dd)&nbsp;&nbsp;&nbsp;&nbsp;<u>Accountants</u>. The Company&#8217;s independent registered public accounting firm is as set forth in the SEC Reports. To the knowledge and belief of the Company, such accounting firm is a registered public accounting firm as required by the Exchange Act.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(ee)&nbsp;&nbsp;&nbsp;&nbsp; <u>Acknowledgment Regarding Purchasers</u><u>&#8217;</u><u> Purchase of Securities</u>. The Company acknowledges and agrees that each of the Purchasers is acting solely in the capacity of an arm&#8217;s length purchaser with respect to the Transaction Documents and the transactions contemplated thereby. The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with respect to the Transaction Documents and the transactions contemplated thereby and any advice given by any Purchaser or any of their respective representatives or agents in connection with the Transaction Documents and the transactions contemplated thereby is merely incidental to the Purchasers&#8217; purchase of the Securities. The Company further represents to each Purchaser that the Company&#8217;s decision to enter into this Agreement and the other Transaction Documents has been based solely on the independent evaluation of the transactions contemplated hereby by the Company and its representatives.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(ff)&nbsp;&nbsp;&nbsp;&nbsp;<u>Acknowledgment Regarding Purchaser</u><u>&#8217;</u><u>s Trading Activity</u>. Anything in this Agreement or elsewhere herein to the contrary notwithstanding (except for Sections 3.2(f) and 4.13 hereof), it is understood and acknowledged by the Company that: (i) none of the Purchasers has been asked by the Company to agree, nor has any Purchaser agreed, to desist from purchasing or selling, long and/or short, securities of the Company, or &#8220;derivative&#8221; securities based on securities issued by the Company or to hold the Shares for any specified term; (ii) past or future open market or other transactions by any Purchaser, specifically including, without limitation, Short Sales or &#8220;derivative&#8221; transactions, before or after the closing of this or future private placement transactions, may negatively impact the market price of the Company&#8217;s publicly-traded securities; (iii) any Purchaser, and counter-parties in &#8220;derivative&#8221; transactions to which any such Purchaser is a party, directly or indirectly, presently may have a &#8220;short&#8221; position in the shares of Common Stock, and (iv) each Purchaser shall not be deemed to have any affiliation with or control over any arm&#8217;s length counter-party in any &#8220;derivative&#8221; transaction. The Company further understands and acknowledges that (y) one or more Purchasers may engage in hedging activities at various times during the period that the shares of Common Stock are outstanding, and (z) such hedging activities (if any) could reduce the value of the existing shareholders&#8217; equity interests in the Company at and after the time that the hedging activities are being conducted. The Company acknowledges that such aforementioned hedging activities do not constitute a breach of any of the Transaction Documents.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(gg)&nbsp;&nbsp;&nbsp;&nbsp;<u>Regulation M Compliance</u>.&nbsp; The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of any of the shares of Common Stock, (ii) sold, bid for, purchased, or, paid any compensation for soliciting purchases of, any of the shares of Common Stock, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities of the Company, other than, in the case of clauses (ii) and (iii), compensation paid to the Company&#8217;s placement agent in connection with the placement of the shares of Common Stock.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(hh)&nbsp;&nbsp;&nbsp;&nbsp;<u>Regulatory</u>. Except as set forth on <u>Schedule 3.1(hh)</u>, as applicable, the Company and its Subsidiaries (i) are and at all times have been in material compliance with all statutes, rules and regulations applicable to the ownership, testing, development, manufacture, packaging, processing, use, distribution, marketing, advertising, labeling, promotion, sale, offer for sale, storage, import, export or disposal of any product manufactured or distributed by the Company including, without limitation the Federal Food, Drug and Cosmetic Act (21 U.S.C. &#167;301 et seq.), the federal Anti-Kickback Statute (42 U.S.C. &#167;1320a-7b(b)), the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, and the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Affordability Reconciliation Act of 2010, the regulations promulgated pursuant to such laws, and any successor government programs and comparable state laws, regulations relating to Good Clinical Practices and Good Laboratory Practices and all other local, state, federal, national, supranational and foreign laws, manual provisions, policies and administrative guidance relating to the regulation of the Company (collectively, the &#8220;<u>Applicable Laws</u>&#8221;); (ii) have not received any notice from any court or arbitrator or governmental or regulatory authority or third party alleging or asserting material noncompliance with any Applicable Laws or any licenses, exemptions, certificates, approvals, clearances, authorizations, permits, registrations and supplements or amendments thereto required by any such Applicable Laws (&#8220;<u>Authorizations</u>&#8221;); (iii) possess all material Authorizations and such Authorizations are valid and in full force and effect and are not in material violation of any term of any such Authorizations; (iv) have not received written notice of any claim, action, suit, proceeding, hearing, enforcement action, investigation arbitration or other action from any court or arbitrator or governmental or regulatory authority or third party alleging that any product operation or activity is in material violation of any Applicable Laws or Authorizations nor is any such claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action threatened which (A) contests the licensure, registration, or approval of, the uses of, the distribution of, the manufacturing or packaging of, the testing of, the sale of, or the labeling and promotion of any products of the Company, (B) withdraws its approval of, requests the recall, suspension, or seizure of, or withdraws or orders the withdrawal of advertising or sales promotional materials relating to, any Company product, (C) imposes a clinical hold on any clinical investigation by the Company or any of its Subsidiaries, (D) enjoins production at any facility of the Company or any of its Subsidiaries, (E) enters or proposes to enter into a consent decree of permanent injunction with the Company or any of its Subsidiaries, or (F) otherwise alleges any material violation of any laws, rules or regulations by the Company or any of its Subsidiaries, and which, either individually or in the aggregate, would have a Material Adverse Effect; (v) have not received any written notice that any court or arbitrator or governmental or regulatory authority has taken, is taking or intends to take, action to limit, suspend, materially modify or revoke any Authorizations nor is any such limitation, suspension, modification or revocation threatened; (vi) have filed, obtained, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Applicable Laws or Authorizations and that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were complete and accurate on the date filed (or were corrected or supplemented by a subsequent submission); and (vii) are not a party to any corporate integrity agreements, monitoring agreements, consent decrees, settlement orders, or similar agreements with or imposed by any governmental or regulatory authority. The Company has not been informed by the United States Food and Drug Administration (&#8220;<u>FDA</u>&#8221;) that the FDA will prohibit the marketing, sale, license or use in the United States of any product produced or marketed by the Company nor has the FDA halted any approved investigational device exemption, clinical program or other trial of the Company.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;<u>Clinical Trials</u>. The pre-clinical studies<u> </u>and clinical trials conducted by or, to the knowledge of the Company, on behalf of or sponsored by the Company, or in which the Company has participated, that are described in, or the results of which are referred to in, the Registration Statement or the Prospectus Supplement were and, if still pending, are being conducted in accordance with protocols filed with the appropriate regulatory authorities for each such study or trial, as the case may be, and with standard medical and scientific research standards and procedures, all applicable statutes, all applicable rules and regulations of the FDA and comparable regulatory agencies outside of the United States to which they are subject and Good Clinical Practices and Good Laboratory Practices, except to the extent where failure to conduct in such manner would not have a Material Adverse Effect. Each description of the results of such studies and trials contained in the Registration Statement, Prospectus or the Prospectus Supplement is accurate and complete in all material respects and fairly presents the data derived from such studies and trials, and the Company has no knowledge of any other studies or trials the results of which are inconsistent with, or otherwise call into question, the results described or referred to in the Registration Statement, Prospectus, or the Prospectus Supplement. The Company has not received any written notices, correspondence or other written communications from the FDA or any committee thereof or from any other U.S. or foreign government or drug or medical device regulatory agency requiring or, to the Company&#8217;s knowledge, threatening the termination, suspension or modification of any clinical trials that are described or referred to in the Registration Statement, Prospectus, or the Prospectus Supplement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(jj)&nbsp;&nbsp;&nbsp;&nbsp;<u>Compliance with Healthcare Laws.</u> The tests, studies, and trials conducted by or on behalf of or sponsored by the Company or any of its subsidiaries were and, if still pending, are being conducted in all material respects in accordance with all applicable Health Care Laws (as defined below) and standard medical and scientific research protocols, procedures, and controls; none of the Company or any of its subsidiaries has received any written notice, correspondence, or other written communication from any regulatory agency or any institutional review board or comparable body requiring or threatening the termination, suspension, or material modification of any tests, studies, or trials, or commercial distribution, and to the knowledge of the Company and its subsidiaries, there are no reasonable grounds for the same. Each of the Company and its Subsidiaries has obtained (or caused to be obtained) the informed consent of each human subject who participated in a test, study, or trial. None of the tests, studies, or trials involved any investigator who has been disqualified as a clinical investigator. The Company and its directors, officers, employees, and agents are, and at all times prior hereto have been, in material compliance with, all health care laws and regulations applicable to the Company or any of its product candidates or activities, including development and testing of pharmaceutical products, kickbacks, recordkeeping, documentation requirements, the hiring of employees (to the extent governed by Health Care Laws), quality, safety, privacy, security, licensure, accreditation or any other aspect of developing and testing health care or pharmaceutical products (collectively, &#8220;<u>Health Care Laws</u>&#8221;). The Company has not received any notification, correspondence or any other written or oral communication, including notification of any pending or threatened claim, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any governmental authority, including, without limitation, the United States Food and Drug Administration, the Drug Enforcement Agency, the Centers for Medicare &amp; Medicaid Services, and the U.S. Department of Health and Human Services Office of Inspector General, of potential or actual non-compliance by, or liability of, the Company under any Health Care Laws. To the Company&#8217;s knowledge, there are no facts or circumstances that would reasonably be expected to give rise to liability of the Company under any Health Care Laws, except that would not individually or in the aggregate have a Material Adverse Effect</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(kk)&nbsp;&nbsp;&nbsp;&nbsp;<u>Material Agreements</u>. The material agreements and any other material documents described in the Registration Statement or Prospectus conform in all material respects to the descriptions thereof contained or incorporated by reference therein which descriptions conformed in all material respects to the requirements of the Securities Act or the Exchange Act, as applicable at the time filed, and there are no other material agreements or other material documents required by the Securities Act and the rules and regulations thereunder to be described in the Prospectus or to be filed with the Commission as exhibits to the Registration Statement or to be incorporated by reference in the Registration Statement or Prospectus, that have not been so described or filed or incorporated by reference.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(ll)&nbsp;&nbsp;&nbsp;&nbsp;<u>Stock Option Plans</u>. Each stock option granted by the Company under the Company&#8217;s equity incentive plan was granted (i) in accordance with the terms of the Company&#8217;s equity incentive plan and (ii) with an exercise price at least equal to the fair market value of the Common Stock on the date such stock option would be considered granted under GAAP and applicable law. No stock option granted under the Company&#8217;s equity incentive plan has been backdated. The Company has not knowingly granted, and there is no and has been no Company policy or practice to knowingly grant, stock options prior to, or otherwise knowingly coordinate the grant of stock options with, the release or other public announcement of material information regarding the Company or its Subsidiaries or their financial results or prospects.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(mm)&nbsp;&nbsp;&nbsp;&nbsp;<u>Cybersecurity</u>.&nbsp; (i)(x) To the Company&#8217;s knowledge, there has been no material security breach or other material compromise of or relating to any of the Company&#8217;s or any Subsidiary&#8217;s information technology and computer systems, networks, hardware, software, data (including the data of its respective customers, employees, suppliers, vendors and any third party data maintained by it), equipment or technology (collectively, &#8220;<u>IT Systems and Data</u>&#8221;) and (y) the Company and the Subsidiaries have not been notified of any security breach or other material compromise to its IT Systems and Data, except as would not, individually or in the aggregate for all such matters referred to in this clause (i), have a Material Adverse Effect; (ii) the Company and the Subsidiaries are presently in compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems and Data and to the protection of such IT Systems and Data from unauthorized use, access, misappropriation or modification, except as would not, individually or in the aggregate, have a Material Adverse Effect; (iii) the Company and the Subsidiaries take commercially reasonable efforts to maintain and protect its material confidential information and the integrity of all IT Systems and Data; and (iv) the Company and the Subsidiaries (or, to the Company&#8217;s and its Subsidiaries&#8217; knowledge, their applicable third-party providers of such technology) have implemented backup and disaster recovery technology consistent with commercially reasonable industry standards and practices for companies comparable in size to the Company, except where the failure to do so would not have a Material Adverse Effect.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(nn)&nbsp;&nbsp;&nbsp;&nbsp;<u>Office of Foreign Assets Control</u>. Neither the Company nor any Subsidiary nor, to the Company&#8217;s knowledge, any director, officer, agent, employee or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Treasury Department (&#8220;<u>OFAC</u>&#8221;).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(oo)&nbsp;&nbsp;&nbsp;&nbsp;<u>U.S. Real Property Holding Corporation</u>. The Company is not and has never been a U.S. real property holding corporation within the meaning of Section 897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon Purchaser&#8217;s request.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(pp)&nbsp;&nbsp;&nbsp;&nbsp;<u>Bank Holding Company Act</u>. Neither the Company nor any of its Subsidiaries or Affiliates is subject to the Bank Holding Company Act of 1956, as amended (the &#8220;<u>BHCA</u>&#8221;) and to regulation by the Board of Governors of the Federal Reserve System (the &#8220;<u>Federal Reserve</u>&#8221;). Neither the Company nor any of its Subsidiaries or Affiliates owns or controls, directly or indirectly, five percent (5%) or more of the outstanding shares of any class of voting securities or twenty-five percent (25%) or more of the total equity of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither the Company nor any of its Subsidiaries or Affiliates exercises a controlling influence over the management or policies of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(qq)&nbsp;&nbsp;&nbsp;&nbsp;<u>Money Laundering</u>. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, applicable money laundering statutes and applicable rules and regulations thereunder (collectively, the &#8220;<u>Money Laundering Laws</u>&#8221;), and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company or any Subsidiary, threatened.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(rr)&nbsp;&nbsp;&nbsp;&nbsp;<u>Information Technology</u>. The Company&#8217;s, the Subsidiaries&#8217; and, to the knowledge of the Company, the Related Parties&#8217; information technology assets and equipment, computers, systems, networks, hardware, software, websites, applications, and databases (collectively, &#8220;<u>IT Systems</u>&#8221;) operate and perform in all material respects as required in connection with the operation of the business of the Company, the Subsidiaries and the Related Entities as currently conducted. The Company, the Subsidiaries and, to the knowledge of the Company, the Related Parties maintain commercially reasonable controls, policies, procedures, and safeguards to maintain and protect their material confidential information and the integrity, continuous operation, redundancy and security of all IT Systems and all personal, personally identifiable, sensitive, confidential or regulated data (&#8220;<u>Personal Data</u>&#8221;) processed and stored thereon, and to the knowledge of the Company, there have been no breaches, incidents, violations, outages, compromises or unauthorized uses of or accesses to same, except for those that have been remedied without material cost or liability or the duty to notify any other person, nor any incidents under internal review or investigations relating to the same. The Company, the Subsidiaries and, to the knowledge of the Company, the Related Parties are presently in compliance in all material respects with all applicable laws or statutes and all applicable judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems and Personal Data and to the protection of such IT Systems and Personal Data from unauthorized use, access, misappropriation or modification, except for any such noncompliance that would not have a Material Adverse Effect.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(ss)&nbsp;&nbsp;&nbsp;&nbsp;<u>Promotional Stock Activities</u>.&nbsp; Neither the Company nor any Subsidiary of the Company and none of their respective officers, directors, managers, affiliates or agents have engaged in any stock promotional activity that could give rise to a complaint, inquiry, or trading suspension by the SEC alleging (i) a violation of the anti-fraud provisions of the federal securities laws, (ii) violations of the anti-touting provisions, (iii) improper &#8220;gun-jumping; or (iv) promotion without proper disclosure of compensation.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">3.2&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<u>Representations and Warranties of the Purchasers</u>. Each Purchaser, for itself and for no other Purchaser, hereby represents and warrants as of the date hereof and as of the Closing Date to the Company as follows (unless as of a specific date therein, in which case they shall be accurate as of such date):</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 21pt; text-indent: 51pt; text-align: justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Organization; Authority</u>. Such Purchaser is either an individual or an entity duly incorporated or formed, validly existing and in good standing under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited liability company or similar power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of the Transaction Documents and performance by such Purchaser of the transactions contemplated by the Transaction Documents have been duly authorized by all necessary corporate, partnership, limited liability company or similar action, as applicable, on the part of such Purchaser. Each Transaction Document to which it is a party has been duly executed by such Purchaser, and when delivered by such Purchaser in accordance with the terms hereof, will constitute the valid and legally binding obligation of such Purchaser, enforceable against it in accordance with its terms, except: (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors&#8217; rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 21pt; text-indent: 51pt; text-align: justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Understandings or Arrangements</u>. Such Purchaser is acquiring the Securities as principal for its own account and has no direct or indirect arrangement or understandings with any other persons to distribute or regarding the distribution of such Securities (this representation and warranty not limiting such Purchaser&#8217;s right to sell the Securities pursuant to the Registration Statement or otherwise in compliance with applicable federal and state securities laws). Such Purchaser is acquiring the Securities hereunder in the ordinary course of its business.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 21pt; text-indent: 36pt; text-align: justify;">(c)&nbsp;&nbsp;&nbsp;&nbsp; <u>Purchaser Status</u>. At the time such Purchaser was offered the Securities, it was, and as of the date hereof it is, and on each date on which it exercises any Warrants, it will be an &#8220;accredited investor&#8221; as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7), (a)(8), (a)(9), (a)(12), or (a)(13) under the Securities Act.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 21pt; text-indent: 51pt; text-align: justify;">(d)&nbsp;&nbsp;&nbsp;&nbsp;<u>Experience of Such Purchaser</u>. Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Securities, and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the economic risk of an investment in the Securities and, at the present time, is able to afford a complete loss of such investment.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 21pt; text-indent: 51pt; text-align: justify;">(e<u>)</u>&nbsp;&nbsp;&nbsp;&nbsp;<u>Access to Information</u>. Such Purchaser acknowledges that it has had the opportunity to review the Transaction Documents (including all exhibits and schedules thereto) and the SEC Reports and has been afforded, (i) the opportunity to ask such questions as it has deemed necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions of the offering of the Securities and the merits and risks of investing in the Securities; (ii) access to information about the Company and its financial condition, results of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment; and (iii) the opportunity to obtain such additional information that the Company possesses or can acquire without unreasonable effort or expense that is necessary to make an informed investment decision with respect to the investment.&nbsp; Such Purchaser acknowledges and agrees that neither the Placement Agent nor any Affiliate of the Placement Agent has provided such Purchaser with any information or advice with respect to the Securities nor is such information or advice necessary or desired.&nbsp; Neither the Placement Agent nor any Affiliate has made or makes any representation as to the Company or the quality of the Securities and the Placement Agent and any Affiliate may have acquired non-public information with respect to the Company which such Purchaser agrees need not be provided to it.&nbsp; In connection with the issuance of the Securities to such Purchaser, neither the Placement Agent nor any of its Affiliates has acted as a financial advisor or fiduciary to such Purchaser.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 21pt; text-indent: 51pt; text-align: justify;">(f)&nbsp;&nbsp;&nbsp;&nbsp;<u>Certain Transactions and Confidentiality</u>. Other than consummating the transactions contemplated hereunder, such Purchaser has not, nor has any Person acting on behalf of or pursuant to any understanding with such Purchaser, directly or indirectly executed any purchases or sales, including Short Sales,&nbsp;of the securities of the Company during the period commencing as of the time that such Purchaser first received a term sheet (written or oral) from the Company or any other Person representing the Company setting forth the material terms of the transactions contemplated hereunder and ending immediately prior to the execution hereof. Notwithstanding the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser&#8217;s assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions of such Purchaser&#8217;s assets, the representation set forth above shall only apply with respect to the portion of assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement. Other than to other Persons party to this Agreement or to such Purchaser&#8217;s representatives, including, without limitation, its officers, directors, partners, legal and other advisors, employees, agents and Affiliates, such Purchaser has maintained the confidentiality of all disclosures made to it in connection with this transaction (including the existence and terms of this transaction). Notwithstanding the foregoing, for the avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions, with respect to locating or borrowing shares in order to effect Short Sales or similar transactions in the future.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Company acknowledges and agrees that the representations contained in this Section 3.2 shall not modify, amend or affect such Purchaser&#8217;s right to rely on the Company&#8217;s representations and warranties contained in this Agreement or any representations and warranties contained in any other Transaction Document or any other document or instrument executed and/or delivered in connection with this Agreement or the consummation of the transactions contemplated hereby. Notwithstanding the foregoing, for the avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions, with respect to locating or borrowing shares in order to effect Short Sales or similar transactions in the future.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>ARTICLE IV.</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">OTHER AGREEMENTS OF THE PARTIES</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">4.1&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<u>Warrant Shares</u>. If all or any portion of a Warrant is exercised at a time when there is an effective registration statement to cover the issuance or resale of the Warrant Shares or if the Warrant is exercised via cashless exercise, the Warrant Shares issued pursuant to any such exercise shall be issued free of all legends. If at any time following the date hereof the Registration Statement (or any subsequent registration statement registering the sale or resale of the Warrant Shares) is not effective or is not otherwise available for the sale or resale of the Warrant Shares, the Company shall immediately notify the holders of the Warrants in writing that such registration statement is not then effective and thereafter shall promptly notify such holders when the registration statement is effective again and available for the sale or resale of the Warrant Shares (it being understood and agreed that the foregoing shall not limit the ability of the Company to issue, or any Purchaser to sell, any of the Warrant Shares in compliance with applicable federal and state securities laws). The Company shall use commercially reasonable efforts to keep a registration statement (including the Registration Statement) registering the issuance or resale of the Warrant Shares effective during the term of the Warrants.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">4.2&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<u>Furnishing of Information</u>. Until the earliest of the time that (i) no Purchaser owns Securities or (ii) the Warrants have expired, the Company covenants to timely file (or obtain extensions in respect thereof and file within the applicable grace period) all reports required to be filed by the Company after the date hereof pursuant to the Exchange Act.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">4.3&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<u>Integration</u>. The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section 2 of the Securities Act) that would be integrated with the offer or sale of the Securities for purposes of the rules and regulations of any Trading Market such that it would require shareholder approval prior to the closing of such other transaction unless shareholder approval is obtained before the closing of such subsequent transaction.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">4.4&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<u>Securities Laws Disclosure; Publicity</u>. The Company shall (a) by the Disclosure Time, issue a press release disclosing the material terms of the transactions contemplated hereby, and (b) file a Current Report on Form 8-K, including the Transaction Documents as exhibits thereto, with the Commission within the time required by the Exchange Act. From and after the issuance of such press release, the Company represents to the Purchasers that it shall have publicly disclosed all material, non-public information delivered to any of the Purchasers by the Company or any of its Subsidiaries, or any of their respective officers, directors, employees, Affiliates or agents, including, without limitation, the Placement Agent, in connection with the transactions contemplated by the Transaction Documents. In addition, effective upon the issuance of such press release, the Company acknowledges and agrees that any and all confidentiality or similar obligations under any agreement, whether written or oral, between the Company, any of its Subsidiaries or any of their respective officers, directors, agents, employees, Affiliates or agents, including, without limitation, the Placement Agent, on the one hand, and any of the Purchasers or any of their Affiliates on the other hand, shall terminate and be of no further force or effect. The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company. The Company and each Purchaser shall consult with each other in issuing any other press releases with respect to the transactions contemplated hereby, and neither the Company nor any Purchaser shall issue any such press release nor otherwise make any such public statement without the prior consent of the Company, with respect to any press release of any Purchaser, or without the prior consent of each Purchaser, with respect to any press release of the Company, which consent shall not unreasonably be withheld or delayed, except if such disclosure is required by law, in which case the disclosing party shall promptly provide the other party with prior notice of such public statement or communication. Notwithstanding the foregoing, the Company shall not publicly disclose the name of any Purchaser, or include the name of any Purchaser in any filing with the Commission or any regulatory agency or Trading Market, without the prior written consent of such Purchaser, except (a) as required by federal securities law in connection with the filing of final Transaction Documents with the Commission and (b) to the extent such disclosure is required by law or Trading Market regulations, in which case the Company shall provide the Purchasers with prior notice of such disclosure permitted under this clause (b) and reasonably cooperate with such Purchaser regarding such disclosure.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">4.5&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<u>Shareholder Rights Plan</u>. No claim will be made or enforced by the Company or, with the consent of the Company, any other Person, that any Purchaser is an &#8220;<u>Acquiring Person</u>&#8221; under any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted by the Company, or that any Purchaser could be deemed to trigger the provisions of any such plan or arrangement, by virtue of receiving Securities under the Transaction Documents or under any other agreement between the Company and the Purchasers.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">4.6&nbsp;&nbsp; &nbsp; &nbsp;&nbsp;<u>Non-Public Information</u>. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, which shall be disclosed pursuant to Section 4.4, the Company covenants and agrees that neither it, nor any other Person acting on its behalf will provide any Purchaser or its agents or counsel with any information that constitutes, or the Company reasonably believes constitutes, material non-public information, unless prior thereto such Purchaser shall have consented in writing to the receipt of such information and agreed in writing with the Company to keep such information confidential. The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company. To the extent that the Company, any of its Subsidiaries, or any of their respective officers, directors, agents, employees or Affiliates delivers any material, non-public information to a Purchaser without such Purchaser&#8217;s consent, the Company hereby covenants and agrees that such Purchaser shall not have any duty of confidentiality to the Company, any of its Subsidiaries, or any of their respective officers, directors, employees, Affiliates or agents, including, without limitation, the Placement Agent, or a duty to the Company, any of its Subsidiaries or any of their respective officers, directors, employees, Affiliates or agents, including, without limitation, the Placement Agent, not to trade on the basis of, such material, non-public information, provided that the Purchaser shall remain subject to applicable law. To the extent that any notice provided pursuant to any Transaction Document constitutes, or contains, material, non-public information regarding the Company or any Subsidiaries, the Company shall simultaneously with the delivery of such notice file such notice with the Commission pursuant to a Current Report on Form 8-K. The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">4.7&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<u>Use of Proceeds</u>. Except as set forth on <u>Schedule 4.7</u> attached hereto, the Company shall use the net proceeds from the sale of the Securities hereunder for working capital purposes and general corporate purposes and shall not use such proceeds: (a) for the satisfaction of any portion of the Company&#8217;s debt (other than payment of trade payables in the ordinary course of the Company&#8217;s business and prior practices), (b) for the redemption of any Common Stock or Common Stock Equivalents, (c) for the settlement of any outstanding litigation or (d) in violation of FCPA or OFAC regulations.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">4.8&nbsp; &nbsp; &nbsp; &nbsp;<u>Indemnification of Purchasers</u>. Subject to the provisions of this Section 4.8, the Company will indemnify and hold each Purchaser and its directors, officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title), each Person who controls such Purchaser (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, shareholders, agents, members, partners or employees (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title) of such controlling persons (each, a &#8220;<u>Purchaser Party</u>&#8221;) harmless from any and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in settlements, court costs and reasonable attorneys&#8217; fees and costs of investigation that any such Purchaser Party may suffer or incur as a result of or relating to (a) any breach of any of the representations, warranties, covenants or agreements made by the Company in this Agreement or in the other Transaction Documents or (b) any action instituted against the Purchaser Parties in any capacity, or any of them or their respective Affiliates, by any stockholder of the Company who is not an Affiliate of such Purchaser Party, with respect to any of the transactions contemplated by the Transaction Documents (unless such action is based upon a material breach of such Purchaser Party&#8217;s representations, warranties or covenants under the Transaction Documents or any agreements or understandings such Purchaser Party may have with any such stockholder or any violations by such Purchaser Party of state or federal securities laws or any conduct by such Purchaser Party which is finally judicially determined to constitute fraud, gross negligence or willful misconduct). If any action shall be brought against any Purchaser Party in respect of which indemnity may be sought pursuant to this Agreement, such Purchaser Party shall promptly notify the Company in writing, and, the Company shall have the right to assume the defense thereof with counsel of its own choosing reasonably acceptable to the Purchaser Party. Any Purchaser Party shall have the right to employ separate counsel in any such action and participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Purchaser Party except to the extent that (i) the employment thereof has been specifically authorized by the Company in writing, (ii) the Company has failed after a reasonable period of time to assume such defense and to employ counsel or (iii) in such action there is, in the reasonable opinion of counsel a material conflict on any material issue between the position of the Company and the position of such Purchaser Party, in which case the Company shall be responsible for the reasonable fees and expenses of no more than one such separate counsel. The Company will not be liable to any Purchaser Party under this Agreement (y) for any settlement by a Purchaser Party effected without the Company&#8217;s prior written consent, which shall not be unreasonably withheld or delayed; or (z) to the extent, but only to the extent that a loss, claim, damage or liability is attributable to any Purchaser Party&#8217;s breach of any of the representations, warranties, covenants or agreements made by such Purchaser Party in this Agreement or in the other Transaction Documents. The indemnification required by this Section 4.8 shall be made by periodic payments of the amount thereof during the course of the investigation or defense, as and when bills are received or are incurred. The indemnity agreements contained herein shall be in addition to any cause of action or similar right of any Purchaser Party against the Company or others and any liabilities the Company may be subject to pursuant to law.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">4.9&nbsp; &nbsp; &nbsp; &nbsp;<u>Reservation of Common Stock</u>. As of the date hereof, the Company has reserved and the Company shall continue to reserve and keep available at all times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling the Company to issue Shares pursuant to this Agreement and Warrant Shares pursuant to any exercise of the Warrants.<u> </u></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">4.10&nbsp; &nbsp; &nbsp; &nbsp;<u>Listing of Common Stock</u>. The Company hereby agrees to use commercially reasonable best efforts to maintain the listing or quotation of the Common Stock on the Trading Market on which it is currently listed, and concurrently with the Closing, the Company shall apply to list or quote all of the Shares and Warrant Shares on such Trading Market and promptly secure the listing of all of the Shares and Warrant Shares on such Trading Market. The Company further agrees, if the Company applies to have the Common Stock traded on any other Trading Market, it will then include in such application all of the Shares and Warrant Shares, and will take such other action as is necessary to cause all of the Shares and Warrant Shares to be listed or quoted on such other Trading Market as promptly as possible. The Company will then take all action reasonably necessary to continue the listing and trading of its Common Stock on a Trading Market and will comply in all material respects with the Company&#8217;s reporting, filing and other obligations under the bylaws or rules of the Trading Market. The Company agrees to use commercially efforts to maintain the eligibility of the Common Stock for electronic transfer through the Depository Trust Company or another established clearing corporation, including, without limitation, by timely payment of fees to the Depository Trust Company or such other established clearing corporation in connection with such electronic transfer.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">4.11&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<u>Subsequent Equity Sales</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp;From the date hereof until sixty (60) days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or amendment or supplement thereto, other than the Prospectus Supplement, any filing in connection with the Warrant Amendment, or filing a registration statement on Form S-8 in connection with any employee benefit plan. Notwithstanding the foregoing, the prohibition set forth in this Section 4.11(a) shall no longer apply solely with respect to the sale and issuance of shares of Common Stock in an &#8220;at the market&#8221; offering with the Placement Agent as sales agent after any Trading Day on which the Closing Price of the Common Stock on such Trading Day equals or exceeds $8.00 per share (subject to adjustment for reverse and forward stock splits, stock combinations and other similar transactions of the Common Stock that occur after the date hereof); <u>provided</u>, <u>however</u>, that any securities issued pursuant to the &#8220;at the market&#8221; offering with the Placement Agent be at a price per share greater than or equal to $8.00 (subject to adjustment for reverse and forward stock splits, stock combinations and other similar transactions of the Common Stock that occur after the date hereof) during the prohibition set forth in this Section 4.11(a).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp;From the date hereof until twelve (12) months after the Closing Date, the Company shall be prohibited from effecting or entering into an agreement to effect any issuance by the Company or any of its Subsidiaries of Common Stock or Common Stock Equivalents (or a combination of units thereof) involving a Variable Rate Transaction. &#8220;<u>Variable Rate Transaction</u>&#8221; means a transaction in which the Company (i) issues or sells any debt or equity securities that are convertible into, exchangeable or exercisable for, or include the right to receive additional shares of Common Stock either (A) at a conversion price, exercise price or exchange rate or other price that is based upon and/or varies with the trading prices of or quotations for the shares of Common Stock at any time after the initial issuance of such debt or equity securities, or (B) with a conversion, exercise or exchange price that is subject to being reset at some future date after the initial issuance of such debt or equity security or upon the occurrence of specified or contingent events directly or indirectly related to the business of the Company or the market for the Common Stock or (ii) enters into, or effects a transaction under, any agreement, including, but not limited to, an equity line of credit or an &#8220;at-the-market offering&#8221;, whereby the Company may issue securities at a future determined price regardless of whether shares pursuant to such agreement have actually been issued and regardless of whether such agreement is subsequently canceled. Notwithstanding the foregoing, that, after sixty (60) days after the Closing Date (or such earlier date as contemplated by the last sentence of Section 4.11(a) herein upon the satisfaction of the conditions set forth in such last sentence of Section 4.11(a)), the issuance of shares of Common Stock in an &#8220;at the market&#8221; offering with the Placement Agent as sales agent shall not be deemed a Variable Rate Transaction. Any Purchaser shall be entitled to obtain injunctive relief against the Company to preclude any such issuance, which remedy shall be in addition to any right to collect damages.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(c)&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding the foregoing, this Section 4.11 shall not apply in respect of an Exempt Issuance, except that no Variable Rate Transaction shall be an Exempt Issuance.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">4.12&nbsp; &nbsp; &nbsp;&nbsp;&nbsp;<u>Equal Treatment of Purchasers</u>. No consideration (including any modification of any Transaction Document) shall be offered or paid to any Person to amend or consent to a waiver or modification of any provision of the Transaction Documents unless the same consideration is also offered to all of the parties to the Transaction Documents. For clarification purposes, this provision constitutes a separate right granted to each Purchaser by the Company and negotiated separately by each Purchaser, and is intended for the Company to treat the Purchasers as a class and shall not in any way be construed as the Purchasers acting in concert or as a group with respect to the purchase, disposition or voting of Securities or otherwise.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">4.13&nbsp; &nbsp; &nbsp; &nbsp;<u>Certain Transactions and Confidentiality</u>. Each Purchaser, severally and not jointly with the other Purchasers, covenants that neither it nor any Affiliate acting on its behalf or pursuant to any understanding with it will execute any purchases or sales, including Short Sales of any of the Company&#8217;s securities during the period commencing with the execution of this Agreement and ending at such time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described in Section 4.4.&nbsp; Each Purchaser, severally and not jointly with the other Purchasers, covenants that until such time as the transactions contemplated by this Agreement are publicly disclosed by the Company pursuant to the initial press release as described in Section 4.4, such Purchaser will maintain the confidentiality of the existence and terms of this transaction and the information included in the Disclosure Schedules (other than as disclosed to its legal representatives).&nbsp; Notwithstanding the foregoing and notwithstanding anything contained in this Agreement to the contrary, the Company expressly acknowledges and agrees that (i) no Purchaser makes any representation, warranty or covenant hereby that it will not engage in effecting transactions in any securities of the Company after the time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described in Section 4.4, (ii) no Purchaser shall be restricted or prohibited from effecting any transactions in any securities of the Company in accordance with applicable securities laws from and after the time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described in Section 4.4 and (iii) no Purchaser shall have any duty of confidentiality or duty not to trade in the securities of the Company to the Company, any of its Subsidiaries, or any of their respective officers, directors, employees, Affiliates, or agent, including, without limitation, the Placement Agent, after the issuance of the initial press release as described in Section 4.4.&nbsp; Notwithstanding the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser&#8217;s assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions of such Purchaser&#8217;s assets, the covenant set forth above shall only apply with respect to the portion of assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">4.14&nbsp; &nbsp; &nbsp; &nbsp;<u>Exercise Procedures</u>. The form of Notice of Exercise included in the Warrants set forth the totality of the procedures required of the Purchasers in order to exercise the Warrants. No additional legal opinion, other information or instructions shall be required of the Purchasers to exercise their Warrants. Without limiting the preceding sentences, no ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise form be required in order to exercise the Warrants. The Company shall honor exercises of the Warrants and shall deliver Warrant Shares in accordance with the terms, conditions and time periods set forth in the Transaction Documents.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>ARTICLE V.</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">MISCELLANEOUS</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">5.1&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<u>Termination</u>.&nbsp; This Agreement may be terminated by any Purchaser, as to such Purchaser&#8217;s obligations hereunder only and without any effect whatsoever on the obligations between the Company and the other Purchasers, by written notice to the other parties, if the Closing has not been consummated on or before the fifth (5<sup style="vertical-align:top;line-height:120%;">th</sup>) Trading Day following the date hereof; <u>provided</u>, <u>however</u>, that no such termination will affect the right of any party to sue for any breach by any other party (or parties).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">5.2&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<u>Fees and Expenses</u>. Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the fees and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay all Transfer Agent fees (including, without limitation, any fees required for same-day processing of any instruction letter delivered by the Company and any exercise notice delivered by a Purchaser), stamp taxes and other taxes and duties levied in connection with the delivery of any Securities to the Purchasers.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">5.3&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<u>Entire Agreement</u>. The Transaction Documents, together with the exhibits and schedules thereto, the Prospectus and the Prospectus Supplement, contain the entire understanding of the parties with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">5.4&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<u>Notices</u>. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall be deemed given and effective on the earliest of: (a) the time of transmission, if such notice or communication is delivered via email attachment at the email address as set forth on the signature pages attached hereto at or prior to 5:30 p.m. (New York City time) on a Trading Day, (b) the next Trading Day after the time of transmission, if such notice or communication is delivered via email attachment at the email address as set forth on the signature pages attached hereto on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (c) the second (2<sup style="vertical-align:top;line-height:120%;">nd</sup>) Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service or (d) upon actual receipt by the party to whom such notice is required to be given. The address for such notices and communications shall be as set forth on the signature pages attached hereto.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">5.5&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<u>Amendments; Waivers</u>. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument signed, in the case of an amendment, by the Company and Purchasers which purchased at least 50.1% in interest of the Shares and Pre-Funded Warrants based on the initial Subscription Amounts hereunder (or, prior to the Closing, the Company and each Purchaser) or, in the case of a waiver, by the party against whom enforcement of any such waived provision is sought, provided that if any amendment, modification or waiver disproportionately and adversely impacts a Purchaser (or group of Purchasers), the consent of at least 50.1% in interest of such disproportionately impacted Purchaser (or group of Purchasers) shall also be required. No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner impair the exercise of any such right. Any proposed amendment or waiver that disproportionately, materially and adversely affects the rights and obligations of any Purchaser relative to the comparable rights and obligations of the other Purchasers shall require the prior written consent of such adversely affected Purchaser. Any amendment effected in accordance with this Section 5.5 shall be binding upon each Purchaser and holder of Securities and the Company.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">5.6&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<u>Headings</u>. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions hereof.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">5.7&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<u>Successors and Assigns</u>. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of each Purchaser (other than by merger). Any Purchaser may assign any or all of its rights under this Agreement to any Person to whom such Purchaser assigns or transfers any Securities, provided that such transferee agrees in writing to be bound, with respect to the transferred Securities, by the provisions of the Transaction Documents that apply to the &#8220;Purchasers.&#8221;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">5.8&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<u>No Third-Party Beneficiaries</u>. The Placement Agent shall be the third party beneficiary of the representations, warranties and covenants of the Company in this Agreement and the representations, warranties and covenants of the Purchasers in this Agreement. This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except as otherwise set forth in Section 4.8 and this Section 5.8.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">5.9&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<u>Governing Law</u>. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Each party agrees that all legal Proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto or its respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any Action or Proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such Action or Proceeding is improper or is an inconvenient venue for such Proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such Action or Proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If any party shall commence an Action or Proceeding to enforce any provisions of the Transaction Documents, then, in addition to the obligations of the Company under Section 4.8, the prevailing party in such Action or Proceeding shall be reimbursed by the non-prevailing party for its reasonable attorneys&#8217; fees and other costs and expenses incurred with the investigation, preparation and prosecution of such Action or Proceeding.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">5.10&nbsp; &nbsp; &nbsp; &nbsp;<u>Survival</u>. The representations and warranties contained herein shall survive the Closing and the delivery of the Securities.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">5.11&nbsp; &nbsp; &nbsp; &nbsp;<u>Execution</u>. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to each other party, it being understood that the parties need not sign the same counterpart. In the event that any signature is delivered by e-mail delivery of a &#8220;.pdf&#8221; format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such &#8220;.pdf&#8221; signature page were an original thereof.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">5.12&nbsp; &nbsp; &nbsp;&nbsp;<u>Severability</u>. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">5.13&nbsp; &nbsp; &nbsp;&nbsp;<u>Rescission and Withdrawal Right</u>. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions of) any of the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction Document and the Company does not timely perform its related obligations within the periods therein provided, then such Purchaser may rescind or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand or election in whole or in part without prejudice to its future actions and rights; <u>provided</u>, <u>however</u>, that, in the case of a rescission of an exercise of a Warrant, the applicable Purchaser shall be required to return any shares of Common Stock subject to any such rescinded exercise notice concurrently with the return to such Purchaser of the aggregate exercise price paid to the Company for such shares and the restoration of such Purchaser&#8217;s right to acquire such shares pursuant to such Purchaser&#8217;s Warrant (including, issuance of a replacement warrant certificate evidencing such restored right).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">5.14&nbsp; &nbsp;&nbsp; &nbsp;<u>Replacement of Securities</u>. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation), or in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction. The applicant for a new certificate or instrument under such circumstances shall also pay any reasonable third-party costs (including customary indemnity) associated with the issuance of such replacement Securities.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">5.15&nbsp; &nbsp; &nbsp;&nbsp;<u>Remedies</u>. In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, each of the Purchasers and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations contained in the Transaction Documents and hereby agree to waive and not to assert in any Action for specific performance of any such obligation the defense that a remedy at law would be adequate.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">5.16&nbsp; &nbsp; &nbsp;&nbsp;<u>Payment Set Aside</u>. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction Document or a Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or exercise or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged by or are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other Person under any law (including, without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action), then to the extent of any such restoration the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect as if such payment had not been made or such enforcement or setoff had not occurred.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">5.17&nbsp;&nbsp;&nbsp;&nbsp;<u>Independent Nature of Purchasers</u><u>&#8217;</u><u> Obligations and Rights</u>. The obligations of each Purchaser under any Transaction Document are several and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance or non-performance of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any other Transaction Document, and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the Purchasers as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction Documents. Each Purchaser shall be entitled to independently protect and enforce its rights including, without limitation, the rights arising out of this Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Purchaser to be joined as an additional party in any Proceeding for such purpose. Each Purchaser has been represented by its own separate legal counsel in its review and negotiation of the Transaction Documents. For reasons of administrative convenience only, each Purchaser and its respective counsel have chosen to communicate with the Company through EGS. EGS does not represent any of the Purchasers and only represents the Placement Agent. The Company has elected to provide all Purchasers with the same terms and Transaction Documents for the convenience of the Company and not because it was required or requested to do so by any of the Purchasers. It is expressly understood and agreed that each provision contained in this Agreement and in each other Transaction Document is between the Company and a Purchaser, solely, and not between the Company and the Purchasers collectively and not between and among the Purchasers.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">5.18&nbsp; &nbsp; &nbsp; &nbsp;<u>Liquidated Damages</u>. The Company&#8217;s obligations to pay any partial liquidated damages or other amounts owing under the Transaction Documents is a continuing obligation of the Company and shall not terminate until all unpaid partial liquidated damages and other amounts have been paid notwithstanding the fact that the instrument or security pursuant to which such partial liquidated damages or other amounts are due and payable shall have been canceled.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">5.19&nbsp; &nbsp; &nbsp; &nbsp;<u>Saturdays, Sundays, Holidays, etc.</u>&nbsp;If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business Day.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">5.20&nbsp; &nbsp; &nbsp; &nbsp;<u>Construction</u>. The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise the Transaction Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each and every reference to share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">5.21<b>&nbsp; &nbsp; &nbsp;<u>WAIVER OF JURY TRIAL</u></b><b>. </b><b><u>IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY. </u></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>(Signature Pages Follow)</i></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">IN WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 100%;">

		<tr>
			<td colspan="2" style="vertical-align: top; width: 3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>GENPREX, INC.</b></p>
			</td>
			<td style="vertical-align: top; width: 5%;">&nbsp;</td>
			<td style="vertical-align: top; width: 35%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>Address for Notice:</u></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3300 Bee Cave Road, #650-227</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Austin, Texas 78746</p>
			</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align: top; width: 3%;">&nbsp;</td>
			<td style="vertical-align: top; width: 5%;">&nbsp;</td>
			<td style="vertical-align: top; width: 35%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align: top; width: 3%;">&nbsp;</td>
			<td style="vertical-align: top; width: 5%;">&nbsp;</td>
			<td style="vertical-align: top; width: 35%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 3%;">By:</td>
			<td style="vertical-align: top; width: 57%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="vertical-align: top; width: 5%;">&nbsp;</td>
			<td style="vertical-align: top; width: 35%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align: top; width: 3%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Name: J. Rodney Varner</p>

			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Title: Chief Executive Officer</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">With a copy to (which shall not constitute notice):</p>
			</td>
			<td style="vertical-align: top; width: 5%;">&nbsp;</td>
			<td style="vertical-align: top; width: 35%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">E-Mail: rvarner@genprex.com</p>
			</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align: top; width: 3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Lowenstein Sandler LLP</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">1251 Avenue of the Americas</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">New York, New York 10020</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Attn: Alan Wovsaniker</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Email: AWovsaniker@lowenstein.com</p>
			</td>
			<td style="vertical-align: top; width: 5%;">&nbsp;</td>
			<td style="vertical-align: top; width: 35%;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">SIGNATURE PAGE FOR PURCHASER FOLLOWS]</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">[PURCHASER SIGNATURE PAGES TO GNPX SECURITIES PURCHASE AGREEMENT]</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">IN WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td nowrap="true" style="width: 5%; padding: 0px;">Name of Purchaser:&nbsp;</td>
			<td style="width: 95%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>

</table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td nowrap="true" style="width: 5%; padding: 0px;"><i>Signature of Authorized Signatory of Purchaser</i>:&nbsp;</td>
			<td style="width: 95%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>

</table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td nowrap="true" style="width: 5%; padding: 0px;">Name of Authorized Signatory:&nbsp;</td>
			<td style="width: 95%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>

</table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td nowrap="true" style="width: 5%; padding: 0px;">Title of Authorized Signatory:&nbsp;</td>
			<td style="width: 95%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>

</table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td nowrap="true" style="width: 5%; padding: 0px;">Email Address of Authorized Signatory:&nbsp;</td>
			<td style="width: 95%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Address for Notice to Purchaser:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Address for Delivery of Warrants to Purchaser (if not same as address for notice):</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Subscription Amount: $_________________&nbsp; &nbsp;&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Shares: _________________</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Pre-Funded Warrant Shares: ___________ Beneficial Ownership Blocker &#9744; 4.99% or &#9744; 9.99%</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Common Warrant Shares: __________________ Beneficial Ownership Blocker &#9744; 4.99% or &#9744; 9.99%</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">EIN Number: ____________________</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#9744; Notwithstanding anything contained in this Agreement to the contrary, by checking this box (i) the obligations of the above-signed to purchase the securities set forth in this Agreement to be purchased from the Company by the above-signed, and the obligations of the Company to sell such securities to the above-signed, shall be unconditional and all conditions to Closing shall be disregarded, (ii) the Closing shall occur on the second (2<sup style="vertical-align:top;line-height:120%;">nd</sup>) Trading Day following the date of this Agreement and (iii) any condition to Closing contemplated by this Agreement (but prior to being disregarded by clause (i) above) that required delivery by the Company or the above-signed of any agreement, instrument, certificate or the like or purchase price (as applicable) shall no longer be a condition and shall instead be an unconditional obligation of the Company or the above-signed (as applicable) to deliver such agreement, instrument, certificate or the like or purchase price (as applicable) to such other party on the Closing Date.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">[SIGNATURE PAGES CONTINUE]</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>8
<FILENAME>ex_635393.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html><head>
	<title>ex_635393.htm</title>
	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; padding:0in .1in;">
<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><b>Exhibit 99.1</b></p>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>Genprex Announces $6.5 Million Registered Direct Offering</b> <b>Priced</b>&nbsp;<b>At-the-Market</b>&nbsp;<b>Under Nasdaq Rules</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;">AUSTIN, Texas &#8212; (March 19, 2024) &#8212;&nbsp;Genprex, Inc.&nbsp;(&#8220;Genprex&#8221; or the &#8220;Company&#8221;) (NASDAQ:&nbsp;GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it has entered into definitive agreements for the sale and issuance of 1,542,112 shares of common stock (or prefunded warrants in lieu thereof) of the Company and warrants to purchase up to 1,542,112 shares of common stock at a combined offering price of $4.215 per share of common stock (or per prefunded warrant in lieu thereof) and accompanying warrant, in a registered direct offering priced&nbsp;at-the-market&nbsp;under the Nasdaq rules. The warrants have an exercise price of $4.09 per share, will be exercisable on the date of issuance, and will expire five years following the date of issuance. The closing of the offering is expected to occur on or about March 21, 2024, subject to the satisfaction of customary closing conditions.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">H.C. Wainwright&nbsp;&amp; Co. is acting as the exclusive placement agent for the offering.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;">The gross proceeds to Genprex from this offering are expected to be approximately $6.5&nbsp;million, before deducting the placement agent&#8217;s fees and other offering expenses. Genprex intends to use the net proceeds from this offering for working capital and general corporate purposes.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;">A &#8220;shelf&#8221; registration statement (File Number&nbsp;333-271386)&nbsp;relating to the offered securities was filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on April 21, 2023 and was declared effective on June 9, 2023. The offering of the securities is being made only by means of a prospectus, including a prospectus supplement, forming a part of an effective registration statement. A prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC. Electronic copies of the prospectus supplement and accompanying prospectus may be obtained, when available, on the SEC&#8217;s website at www.sec.gov or by contacting H.C. Wainwright&nbsp;&amp; Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (212)&nbsp;856-5711&nbsp;or&nbsp;e-mail&nbsp;at placements@hcwco.com.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;">The Company also has agreed to amend certain existing warrants to purchase up to an aggregate of 194,248 shares of the Company&#8217;s common stock that were previously issued to investors in March 2023 and July 2023, with exercise prices of $44.00 and $35.40 per share and expiration dates of March 1, 2028 and July 21, 2028 for $0.125 per amended warrant, effective upon the closing of the offering, such that the amended warrants will have a reduced exercise price of $4.09 per share and an expiration date of five years from the closing of the offering.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;">This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><b>About Genprex, Inc.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;">Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex&#8217;s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex&#8217;s oncology program utilizes its systemic, non-viral Oncoprex&#174; Delivery System which encapsulates the gene-expressing plasmids using lipid nanoparticles. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. The Company&#8217;s lead product candidate, Reqorsa&#174; Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC. Each of Genprex&#8217;s three lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and Genprex&#8217;s SCLC program has received an FDA Orphan Drug Designation. Genprex&#8217;s diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body&#8217;s immune system. In a similar approach, GPX-003 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells.&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">For more information, please visit the Company&#8217;s web site at&nbsp;www.genprex.com&nbsp;or follow Genprex on&nbsp;Twitter,&nbsp;Facebook&nbsp;and&nbsp;LinkedIn.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><b>Forward Looking Statements</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;">This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the&nbsp;completion of the registered direct offering, the satisfaction of customary closing conditions related to the registered direct offering, &nbsp;the intended use of proceeds from the registered direct offering and other statement that are predictive in nature.&nbsp; These statements may be identified by the use of forward-looking expressions, including, but not limited to, &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;would&#8221; and similar expressions and the negatives of those terms.&nbsp; These statements relate to future events and involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any results, performance or achievements expressed or implied by the forward-looking statements.&nbsp;Such factors include the risk factors set forth in the Company&#8217;s filings with the SEC, including, without limitation, its Annual Report on Form 10-K for the year ended December 31, 2022, its periodic reports on Form 10-Q, and its Current Reports on Form 8-K filed in 2023 and 2024, as well as the risks identified in the shelf registration statement and the prospectus supplement relating to the offering. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. Genprex undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><b>Genprex, Inc.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">(877) 774-GNPX (4679)</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><b>GNPX Investor Relations</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">investors@genprex.com</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><b>GNPX Media Contact</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">Kalyn Dabbs</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">media@genprex.com</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>gnpx-20240319.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 3/20/2024 3:32:45 AM-->
<xsd:schema xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:gnpx="http://www.gnpx.com/20240319" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.gnpx.com/20240319">
<xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
<xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"/>
<xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
<xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/currency/2023" schemaLocation="https://xbrl.sec.gov/currency/2023/currency-2023.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/exch/2023" schemaLocation="https://xbrl.sec.gov/exch/2023/exch-2023.xsd"/>

<xsd:annotation>
<xsd:appinfo>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gnpx-20240319_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gnpx-20240319_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gnpx-20240319_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
<link:roleType id="statement-document-and-entity-information" roleURI="http://www.gnpx.com/20240319/role/statement-document-and-entity-information">
<link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:presentationLink</link:usedOn>
</link:roleType>
</xsd:appinfo>
</xsd:annotation>
<xsd:element abstract="true" id="gnpx_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>gnpx-20240319_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 3/20/2024 3:32:45 AM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
<link:roleRef roleURI="http://www.gnpx.com/20240319/role/statement-document-and-entity-information" xlink:href="gnpx-20240319.xsd#statement-document-and-entity-information" xlink:type="simple"/>
<link:definitionLink xlink:role="http://www.gnpx.com/20240319/role/statement-document-and-entity-information" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>

<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>


<link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
<link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
<link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
<link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
<link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
<link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
<link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
<link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" xlink:type="arc"/>
<link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
<link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
<link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
<link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
<link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
<link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" xlink:type="arc"/>
<link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" xlink:type="arc"/>
<link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" xlink:type="arc"/>
<link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:type="arc"/>
<link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
<link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
<link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
<link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
<link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
<link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>

</link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>gnpx-20240319_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 3/20/2024 3:32:45 AM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
<link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Type</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Period End Date</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Registrant Name</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:label xlink:label="dei_EntityIncorporationStateCountryCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Incorporation, State or Country Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:label xlink:label="dei_EntityFileNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, File Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:label xlink:label="dei_EntityTaxIdentificationNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Tax Identification Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressAddressLine1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Address Line One</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressAddressLine2-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Address Line Two</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressCityOrTown-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, City or Town</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressStateOrProvince-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, State or Province</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressPostalZipCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Postal Zip Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:label xlink:label="dei_CityAreaCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:label xlink:label="dei_LocalPhoneNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:label xlink:label="dei_WrittenCommunications-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:label xlink:label="dei_SolicitingMaterial-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:label xlink:label="dei_PreCommencementTenderOffer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:label xlink:label="dei_PreCommencementIssuerTenderOffer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:label xlink:label="dei_Security12bTitle-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:label xlink:label="dei_SecurityExchangeName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:label xlink:label="dei_EntityEmergingGrowthCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Emerging Growth Company</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Central Index Key</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>

</link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>gnpx-20240319_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 3/20/2024 3:32:45 AM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.gnpx.com/20240319/role/statement-document-and-entity-information" xlink:href="gnpx-20240319.xsd#statement-document-and-entity-information" xlink:type="simple"/>
<link:presentationLink xlink:role="http://www.gnpx.com/20240319/role/statement-document-and-entity-information" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>

<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>

<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
<link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
<link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" xlink:type="arc"/>
<link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
<link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
<link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
<link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
<link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
<link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" xlink:type="arc"/>
<link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" xlink:type="arc"/>
<link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" xlink:type="arc"/>
<link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:type="arc"/>
<link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
<link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
<link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
<link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
<link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
<link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>

</link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>a01.jpg
<TEXT>
begin 644 a01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  R *$# 2(  A$! Q$!_\0
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0H **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140465951860144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Mar. 19, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity, Registrant Name</a></td>
<td class="text">GENPREX, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document, Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document, Period End Date</a></td>
<td class="text">Mar. 19,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity, Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity, File Number</a></td>
<td class="text">001-38244<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity, Tax Identification Number</a></td>
<td class="text">90-0772347<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity, Address, Address Line One</a></td>
<td class="text">3300 Bee Cave Road<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity, Address, Address Line Two</a></td>
<td class="text">#650-227<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity, Address, City or Town</a></td>
<td class="text">Austin<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity, Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity, Address, Postal Zip Code</a></td>
<td class="text">78746<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">512<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">537-7997<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GNPX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity, Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity, Central Index Key</a></td>
<td class="text">0001595248<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>16
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M3&K#(O*'2*\Z285DN]-NM#"XHB;XN*EG0SB$]=QU%%R@Z5,,I"@+/F[FGV0
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ML0(  .(,   -    >&PO<W1Y;&5S+GAM;-U7;6O;,!#^*T(_8&YB:N*1&+9
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M8*<D3?,\C@ 69Y"F& *G$4<P!L !0])T> \^>Q\ETWLJ.?]74_P$4$L#!!0
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M              "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%
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M+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( "U#=%@D'INBK0   /@!   :
M          "  <@1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4
M Q0    ( "U#=%AED'F2&0$  ,\#   3              "  :T2  !;0V]N
E=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  /<3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="gnpx20240305_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gnpx.com/20240319/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>gnpx-20240319.xsd</File>
    <File>gnpx-20240319_def.xml</File>
    <File>gnpx-20240319_lab.xml</File>
    <File>gnpx-20240319_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" original="gnpx20240305_8k.htm">gnpx20240305_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>22
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "gnpx20240305_8k.htm": {
   "nsprefix": "gnpx",
   "nsuri": "http://www.gnpx.com/20240319",
   "dts": {
    "schema": {
     "local": [
      "gnpx-20240319.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/exch/2023/exch-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "gnpx-20240319_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "gnpx-20240319_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "gnpx-20240319_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "gnpx20240305_8k.htm"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 27,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 23
   },
   "report": {
    "R1": {
     "role": "http://www.gnpx.com/20240319/role/statement-document-and-entity-information",
     "longName": "000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "d20248K",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gnpx20240305_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d20248K",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gnpx20240305_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.gnpx.com/20240319/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.gnpx.com/20240319/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.gnpx.com/20240319/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationTable",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.gnpx.com/20240319/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document, Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.gnpx.com/20240319/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document, Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.gnpx.com/20240319/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.gnpx.com/20240319/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.gnpx.com/20240319/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.gnpx.com/20240319/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.gnpx.com/20240319/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.gnpx.com/20240319/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.gnpx.com/20240319/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.gnpx.com/20240319/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.gnpx.com/20240319/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.gnpx.com/20240319/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.gnpx.com/20240319/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.gnpx.com/20240319/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.gnpx.com/20240319/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.gnpx.com/20240319/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.gnpx.com/20240319/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.gnpx.com/20240319/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.gnpx.com/20240319/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.gnpx.com/20240319/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.gnpx.com/20240319/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.gnpx.com/20240319/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.gnpx.com/20240319/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>23
<FILENAME>0001437749-24-008592-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001437749-24-008592-xbrl.zip
M4$L#!!0    ( "U#=%ACQ9*0=4(   :; 0 -    97A?-C,U,S@Y+FAT;>U]
M>W/;1I;OWY-/@>N=F15O4;(DVTELV:Z2;3GQ3ORXDC+)UM34%$@T2<0@P %
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M;"_1E)3:?M3*=2+BO27"'L#(4YC/65T,W^^!7JSL<H#&0X7/@/;*XX=?B&A
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M!<0A[N6203(\ KMCRS,;\<Q%1WDM<(;**_;TXD%_-E_LOB*0L)? + CX!3N
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M7YLDZ#"KB0_:E46<>I?^VK<Y X'5WU 1U]/ JU3G?U#N7^P"U5",9Y/U7SJ
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M=^S=CK-Y<_S^?[@IR+WO'Q!X,".%:$<8]ALJRIZSS2Z"A6N>V>/PR?I-GR!
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M^X55);N.?M"_#M366>UTM/5-:S"(T>N58=- 9HDF#'*8E&$A<1QL&9U=Q!E
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M?7ESVT:V[]_)I\#SG45\!<F2;">QY:A*EN7$=^+EV<IR:^K6%$@T*<0@P %
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M1>\0XYA L'I494-%JX63FLUAC 2F/*[**:J.<'2_!ZE?C': '-%3E2<7(-&
M=M6LK'BT8"+'Y70&5'/'Q]7"\63A:Q**T592NTN6I,B^4UAA(BOIJ7'4R7@B
M5KU7A&6 D:<PG[=-.7JW ZJNLJ\#9!XIO 844AX_O"&B 6$\X#(]#%R8YQ&0
M1_U[#NLI?&66]34^%,A21RGH-P5HV*"+OF5-.-K?&@YP$L[CX->LKN>*R%S/
M\2-Z)+ 9[IX$[CXI)LE$$1&.)I6BWV)4W'%QAJJY4(JY7JA,G_^\<[P#@V3%
M!9T9T=^2Z>P KH E^^67XYA8-<5IPBL_4\-JGE2+2 Z.G2]:XMW[CA68^:%>
MECUDFIU+' CSPZ>XN"PHZ.;H.)EEJ)_^!ZC*TF=>(X%A*7"3E;C++I!!-%NP
M>!%V.DO.%2WA5"4%J"RUE3C(/QX[P*SG%0P-%'JM6=GP1;CQVE?X>Y#9P),B
M]X%[80=,6BS5.)NG@AD"K9.F!+8A"=*47QO;[%^2;0(6TB*#GG+3I%MN6'=K
MS7K$2(:,9,P(+C'_)[)%+B'=CT2MU:2_<Y@,>*[1&H1#T>5H'3N1^X7+K*PV
MUZ!TP,E5DU6,XM,3Z]-D@4)]FJ0@O6&779R58&"@.E)$,S!-@X._HI]U2P/H
M/.:=HWVH8%/S5@\/9YQ2JG+0BG!+E=[V@Q=*HG2>+U!C&<WQ!5X_?08G[FR!
MQR7H-/).:GN:9'FT!4/)KTG3)*,SW/D#39>792,GGYEFQB<(^FY@M@6,PA(*
MYA%(E/;-KD2!,R<#NO+35%+E&1 &M:%L$#47\+#]071:)6BFP4LO6$?;RO!;
MN 'L_R%?[UTS BI469V)3'K;P$U)E8(D;$#O(['W&JRR,B7UH?/<30<X Y:Y
M WC-/"\O]/-(:X,QK3((T\)EJI,L96V#%4\1UK)(]$4R ;DZP0?X&@ I3WB!
MKYU$]4R-4"-.-<71%9.-R)KM6!98T8L,^06>48^1-%4T2NHSH"I2?._[ Z#.
MF0)-):V2BP*9+(E^!1Z$ 8!,#8PX3 K48W)5UZSAPNWTAWG=656.5#J'8;S9
M6>*-0%E40#!45B[W CN/AX<1N@9>EG#]N^T2=B+P?-[UKD:QJD"S@I<&TH-@
MD8]Q$TQ5"K_BE":@K0!1E2)&I[,U:A8S>I[]#KZ"HQ>$U']HDQ'[XW.ZZ&Q'
MW<'O+X"):V0SY!&X!UEZHH]LV9OH8:M :^K@$#SQG4?B';.S10UDRG/<L%6E
MVHIEL.7G8-7D[J-!DAF)!HH%#"/;.6"QY!RV/:V'49G-\:TOQ6<-46W43$#+
M.9[GN0B_#/0!X!35\7+K37],G%J@&X9%W(66"Q4NV[U #,BK\%;4$R")U,<N
M6:TW(A/8&7PG>@T2&\6P?CT9P)DN4&J>-S@^"G@A:\V"%JP8FK),JBG1)6YE
MTQKT#K0Z-1ZC00/WPBX"226"IYPWALEZ'R]S"P: 22<%ZFG )KXEXNS'5<]$
M9C^URZN91"\AOP0<(@7IG6"REU4*$N#,BL[5(YBG:BE;SV%E#<%Y OZ(6K[2
MP4>F("X&6H/=FU<X"ZVXK;U!]&0.)P4*.& LO(Y<#;/&C%W0$W8B$$W!RY.B
M2YX'I=C &HW4K$$N#OD'U('1NZ*\R%4ZX?,]005;_!QP*YC4M64A$+'G<("1
MUT$>!$H%W)+,SN+@.#):2Q<O!F0.C.(U>!3WI1G!$1"LW$R \ 6K.*(0R;F1
MB+!GAJL;,AO$V3).1MKK<=UN8(ITY+!F/]YY_=.3?]P)_*?DG16U=#M7XX9T
M4_,)J87T$0:&O&<].WUC'N9JJN(*=]V_P;UGX^VJO&A_B)(P>OW3RU]?V)#(
M$)W7>ST!$1/^6#*-#P^6W3G<D\")_^/;QV>5'O'UT4\GVT_>G!S]8_OHV>G)
MFT=PZER M#X0QSMJ_H7R?>' "$S5_=G[ S@C<PR^_=<N_8/[8-=,*N"A=-O_
MJK4 /S_M7@!<Q0\F_^FKXU] #0DB1SUTZ+:36@P<!@9:2^)81;[5@Z]R$V:M
M;YO=.7PFJFIR7F:I%G9I.1\V,9OV>-86933*JA&&\>@2<DE<E/,\U6J.=W:
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M;S5[CY>QM]/F5"-VVB8P7SNA+]F-;6DO-HO9A33V$QM8J/Q^I@IU+KIDD/D
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MJ=S@]HM'[@/ZA$CLT )M<"RZL\Z8H^,T>;-"&C1<BU%"<R<'+4L2@1>OL=D
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M=K  /_+D"3)(5>=UXMKK6.:.S%O'&.8, 3L<A['Q#)87KUUHCMIIGJE1&V&
M#)4("SAI#?% \[)-G)'M4;)KKX-SH;7.5X7>3*6W=5.PQK*1,%>*1AO& ;28
M"3F[TG$"OXZ19 I[8#6?HFM(ZG@"A"'F\:0Q+OL VZ%K+A8,I$-/$]>O5@=8
MFG'Q$+5=*.FG_SJXRS')A'4@K*N11_&8RCRNQ>2L>R1#"@,I1G$T@[:#$5ZU
MNERF';8=N*IN=W/*T\8,1G9 2TY-C&-33'O4S"F0Z/K*M/9U^_;'%^'+VK\I
M7];^QI>U\66M[\MZ\'&^K!=9C4O D82-%^O*O5@<9ADM; )G6N98U<.8%3JI
MGDWD,,B$.C)\]BOH9'#!VX:PS)[2_76T9<]1JA:6S]TSE ?4(W&5:T<*O.T+
MAK8 #N@\SW^&T>Q9%^7S2@HA,E>C=!'AZ+ARGND6# ET1T]%F8GDO1%;VXT?
M.9FP;C&Z=T^K##UF)"&IN=6=GBQ^B"R7J#8!KIU+EW8]IX=(YKVNGE$E<7 *
M"M9GECB_(]7>@G*BFNB_RWF%J%A;+_\G4HR19;*0,!9Z3G&V#AIL-NY5=@Q[
M6>K&0;!@;YWLI%\)SEFGH!U$+[$C6--PZVI<T..D/NLPWM-2<8:)1%%=*U?X
M4/#U=*Y4:IJ!FMR$RDPI698RY67LA#HIW&SCH1ZJ6#K8R@:Q8[1U15"=.^[M
M1+^[[G7Q%9J,%<RNL6^H$3\"PP]KT_3VQ40,<OKI.>N]V]5_;7]K-)!>XOK1
ME,@ACN+NIFWRDJ1U^Y^=#\2]22*B*"7LS!+-)6[@URR ,C1N35S@%0X&)L5F
MBUZ!*1LH,+^4-6P5,/C&('F?*G2SC[17_@4"19@:03=4YUF(HQ)6FATO:*QJ
M$U=E,.40,W=LRGB7529;#/B<IM?P]%)_>E-O>CZ65&6S(L&LJ!I.-]+%H;8$
MS]],)D:AFTXZPW.8PDP@IFI[6(5I(0UZ30'S\A?3C7B#]I;.9+J:\7*THFXD
M#$3[J"Q2*0 , FKXD80C_ I/ASPMTI!_7$B*[D3?GP_3D=8X2QQU;7(C";-W
MV*V08C%%*JXR3F83# \[4:)*GJGY6C/>B(,K0$=W>GPFS;S"A-4X>HOYP O&
M)\OX-]6,O$;:E#Z+:SJ;E0C(DQ(XC7;K-"9@2?JAV;)\GLZRRO"E.>_LH4#0
MNPD]4P)F7E L<:-) J/(U0,\C,9LHJ374A( >8A64$?TP@((ILN(\<'. !LF
MN]*BO".=/9Z*R-W8S$WT_7Z+QM_=ZY]I_]D;=R00NJ=<JQM:PZ(=8UR5!I.C
M>)%=)CI?"HF%] %3N'D-K1)"#%YS'JB1#WX_KI9.Z^ _>?J?IW;H?-E _<@D
M<M/5[DN7"YCD4PH3Z[=MY(BN)9Y7(3YX25X$,$"KB9LRF\XY_Q=',@$\A57L
M6/L0OH[.X_ 56R=V+!I_V[G@OS(M5D/G<)[K=&J#FJN1*FHMY^R$!.-&8W5[
M1ZM,4D?S;.VFK:1 FUMG\HI(UK'M\ZS,/6'N%#CDR07#[$_F^GQW*EI8W$]=
MO%XM=U\DU3LEFJ2']&-93J:;8Q B7:J/)C:FMX*_@K@F4V+MQ:N4Q(IU(,=]
M<(;)%1TH+9=[#.-=+G0Z1.<Z]B4T8)@2<Y?LUHXYDQT3GB2$C+MAH0$:L1E5
M@=TWZMI SA#^'F-H$">^1YT9%+:" ]>\3>IH1/!KK7B6#T*MY8 RV?9;3E=#
MSH3R[_!BT P@POCH!+Y75B:?VP9V:8!-A]E/$^.Y=U,QGGN;&,_7&>-9IC+M
M?]^_]T[$)5>DUJM'!2MPLETDA!#+12@B>-%][>;1=.6ND#FR< P<!Q"Z)V]V
M*N"'J&,$9C+<ZC>':,Z V29G<E;ZO5%<Q#_NC]1;1>658;8[O=O*'Z^HUY9Q
M&F"O\S)+V<VAWI$^01\@6<HA:H^ZZ1.HG52KXR [B;#'2KL6<A(<3'/10N6L
M;HA90/)/2E!?QPGE3M4U'/369U)5='@C@<NQ589X!"?/U+%#]36ZOTV7FL3V
MK&[0((IKH^N^K%M65Y(&GF#_K)Y@/1-B<,%Y6E%->]O;BX^=J$)52>X4E&%>
MV:0D-FIY8=#Y*HZA2C$2/+4<]<%)^_3T82F]721DHS.-Z01&C6+=9BV2E2MS
MX,QNGH)N/>9IJ4M4TX#F5(^7ZC(X]_7Q3JVPX!+G:L+9VL342U67'G+TJ':!
MPL7=Q+# F&JQJA$GB3N*MQHC"Y"APY"\SHN+MI5(82J,-)5^RE;@U!J6;*'1
M1T5E1J_AL$P7.H/T3]BL=9H9E'9&$C=4C7V-7Q5Z;0T-D:-Y?[*=XT!]==@>
MMTYKNM5GS!-I7,PBQ_%[L541=M_%Y&:+K*&3M?K2^];KFV,K67VLCZ[C:SFG
M<J*CX57#:R[32H)AW+FM5W$T/ A^XL&SA+>_=@[\))!!_^T0VJ95$,AR)HW?
M0#<I]/%$SA(3]-"USR#)L"17\)'YQ(73%RR!ICLB8W-E;<7]FCBXP,3:1C[2
M<+<;SK@49TS6"06^P>@6\T5MHWQ:UQF]*\J+7*435=NS.<3_&8D+?^7)*AW:
M&R>/5()O7A\W$_1GR'J.4'L1[IC5(NGV8%] AR%)TP4=K)0:#@(BBJ.Q0L3V
M7)J;@-U7N+IPGES4&PZ[%(>=#3I*,IQLD(+,K$H !F;81%:8["46(,PKYI%4
MP9-18]=(#7E"9X4#[&!8RH:.;.FBL!W6&3J*NIQX,Z4SB))(IJ/CC/P<G2=R
MP4B\ZD\PYD9NIHE%I9<<$T)7K=G+B6JRJGMR.@PV1@#ZY00XNR6=:5CDF@&L
M[2(M<5?"& AB "2J33G'PJ+[] X:BTK!2@F[#DG19@2&*$VFR4358<9U6Y?
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MXO,XB.K?,7-[)4T\$X/'D=CO[S_TO&_^OTF:/]J.7ZJL,.HZ$C]G\>XFIIN
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MGF"0 6.(_^,A_1_\+IN_7X)M4^4/PJ]&$_#CL_@$X"Q^]/#?O7[ZLJC>[YP
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MR%T&!R\9;A;65/A$6'-_<M,FPG,K?79O=DO-;G_:-Z0_L>NFZ$2])A_!K_H
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MQ2SLO918BG"6:.3HBLA-D Z6X55^4+0^0!X.AAU0W]=@?6)3S\BG@/4")Z)
M9,^#Z,T10A@"!W$XI.+Q3^T?HFUEU13.\*WMV?D&=:FL;'$I)Q9K<I680Q:5
M@X)*9K(?<.N%(_)5$[F(VQ37A8YV'N_DSV(UFQ!O.Q,Y:?6I<(CR0';\[Y3?
MJ)AR\6FZK^FQ6<%*DM_MP]5U]SFZ0I89ROO@^TB'\/A0AYQ20_I$:T-E.$X)
MO[&7B!J78)^M!:]L"XQC-?VFFQ.POJW+*U/AOV& @;*OXESN<#L#PKY0VN7S
M2E<=55#P4HU<20WRX]2>NET\/"YH:'678$STJL:4K!=;#G3.0W/:D$,2B@:
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M@]"UM:6F=3GNC-6,Q!X&:G.,2C\Z)CSX'JQV8W+9^%4^H\#D=T\*''P"!Y_
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M+,7*_<9L<P0_\?=*T%@'0I\*!2AR608K%&OVU%MU;-E7#W[IU^AL>((C(5B
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MB7/0VV*!U)L'AZ-89[EA(MCWHB@.K:AV&*X1+(B05>XX?,,>6(H"WP-T.W%
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MC1[E-6I1XX+,(7YFE$Y%:ZH6Y3>B;@K8&N 91LLHG0(;+!2"YR.RB>6:QI9
MP\BW9PH'G&%65D5VHUS:8]DL]'%/T75AXD0:TH_&!CF$@"6+PT^%6X+$IT,$
M7$QO85FX,;GIFB,-+K4I&,\8EI/V3"UISSC_I8GXAYP"JHC>5;":6T#(PMP"
MI0REOA*K3]''&RG1>NAYBJH5YX^!+'&8<\&F?[4IA]="!]R6PY^3I!=JWG!V
M+"I1@6-"I=Y#GJRNR>E&'WR8#(!(A!"#&8]0#:X\I%\!(Y7ZN*"?XJ[N+:I"
MMI-.7K5,^QJ)H0 ;Y5-%G@)YX2K&.)%&2@F/:J>"VC9B/FT5 &H,7A=K?(!
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M2;: 0ARA:PACL%0!W;.)\7V5 :0(SQ2M*:DT4YTE'=&6LDM-W/Z4HI> N"&
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M0A+JP>V]@V*TIG?@QAK&A+(K8PPO@8GP>O]T/R'SGZE>AN5%@>1]$(,OT ,
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M96&M.2I(8^>*MIYU_N"M.8HEU>H-'X*2Y"4W,LX3PY:H8$JHK]<\'>AMPL-
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MI,>-#M^<G80S?RVR)MF*_K%11,F=O'+&$)A\D& P8/>9A.N]YX10HSV*9%
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MP@:ZZ<):&[CW[S\^?[)@W[_I'_PR.$F.7R3_?'WR6W)V<M _Q# E2*.<NV.
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MI1JJ]$(E?;T/^%\$%Z1U%<55!7.KPC%^+3+8\=X0:17!>Z%&!<^:SXH\PEM
M*$[A*3ELJ?G@3]!^HKJ@+[)T"B<N*D-5!-<JO8/P4OP>SF4XDNGKB2I5FL<C
M>!9L^QHG7T_Z45S#Q8NHAO7!)\"$^1*\&TY"1?<5HW#JK7O6>Q.<PAQ>)8-'
MP5MI>8$O*/<D$6A3HWF6A0\_A]>%J>*\F\\=S&O@BQHG6"J::Q^I 82IAF4Z
M4+0J./AL#O(CAJF-RF**BBGH !_@#,F'N_#:T0N5Q9<@NX!&Y:PH>;1@(D?%
M= ;4<<?'5<'Q9($K$G_1=ERY2Q,GR(536$DB'VG!_:B5P42 >J\(Y(:1IS"?
ML[H8OM\%15K9UYF5Z5#A-:#N\OCA#1$-Z-,=+@1" WG4O^:P;L(_9OG>XD.!
M+%64@**4\]J<L9X='6P/>KNWL,D;._K6Q<W]'[LG!VNJ";:/R[G+LXW:?LB+
MS)^]0&KS#J5[HJ-XEJ+F^6]8 M[V<]PIR-#(]06R_26NF%XGWM>ROI/X0M'"
M3E6<@[90V:V."XIBBZ18S*L[+V%H(-1;S5N'XU(IXMM@)S2O\#=%0C9?>&0#
M0P%3CFE&LI>,:-+\7,(<@9)Q790+WM1UL6&V*S#;@<-L5]8.YL^T"*"G?)MT
M-_]W*+[.(L2]I7O;"%<0SXXZL1NY7[A;@37B"K0).*HJLJ?1C>+)\6F\0"D^
MC1,0U["++R<%V ZH9^31#(S:X$0OZ6?5.-I;SV_:FWSE0('08%$2GL8XI41E
MH.[@ABV\S0TO%$?)/%O@(3^<XPN\??$2CMC9 L]'4%;DG=3.- ;58!N&DE_C
MNHZ'$Y0L/4V7DZ*6H\Y,,V6%"%U!,-L<1F$)"/,()%;S9E=B[4;O4J K/TW%
M998"85#-27M1?0D/.^A%YV6,%AB\](*5K^T4OX4;\OETP-=[UPR!"F5:I2+Q
MSFJX*2X3D+0U*'0D5M^"P54DI"^T'K1)#V? ,KT'KYEEQ:5^'JEC,*;5\F!:
MN$Q5G":L7K!&*8>!+!)]$8]!;H_Q ?Z13]H27N"K(U$U4T-4=1--<73BI$,R
M5%N6!5;T,D5^@6=4(R1-&0WC:@)418KO__08J#-1H)HD97R9(Y/%T>_ @S
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M6J"#>:CPY,U ES-QL2R^K'HX42*V,]<^^X+C6N;JFKZ\FT'M2.GXWEY\?G;
MU?@W#_,<3K.W5@]2_O$EXP.E\V$Z@Y?5,WD=E^]!F8TI^  G,<N-YUE1H- 9
M1[_MOMV-MNV99;[Q8_[&0<;1!Y<@Q@_,[.(0[%-8W?!>,B=WU3J\TF \Y%O/
M3:=]@!((H+N=A -8_'R8S1-6(,C]Z5UIPRS#K&"=Z6/FU5N]A7 J:8N\N9(D
M:7B]VDG=I-F2BS]%,'P\^<)M>AO1VZ_?Q7-P2RZ>@XV+YQMW\3A:FJ^0=6R]
M[>=62VNF.[7XRBLQV"2J3,K!8Q1?=TZ0W''"_^$3OM-V<7QL SPXX&# @XHR
M'[M\#A14&F*0A\Q]/*R=+,G&Q7*HF:==HKO/M];(AV<N*&/K=XF;<>B-47XE
MH_Q5,\A3\DJSJDZ+TT)FCA2AH8V:>'<4JXT;M%9Q'[2*[8<FG\3)>#L<LN>W
MD?= -G@=OU=:E0*=(P6!@(H+%B?%0_@=/DB'1M?5'E_@8-0[C-? R\ERPX<T
M>;:JT-K!P=@#5I$CT$3LV18"7G93'#;L=]5$.5$>C67DF"PL!/K&7XAJ<%^;
M2$-,LJPI^TD97^DH+:M:K[P-B,*Y/:^T/".-&XLB4*E-6\RPE*R)/,I2.FI@
M<*0+1RKCP";CZ0Q@\K-.LTXG\9#5!?OA7W-5B0N9O\@5<G?M&)CXIKW0'A4K
MT$ML6&_BG8;C]H"BZPV;BY*R'SZZOQ?%NU,P+9%%_K<HWT=':<W):SUD_P>/
M]@ZB6=<5/;##3>  "/WF_.C_/<=9X2]_-#T7+D797.H@)@DELHG6H& PJN<.
M@@D..WE TMA;R$D+*I-N&0'MU1'S0V46WWMZS,&JW*X*?(4RZ"VHD]&;&7PC
MB[U-89$JA5T;8][6.,XE$8D\\V.5#S$5:#A4XIDHJ*1A-,^'M4X4X$'P6YY3
MCTD\+:J:')@@7RT#=SO7J\),E\("VXFL+8IXS".B<QG3?:J^1/33$H4$O@<7
M8M!QWOYT\A"YVQF.=Y0@,T5B!!>MC$%N8WE$!@*7CZ=Q420X#IPJ(@'>VL1E
M&FT:_UF4R)(I/@]/"BL@G!.'5L/-I,%5Y/@$,(K)X4#MQX\OR:OBB8&WJ \P
M84D!XEUJ_,9N3$>G&&U.BX\[+5 \?(D'11(#/:.+(IM/4=5%TQ;%\X4J82NO
M.$*N)/6^U7/C!DB[.5 V!\KF0/F67*KW;\FE>G_C4KUS+M6/10-@>M "7*$,
M?F6Y__[/J_=AL^;_ DNEAW$F]]3%[+',[V<9%"Z_51F2](C>WQ&@P#KSOPN3
M!OWTM8+#(A?W4[-XSWF?=8$2O@$SH,5_O<P,2#O+*:ED5VK?FM[LW]%M'287
MA64#0S0 VGR/MA;!IHIQLAZ554GQG)SEDC,$A_.P1-@=G32 KE!,?6^/O0L>
M0:*X>,!\/H@S\I[JN\F+BE-_H<@KB;6YYR70QV:_3D"$CR?T.+D(GXY5=5CB
M%6-!7W0$=Q0)+$]4+4 AG;H9!"_>'1[YT <C5\\P)D/,/F!,5V#7/ZG2\CS2
M7R3/XK!G4WEA1$Y>Q-0I]N!*4B65!% ^W@PUM]H0CF(/N57APT!%P:F+59QU
M7>)G4Z*Z^;P7A> '@8\XNDA;?=]4B5GK6F]XLJ[+LJ67[9-PW-52^"8$-6O-
MRJR^3E^%&$L^TX3,TC>&07<TIVAFM3F(%E[DWP_*Z**@)"F1$+9ZSR>J3+:]
M M'D,>BT)?R :SM9@>XN[K20%]V%K>T#2R:0+NKQ4B3HJ>%Z=59B!B-*P>EU
M59Q^PBM&V\9Z70IB$1G)&()V[+)D#$G11DUGL8T9DB#B -NP)$ %L(-*D$#R
M,.-1$=M #1%L#A\R$28>24%8QWXA20>_S"1A5_.OLVN;18C]*"WE'A0PA9]#
MLWR']KG(BO+(D4]G\8+6:15[N-G@L@V&IOJJ(4$(24:CTMB:QMNH=;:^K]7K
MOQN]\D\!,)2S*DSGAF4RM<W>:=@6T'-RL9?(C26,W/<FQ$PYBQ?^T)0AC*M
M2019^J]YRI 823R-QV)IDU,)$ZG X(ZS>L$25<7 </^YWP<+J$6D.O/W):9U
MD"V-9EPU(:S7A[GLD4_%E668\8;4%X?-?QXT+]%819,4V* I!U=0N6=IT;R7
MWGS)S9*%U[R,@\TV]0R&$%:![\" PC)1EZJ^OB9Q6GA?4UP:&VT"CG>6%5*
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MEEHFIU\/5!EX07*"?T!%V_CU+0'>& +8?>$A U-WL)ZGF[UT,T<-6H?D!YM
M1]BVIH.RX6Q;S1[4[((E;J&&R4!"3[]:'@%=$S:OO=2%X_>"8\ D,V5JW&40
M.^[R;(#RJV?#C^W ],/=%88"#!I_GY0,D[K6(5I64]GNKH#6\$4;J4V]BYT9
M;HX<3H?*B:[.G;E1S[:<KZG]N=J=ZB!)^T$F)[+>$<$QS_#XZ]C$=,&F\RI;
M[,T1 \B9N;MR,H^S8ES,C>GIW(68<[';4/:ZJ>SMNF-NR1$W^M.JEBACWT_O
MUNQ@,URP:*55#AKO!1SQ0T0 %T])!UQ@MQS3[HIRG@F_E 92O/+PQ&LG=)?6
MLH\<],)&TXTP>T%@7#R7=!@\UXT']&O)IJ64!@R ?\RKV<R=JLC0<$1)@?U(
M=#<N4BG0OT,T"-J)P.(W:$NDP%F 6M(\Z#OYC_@@6%^-E"081YZT(E>@$J]7
M:Z=Q$C_;Y&D48F$U;V.+MO"X?X C!59+;FY];AR475(LF)YU/_(VP$6(DK0:
MEJHM&T2O&C55K;24:JUP"_,SI*2\><1_A60E5RH5E4GBBA&9:Z@._8:7TDFS
MS@LWE0(>>($VX4).#DI&(S5T"(2(APOCS/:([*48<MS>78+8!)%8G<2\GSFY
MF7&W*-CI)'(XM<]99H-)=&.R[@8HU534&F= FIN;FHT?W0JZ=O6M;\T?=D=G
MIJCQ*H_AE(:117P29()&(H6+9L5%=NF03]4<(VR,7"62U:CE#@ 41W=DY8Y,
M6I[77LA^;),*8]-@5W=/['/Z&<R(D %X1G-8M"%.II@#]Y#3W8^E$,3!47A?
MD+73O*5NIK]BM2&%7DD16$O5=M;!TRQ^U[%9/0^T.$LB9Z/*H:VRUVG2Z=:A
M:D[%1V72,2*G,=K.Y[62VWST+N\E7K%OUS:VO1+_M4F"#K.:^*!=6<2I=^FO
M?9N!%%C]#15Q/0V\2G4V&642QRX8&<79KO+^EPZH('M$G"3;Y2+?L4%Y)0PM
M__Y@]^'#O_SC[P_IAZ;'5=C4RZ5;LAXK@$C6,_;<%#O)=Y,-&6+!32F/F(J[
M%2=LRN_K&-<M_6)]D>P78*[SR!1G*J%/G2I,1+\IF@?T7FY33U36%=I<01N-
M!E2@BC^G=4$E=[$;'>;.BH@ZN(IJ)GHT4 [RC>W-_>/^DVH^6^+VS$!,[(A#
M?_]@[R^/MYY5]9-[<).X?Q._&E\G92[K;GW>3@734=BQS^#[NIQ+JY@4$W#Q
MP-&!;0ERV?P879H+-Z6PBBB=,?A9+[JZ 7B4IPS<LJ3U]R>T[3<CE&!8+ZS2
MUO2E3 !JVEB186,&1]A&:A6Y:MW$V+;6#]>43Q$3GD]V3E.:SX0D8!TJ=']A
M+3WMUBHM=>(HT!KTB(S;(X?.4VMK\<+8OZL6XRM<(V)-=C40=&=5P> 68L47
M/:]\P05?&=<)394\I-S8O,,%NE(SQ[Z9&2QQCL>%WS8S19NC<2I_6>AH7T.P
M\Z=;"G;^M EVWKE@YTWNK#5QODV/$ J<=667+O\O)G; 48K ,(<FG[*R8(QW
M2:3<:=SUN+5SJR$RZW4O4JK,2-CR/9ME:7MI<-]#3X&CFSIS^SXB1T?DCITS
M K[BE!ONEZKRQ M7TJ&,UR2(_Z,M&#R#G;\K:D-G]%*T?GS=M'1\^U+-49C?
MG)HMQ_;2%2YIWJ7Q,A*1H-.WM#BWT5P=3\))M!@6*LR77*[^]B066LT'3+)J
M'?L,E",*66 >:=E0Y_L2\!P6TP&H))57A8C%?>0APD0GS/+C]:J0%WI7&+N:
M(AI V^#44O&BQ]0@3$?0$U':,M2!N!R[/#_L1I"OAO$LQ31#GF-H09,#P/-.
MULV<:9N"ZV57QUY6N<TFA]=!+:APL//6LIBV.;!'2A.:'?-R80BB2SR[K"HI
M&N:D=++:/#\M^^NY=?G5)[;<E+-C6E=MXY%K!D=MTC HT:S]RU"Z(1RW>M9F
M;"=X4/A@C> USUF?3]C <_+O*;W:3\9S+!;L865F1^B&UKYKDH3CJ81WF&A@
MI-:0B9-;6+4VG&8?K",(/;%'6=17F93]GN;5@%42$5*1=L][W_0,"'?@YG"]
MTN$Z6-$6_6P^J- Y"LS'>!O1&U@LS#"N.G$0+/NV0V<0UU)@@B6(<R"[I\N8
MREG[6MH6U"HAJ^CBKL@W<03/TRV-J=B%?RDELGW/>ZD+$-A"KBE;&_O\Q=I(
ME#VC-X2$\8GMFM+2\:\#^0SVF@4K:2G@=V%!@NJ>>"AY[Z:NB'T73@J3-N*#
ML?J!* J^;M89#6TUM8R:!'7.6%A-3JVUY#,_Q(I7"C^#J.F6L]LZW0&G7"::
MGUQOA"NFV0'C^IO;TB76\)#UV@XMXW N='U[K#D!X8-!W\N-!!VS@]MZ"LM(
M8T&W+TW!0""Y+%WPW+X=W/5VM_-B%_5-%8CCZ6^9[\K)1MMK%J:T).RU>&]L
MP;-&O62)3^I1<WC)%1*'4.KM%_8 ZVC>2K=0N-VLXAM6U/DS:YN515REE]TF
M@)3V9#N&).^,!KK.KM4C]6R)TO(9&96%]BO2=Z 6Q)N:!X0*#CHJ2F!B2T4@
MD(BN69L%D[H=7@Y.0OG4);F#[2J_!M_:S[?D6_MYXUO[-GUK'ZM[#E?HGF]!
M#SM%/>R%ZT1AM?/%G*K<C-QJ@"/[?IP&[!;+QP2-AY*.P*GNM-OP[P0^'7;<
M !LH/!L]?5/4)N<"BB>M/*S[GO.BGI>YZR+P_$SK)(>&\V7H\4K[F,(LK+[5
M?/';&2M:=D:Q(0D\9(;Y#R-0ND*[J^] [Y>*%F$L8,.8&,B%IL['SDRD)-&!
M]^KYZ%?N^OLJ=#L4LA\E=U,04 >P>5^2)]G56F"53N!.2VL_6#_9H0*Y<$7.
MXR15"ONY;91MJ^RV*]L-NM^Z*FU74A(4FJQQ+0KT?ZVA.GNCWA'%.=PDH=HL
M,^O2GGVOZ4KE><EH/9M\8=-#FS>M5IQYJD%T^G;UZ/8<ZJ!-"2^88LQ?2=TO
MC:!PJH&3$+&W9=<Q<)B/,'>-=/3D8.7,[&ZCZ7X-YL/#6S(?'F[,AXWY<!7S
M(5EA/KR$98VGC.9Q;G5+'16^8B2X;XH_392.@5Q8C"( (?]%ZB6F"*-1P;G/
MG(KOZ+>5A#S8F3U5%.SDG/>JR+ [D"-6+0@$5K"6$J;,W8+/OFW)Y .$+")T
MX*>@;96+7O>,W=F@+[ /S$!J<98.$3<'#S&-Y](WD"E]3@]>:)>GL98(LT27
MG1#^*89PD))R[@A*3UOBNQA6EH8Q<;*2UL]-4O9M$:Q^0??U^@Z\Y8@F76O(
M^A$37>DT>?YD6U>V-+/3?:)3;P]]?/H A:QD.IIE0Y^4!H.L-V%<P\[+F1&,
MEAKHQ%&K[4: 7843O4 MQW0EXS[/-G+O3.F'O;\8%I6U<".J869"R^47!7?A
M!DW6P!\/^3:=O1#$M2EZ_EGV4-,<!7,E:"\.U[!);3[KCBWSYL'5G6=5H4/>
M=F6:JTW67[<!86*<A$2K2T-I+SLKGJRYRIR+<)W$1-$SGTZYRLHZ"_BUS1:*
M=0LAN]\'\PI3,2HO,+O231$L3[^Q..QKV"%?@Q60K:Z$GBX5<W<G7LV547"Q
M+8L'[5MWX6F_6GPXU2WLCVB;O!+&\]%Q@/D!1(D,L@UH8K7=2 X-.ZZM#P%%
M^9T.=#[B>R?VLG4_^"C0/E"PM,8B@F)=5ZE<0+>.E^XO \!>[<O +>"E>1?+
M01I[:Q;URS1LVC,*#N*@$(.K*!O2,$57HNY%6LW+"ZX^<.X2X V*J7.,/<Z"
MC.8@X'QH$I^/W,N\9KJ\OFW9ULM6@'.+W+3N->AC0<27U8FV\L?2N5S_@C>+
M"(U;Q8?3;&3++$O-BF<HL<LT2!?2]1SF/3N6+?+Z.%JPZ:[+S2;TD1-1^+,@
M;Z:\K=IUK;6;,'DQ_5M>'J8I?HO.:7*O1.S72;.5$@XIC#1-?:AR&.3+19S-
ME5Z1)$4M#64<'L[P9KEM_-,Q'N6 +E/&L"1"JNHF!;V"04%8JFJQ4]"T=Z/7
MZJ1DNQ=MH$<WSN/&%#JI6.NA*WL&=+I[;:?590O>W9-<=H.(.?+Z+9:^<63Z
M KC\(P@&5N*A'N.(L#,SQ#$-8806;AG@[JER:RL=.\)%[0^.5>F6[E)#LS7K
M .ZL7Q3#.:<NK=5*)4C'2WJ^9BAUID9MHJ>."!"3XOAD% V5W0P+VVRDL&V8
M=9^!M62C2;];>F9V]=EB#!U6<ME3YY)-[P>CNH3K91#R)1=54R"E&B[2''U3
M4$=_VNFB$QXM(&E*6$_>\4&9S5RUA:@4I)ZUG4R-G%LB8^,-MJ4R=1:3F&%6
M[[GYUUHVK S%<(&\.6V79YFN%Y!9>HBMQR$LU76;"/,P;A AT1>&U/!'XPML
M7;\>IHO"VP@.5,?O*4&7G!:PG>9YW2'=EY"TT1M^&>^3ZJT?NFR"_;!^N.M%
M3,Y-0 H&< G0K_!VD!&U<Y(I4-F*:3ITW]75AKK48V.3N=&*CE?OR:KJ#=(E
M49;L,U,.%YE">5]!-QK1LD.NN:'X&*'#@W0?GNE \?AI31# 2,7MJF#C8E06
M/$.G,[U$!U>/WR*@KR+V00M19>G4"%JT!.VHPK[(_%)T,0DW%9L:UY  LC18
M(6H82!&@+IM<^*5G))K.O":16HZ^SWK>F1..8]@""UBAF=(N*#%"3;8?XD@G
M&CI"SX*#VIL8S>>(T>SOW5*09G]O$Z791&FN$J51*Z(T1Q:F3%*[#LGFL)^Z
M\LQHVD$# M,S @_PFEA=P\GHS_;OP<)C!,6VVFBD8371;U9@"]U?TT_DP6M)
M,1V50CD>1<Y/B<4>3!H]SA'0?EV_RSI%6^W3N'L"^TZS]V@9>SM-:#2\BH7N
M_=8)?=7&KLN:_-@":Z2Q[X]BH?)NHG)U(;IDX+""_6P\<WX3U(55)KNV?M :
M A376>VT/?.-:S")L>(OPWX<S!)-=*O0FV:K&9VR0.T69M<M20^/!+Z0"!N$
MH%KIC1M'@Q);O%'S2-U" Y^!5H/&<S2^(SO4AH<_O;M[BY X1%>=903@&D=L
MH#,S0(W3><R5DZMK$@!:<IC),P<KC0R*QJ#QCG>E)R,"7,=XU$,PQG3 O$3?
M$ <^T%-J$ZESCN.7*L&^E8XKJG.\(W^\>%Y/BA*6B,]G*E\2"XU"6-:WN\2)
MH)O$EZ8.D-T) ^SS-6 W4E$ZL<[E!=M.#6"I_RZEO&O[A;2O1??_19P9X]EI
MVA$8;6Y7Y);VLWA)I]6+IO/Q4HI=%-D<[BLE-&S_!+ZHX ]^3I;"!!(3K[I,
M63&9&]#P>#2*TS(T.,.T:IM1W>9(UIFT&AC*R$1?5$J;,B!PK65FDI089Z9\
M2AN( /7.%D=J27>JQ@B[U(RY8<=,A<\\V$,E$]@3;D\0W\'SO#CEE9(FC$YO
MOTR9#5R1S]Q)DQKV&M%><T-2W55Y23$AHZYZ)86.-\FKMNY[6[GO;*I^"X<3
M;Z#"YXQ&_G<[XI(,Z?7V%>7ET,/YJ6Y&\)*I5ZOFWIYWC;R^:".HSOYN5"4X
M*54ZE: O64ZF^9/)=#"^;_(QSQBGDR815+)CMA8VX[$AL@8)T]I_"GJVKDK2
MUF*$]OR@MMAK6_@JJ':6G1C$[J^-D(];8/Z<+K&F/:R#&R<'%T.IX0U4'6%S
MQ4T_JIJ+$IR$]'BD[T%?:YHXD0I;GB*>KP"EVFQAV\"-IT/N.7F'?C2:E_5$
M VWGA=GLC0;'4LV1$OJ<01]#>:LH>JP#AC,2:J7*#,BB>.0^ MU5 $IM511#
MQ[;FAR.)9?)FA33"FQ:C!+U'#EJ6)((%5R$R).Q(./<)EG]'\&#==^4@AO:
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MXDI-+05O$#+\!W\5""<Y^]/$OP%02P,$%     @ +4-T6&"7&MAG P  ;@T
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MQ;-D'C'IO57KRL-OQA9WL)%5CMFK]#^5S-5&089EGD,!VO< 1V(O[1;\[[(
M5\H4WC'8%K0J2JQ\I@=II\JY/@7W)I4^G,*3%)KQEL=IB2=3/DLF:#H29_LP
M%];D(#1LZ0B/\R.WML<B+^;D1?+S2"].G:@AZ^XD/HPXC2X)?O"DG7+@/6:8
MNW.B?W5R1U9 2Z"D7UV2[D,+&)7M%DZ#<W+]1B<99?>8TDXNMG]H3N,JK('3
MX/*8^RUN7-#'G&YVL0M';7.4^0X?1GVSC6&IM?%!1^N*+$NE-X:F=-<MV@OO
M"VQ8N%,7TJ;4+MZ^>45I30G6*W#'=V90L+.P64;4<7G;;;_E<CW!NZ"%O#+0
M[YJA72$%\ON#>RV7SNXR<IC3'.H4_Y>!9+ Y-Q"D**UH$_YWT906SHT&*0XO
M87E>/$1]1!%3^ +$V]"'FYQG)JW" -^J'/^5?^94GK8(^B-&O*]?5F_?Y;5C
MX[5V7AUVIGZHC'D8WL1QC*_DN\;&\?!69^S78(ZM#N:NQ0M;G?G*0?:'O@GC
M5.9IE7=9;4@-8HC0KZKW\2_W[15#]#8JK+QH&&*XI33/,B;7SEN9XJ/,VPK+
MCK::]NI;FR#,3YV>U?$64U=<1N]@5([M@(JS5NTJM*5\1=)/UE3E,@K?(@N%
M)8 OP5"$]0KZA%]&*URGL+!,PRH>$F6RQX#+*EN;$5V0=?_%Z;]02P,$%
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M!>RJH-=C*.<BC.342LQ8'L$M,7V ")'-& XR7$1.@["<N:D,7Y*IPV;+3,;
M,0OO:7@G=X822H4XJVOR&2*<"(ZH^(KB(FIE,*O,1K)HYDO&\ZD\45OJD*54
M\/60A7JB1G=9Y?T9$_B:'I9-1R2/(58935$V"M739XXWU70%O0J\5:Z#,.20
M)-LOM8.UM#Q+L%?FV#Z!8_N:'(?R\(E/V4K_V-4BK\$O7Z%/?,S9"]Z\^I62
MU,"OP73,9%E'_L'+TNVG#&R)I1JX 0>DX574;*L.D ')>,&H?O_302PQ^HMC
M(8OJ(8OCE&XWLZ+ZI!1GB=N$$1S(5PP:/<I)S3$B!<3T($NLQAQ4%D"NKKQ&
M4F\D_&D^+QS-:O!U6(Z2) 5^$E?M+;9&&X)43K)UJSV;8E'XGJ&#6&(TY4AY
MDI-U/&-%4Z^PW7)V[K-@@6@$FEJT#&;U&7 ? X]D,KYPMA(+.8^6B*ZU#X%2
MM"6> SFI0S6Q/Q,4%3 K;+>:LZ'LC",RDBLL^Q/TV=+@=-Q>G9D!#QS&Y?KM
MNTUY5^Y:]0+"$@C[KN#I?FIL#;'S'<DY9W'YBRRKLE1D%U4B6A<7\=9).4M%
ML1VS4W.-02GQ2U\557HTS,"(>%5UGJ[M148%9.*>Y,^9OIM I Y.UGWP\T"I
MSF.7AYWB6UUQ8A;]I/ ^:<<6CH&<=FWEE-@_!KHZM=-5[1T9R+JIJ:P3G"8#
ME;<U5:FSJ@PD_59324;VEH&^WVNJK](6,]#VQ_]&6_MD;=UZ:],9<28/ZDO5
MP9:DE=IW)OKJ5XF8VGXFZNI7F.C-0Q,]]2M(RNU'$TWUJT8,O$L38?4K0*J\
M3Q-5]:M!3#U3$W7UJT!.<UE---:O$BGW:4TTU:\"*3%[3=ZHZU=W5%O%)KKJ
M6F\8.,PF\NI7<)38U":"ZE=Q&'C<!V:J_X,V&?;[Q_UU]:'^A5E>^0]02P,$
M%     @ +4-T6$#B05<0!@  :SX  !4   !G;G!X+3(P,C0P,S$Y7VQA8BYX
M;6S-FVMOXC@4AK^OM/_!RW[9E9JFP,Q*K=J.4*<S0M.;"M6N=K1:A<2 M8D/
M<DR!?[^V Y2 '1**G9&J-I"3\YZ\YTGL7'KY:9[$Z!6SE "]:C1/SQH(TQ B
M0D=7C9>>U^G==+L-E/* 1D$,%%\U*#0^7?_\T^4OGO<54\P"CB,T6*#^>$HC
MS#Y#@M$3,![$R$-MOW4F?EH?4/NBW;KX\!%U[CU/;AX3^M^%_#4(4HQ$&315
M'Z\:8\XG%[X_F\U.YP,6GP(;B11G;7\5W5B&R[417V^P&?S1SU:N0W=2S]HJ
MMGE^?NZKM>O0E.@"1=*F_]?]72\<XR3P")6>A+*6E%RDZLL[" .NC-R["\@8
M(3]YJS!/?N4U6UZ[>3I/H\;:. 8Q?L9#)/^^/'>-BN>^C/ I'LDVW04#'(N*
M58HQPT/]=C%CN<UD%>>RBN8?LHI?==GX8B+82$DRB7'#?V>=3Y@1B&[ID0O6
MI[50>8\'C-NH?3?Q4:OO@SAJCUOW;LKC5BQ.7?C(%>^D/&K%#_C(9&PG/%:U
M!Y3)=TLL55LL8^[$TC),IBLXB2JUY2E[(RV><RQ&H(VS9 SA3OGI:J1(<7@Z
M@E<_PD2.4&VYX,D%5;GX\.\MY80OQ( 6$+J24J5>-4RKLTIB.1  V][#XA1>
MO.E4*0MVK64XA2D+LR%2*,EA'%/OI=>XSK30]TSMGTO_K9A\F1VV<BU@X9XZ
MEA%^"&(LG/#\/@P9) 56P3X/LET2$LK((S7U3APU<:;9F9-4TU=#1,76;F6Q
MW5TEAU8]EHIN.VPR#4JX8:7/GR&<)ICR+AT"2]2\3)QA<)?C1-?T,N$5"2A*
M:1N'E3;:$$??I3Q2^F[A*&4N5'7-%3;]8!#C<LCD0M^/BTI7#RI*NG9*\GZ:
M"=$8996.ODA>0,3FZ@,ID"E<=?X$2;5:>IUS"O998+6GZZO#SV)67=!<;=R!
M7<[E<M?N3%;,%B(DA6OIO-Y&*.V/%1:R&<HS'I&4LX#RAR#1H5 4=M 50#Z5
MFRN!$_2FBJ1L#5<$!@NAK#<6(>C2$-@$F!I?>ESP=P-3RMGB!B(S$Z6V.@B1
MPLRNB,D5<8)4&0@86I:"9"TU8%3.=3C03HN0?2$Q?I@F \R,1.V&'(3/6QI7
MK$A%E$G6@(3&-BCCA\5F]X-Y-Q*#&AF2[#G!GL[OB3\( T-.5TP(>937KX^0
M??9"9=\LLM.)(F%ONOPC+XB;1FX*8@]B1I//%2]+S?4"4G<P'FD=@TR1K5#)
M+Z><M"IPTCHR)ZUZ.>G/X(?@I%66DY9K3F[$XB/KP\S\?,,8^1Y&WK(Y)T1*
MRRFK%*^/#HV=.C9,/MDG0TV)']D3@U>2O>90V%!#^'L8V4KI')3UQ<VJ@OIH
M,;FK0Z;0-OO</$'*@_AO,BF\3"X*?@\SN83.B<G4D9"OZT*XT%<=+06&66%%
MGM Z# <&.G2K*_*PF<(V 6HLD6+N^ZUU"O998.>)NFA-_#0&:KZ580JI^DQ]
M*XWUA^I2#RG!.JY3C:Y!&3NL]/I/1CC'] :29$J7E\*ZQ^F%<16[KLUEN_5+
M4917==K^8@^AM#E60.A!3$+""1W=B_D&(T&LH< <5!&!W42V^_^FB%:23IM?
M8!V4\\1*VY\8EJAA4;MZ1"M?N&./PZ'VK+\_N"(&YH2V<1#*7K@AC3)MI,2=
M@E'"5*CFE@M0NFDZQ:P2+L9-W@?-3EKGZ&05_# $F7W6<[3'0#NC#0ZG8J!;
M-%N#/N':M[%,(55'FJTTMNE0(@B&J-GZ;? [6LF['6M,UD$93ZPTO,\"^3](
MO44R -W,0KN^8JMS.:SW.1-#F9K3]NJ]@KTF6#V2;^?A6/B##6_8%(4=>$1O
MIK(^>UQJHI6H^Q=L"AV$LM98O&%XFV V$NA]93#C8S'"3 *Z,-XQ+(P^Z):A
M-J.K>X8K<92IHZ5\#;<,BXV%BHY9X:4CIAV1G'I\B8.1AA#M^HI,Y'+8IF M
MAJ2:TZ;KO8*])E@\$=P(01;$73&AG'_#YE. (>Z@@W\KEZO#?BF+E"X2PC4<
M\"8;H;0_.RQL[,2=6+I^^XID_\<LOOD?4$L#!!0    ( "U#=%A[DUL?@@0
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MMD0T#^A,6U_=E/("9[U0BO4IHI!(+_R5MPT=$/$*"66II$M"LV/MN>!YM9'
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M>N^:NPDM7Y&/63;C,8LGPD4_QV,R8#*)F3L"7T5$CRD^#1E9 "2\[PO6#R-
M_-NU^AISA>]/N$<1:_,;D.Z:WQK:*^DE(YB]_G<UF0S0L=NYD[$ 'N<OO_[R
MRUZ",8K]O01<K5_PIV<FO111(EWNZZ6-P7'VQ:X"I=G^.PT '>X;J?<A=#'
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M[P:A#[-C1XS+2HPIQ#N/GN#YD:/RN;)LU[8>1-_]!XWXP?0;@_+],/3['*@
M%GAMRZ$_(YD Y6&P*0UTI"2V@O#M)NY;9ZO5VKVG8'JG56L^,,;T(@%5]BK9
M)(WB%!D&>.XL!5IL-=J:>9!KSL&<@HX2 #EP$[;N;+'NAS/6:-9KT/#'L#9>
M>.P)\-AYZ$L7""D8?@9U #K!MQFL]1,P6+Y"-M9+G.<NI\7!S+,8K'?MCG@P
M%$7V:M5KJN4+A[UPV)(<=AH)U&!8_4WUBFA*12>#@6U7M]KMGX#38*55UUKJ
MK3K-:7G5QGK_S7)\I]J^<-X+YWT;YQW&<2JB!?RW^2SYKRFJK75W.?[3;7\,
M_GNP>2U#7'FY(@)'V<8TM$#T*P =$G?:]044[_P4$J,?)DDXWE7 5]6OG1CL
M+H\YDVMFRMA-$':KMOW  ?_^_@4>[5,UI>Z(N3Z/8ZL,;SGF+EUFV0H=Q?I+
MQZA7PY_ST.D2P%[$D0[MPL6'G/Y\.NZ'_GK\YD?=LE;K@32IC;5C719+%"^,
M7 \#=C62\"075^5873[?A$KOZ?+^2J%O+<ZG3J-/$L,V$;;6]M&<  2>)Z'[
M=3XE/>$1N^1^*MBK>JU>=]@$3VB.J.SSKC2[6!K\7+)FI=W28DF)!WNKMM?V
M/QZ??KF3*?>4MN'AY<<%V"??8HRCG)DOKC9L9:S+XK&$%E:M'O/8XW_-[ACK
M\HG$<_>?>?15)"^VISWO8>"A;2_PB@*7LCO0Z2N(=T'%KC.9%QDS'C!P#'#<
M(1M&X54R0A=A@MD8'C-/#&2@CDNHB'.];2S5F7 S/'4ZS29;QY5O[:JPLVDM
MZ:3%!$]:8(6K<C0:?4KS.KN-DB$+/H<:NY6/C;[';'=KCMIM>+^'>Q5V6+X-
MS-H'EOM>O7*\:M*X3Z]6U:.8^3[2=%TUF\52F_7;'-I'1MAR3/,PL!P.;F -
M+$,HY3,YE]P< 1<)'_P]X*(@).\OC06U@GEU#A4O-9)4]*ON/\"=I[G\*4Y^
M)6%JY,@ 5@MO(G$I8^@'O,D#%X/7W*7+7; Q7C/C\<B+5?+4*W<]P<]?YYG7
M:7-;S1Q)UH3R!([5D6OV=NWTX[M/,SXN(R>W>*U)R>4G\ AOSBB,=?S'YVPP
MFP2TNF/6!'- C2+3\_3@8Z_Z[JQW\*EZ\.&B=[;#N'_%I_&N=MO5W2F%T7:9
M/GO-&G3_"AWKSK0[FSOQ;5[1S2&%)?S^_JQT"83)&Q9P*X?=MJLW\E61HQ"6
MI3G[WN<%E^<P$6/FU.I.C?7PU!:6+H2,,Y/;8N]1QTDJ1#L81H+"9+5E#@3^
M1&B29-Q1!)1\>OET%W]/TG^1W#\)6'8XFJ$BKK"/(IA$XKK"#@.WQM918*+I
MT:CO=HU&AU_.[AM&HH/,)2*Q.+=G0 2#B 7!SPV)%08Z-:\S"LS&U,*?X05B
M,DE1> /1RN!2Q GH ENV*R<>A^T:$PZ'4T4ZPO=1;0%85E#2DY$@ TMM? $F
M0PT9)!.P%* /3VB*,5G?.DRL+'46@6$'Z =H^1!F'NHSV^OR#7,VVQ408LKW
MC0L3G=.C;!KH0$=SE5\=HU]]DQ\]NR&9,VX&K,#\\HVB+MC'Z@!!]M3O*QZA
MEE;P&,6G=@1:?K!:_JE;YGM]+2)7QA2B176=3A#-LTMW*LVMK8KC-,S"X9D-
M) $'Z"D 8E;SS7.V6XT;YJPQ9/9LSVE;:3B*"BFDSG2!.3PR,HBLL)>&#5V(
M5ZU:PVE3DV3QP J-"]!Z^_BMSH-9]4_#/%T$A2VH$3OB>J*L2Z $UP]C"N<!
MSGD_3!,MRQJ.D65QVO\/<CPTQKU2M7K<''YD+DP#X(*6Q*%P!G!,/#)-XSOA
MOV2M]."2@PX.$C23P-?Q'V@?[A,:W(\ !"%8VR[(VJS T>P1B,,!"%MPI;W4
M)0L=WTY\KA-R?"BL@N>!$#$Q VYK$.L?ZJ0J"'PYIOL'L_W/6DWX5"6+ID7Y
M3R.9BNED!M0*^BODS@RB<*Q]$I(PPJS"B* *EEL7:*VOBT:O"29_REZU:]MJ
M:P#_/E",DC,&%%4Q&ML.4 %M&0C9XE!R7(715R)#'?/!!0'"1 1_FW.S I7@
M!"C_A407^+(!(7;>R*@4B 5=56TP:$]58GJ\HLP:;=08HX)HUS0A>1,$X+2X
M:F?Q*=YVBB^PL#A$=S5_.*C00.7J20TVM:TG$$(4*T4*)S!0IUBZD'XJ%S;3
MC8L''^#Q9)S!N.DD_>@>"%J5@AGO"DE2('P-#C?75N*#.)U,?(T#8$T!(.&<
MFW7F@?.G.1X18<2HIW5S43)8TMB%]7$PSV =8D+RMG#6P7I!,RGA3>NP\6I6
MC79>8,P(GE2A>549;-J68.L'%Y_?Y+J:K,P2P:27@@A(5&0=5YAGC.PU*GT/
M0(1I5##?"';D\5?;8+OEIELE#U$D(YZH74_1!H&5Q21AX&'67D_ $ZW>P&&C
M 6M@F#/,BB-V;B-I 2MV:80"51>)6C<BL64A]^&H%,S[T+^DG6?$\=B>1!W%
MBK3"7B]&:,MY'"LY$NFSS, - U'%&Z;4+V!;B7>CH\[7]'E/-*O4B4VTICV0
M7D9Y,8:9*?HY!M+3E^N2"!F/A2>5:@&S'3P/BF[AKL%VE$KZ,NFW0(Q^@[%F
M"]JG9 S.;SGA$Q =6_9<) ")B#VN-TI['%*;&!G]QS,V1,4V"C-CT%B;1!)8
M7S(.\IL+2HY[V 8)B1D-=.%$%]*(#[0N?<500/A$B(MKW"T&H!,KX.PI6ZD$
M!' AL]4"YX]EH*#-SY@H@^4V3+D@> +RU32:;^(^=@7: 7;20[,<*-G(;F.Q
MD,Q&D9?+']H-]4)=5^42)R(@.%8<^L(:J _&T$ FLXM$C[\P;(7&'8/L!K%J
M\; OQU*OU$C*= )8T42 2XRXLEOUV"]&UD)6Q(0-[D0)'8"GAG8';6WO>B3[
ML&=.O>8H3PS>=NE6](2=J0OO\!H5&$VM<;OZ28?E]2QB&)(T3,=C2W C56?D
M7@Y#OO.*(/Y*82'VC6AX!0G8,U-# &9)1$V>OH:PHK4_'03+S'"/H2DDB7:R
MVZU?J*44&HRX6KN%$5>3%]S/8R2%Q\856R8Z.Q><G4W$% #7<%OI_Z>&KMZM
M 22*A!2C8WAL>$$T*U$6M?9U,\.58HN%X"+RR!6XL^CZ E]@(CWO2$PS2'U_
MQM.EU!NQ.";IT*]5!F5FR><^=I8/7A1O-)$:2A8FRDXF7LQ&N0I3WP.&BU,_
M,8I(G9:V'()9#"BU@;E#T"7A5:#L+AIX%/KJ/*9' H$/\! G*B!MQN,J.K5.
MY^^9V G1,[]URC!-*#=)<2O+N%,>QE"2N:LM[VS1:HU&WL"^8'H./!.CR4#\
M1(+C5H088C$_=(Q:+24+KE >%E6^\05H/6HQ+W+J-JUV*__-Z;?6]U-OMS#-
MBIJN\C"J[F>3RC-*C#UW#<7N5QFU:O5.KHJ4CLDHW%9* \Q=HTMO15&-\V[B
M%S/=QQ3$\4F&YNHLQ/2@R^.1C[>U]'F,5#]0(2Y<5! NBIF9G"+Y@\;'R8)H
MEJ>4:,:12@KS2RY]@Z3*7.P0] CWQ0U*15T ,37Q!EMK0G=MPRHU<"<ES9ZV
M/F[]?/J8Z:BUNN<;<U,Z>H3Y6PS&XB*M:%A<L::8E4B*749X+Q[59V']#<Z(
M<26I'[[S.6#EW!WA-];8_U"R6>>BLV%<[KNI"E/9B7=.N@->L%@D^'<R,CN?
M)U!,BD:_,-H&6".6 ++B* IHQ&XD^WE4P0SQ8J+<ZGC?;(TTOINS_<0-C^>1
M&4?7.<M>'%#V J6]"&+BK:6JFIX%HDYMT16P7C $"4Y8.Q()"G^["&7N;;$R
MZ7?\GM.?()>O2*CJ&AH^GNP"\FL5=G34+58Z%7<H+](I+UL"H:FB63,;J\P4
M3)<S@0R&;;=J]4P'#L'VB//DLI;SF4C-<LP4; 6<!6:-A1&=U4<L6AG<CT-K
M-<"YXSX@7UBI$YW -U&[XCKMZ+@J%%(E/Z_:=:JF0LMROF2@?*Q,[6*I<"Q\
MJ[( 3(%J.*A.P"P _67&P=JD2UTXQ=4_^.%476N,NDP]U.T95J9?F5S9JX:J
M]\))ULTHKYQVI=.N9\%KUP>CU:YC*&*/LG=%#"Z@AUO34IS!([^XNP0!4A$%
M>;3F<"V),;NWIEXBJ[Y#&1U"5VW@4FE$2#G%*/125X%L$W:_G)J]-#(6+*H5
M8W:(G/6^RZA9_C4N#$=\;0HN*),\!6NG[TM7I<;EI?(M- ME-ZGK<G3UR/2/
MN,KAV'E+!9@BB<R7=QI5^OZ-+M2C.GCU=WX=F%F*2=U01A5<(&[JE[#!G,"Z
M)3\\Q'U'4T&;A3#,0$8Q^C2#-,Y)9562FZ_,E.HX0,$"Q8^5Z&>8V6'],/Q:
MC=(@4)?3H%P",J-7Y.N F$4)C:EC?#:3KJ_@6'PR@;U"_JR8 PEFO4A&"9DH
M8'-*X#T\H\[1:S'[E8RB,!V.LA4MWGB2,_BQTV2JC/U^8F?#=3X_ 6TUFX'N
MV#MM):!U?GI@,D]D<2F**4E%/[MPRP&*0INJ2JF]0.!4\0N8#+2CE95Y6-5I
MF6Q5I3QEDD23#0@*  G536FYZFRON?+5),SKH,M+5SN-2KNQM<AC73>GE'6"
M-F:;EH)69<0HS&\)#@+CS*GM-TKS+%J"Y3\B[R28#B977=7AC(T[H#DYZY;[
M<E2O4M$"0H4-RC!=,F%Y<*A=:VQN;]^0J0AG"MEOKY_]V?BED)$MQ_,"1['Y
M_;*RB_;[:3J./R-)9+:_WA)+9\VP*UEV5+LQ*W6M@Q\JDJ5"A_C9!3L^>I[7
M%-J$<UYMJC_6[=;JT7&H::K9;%8;6TYS>_.-_DJ?50YX<VS5H_W^5QH(IGB_
M279!7K2HHHN%4?*7%=U?U:#,'H:)A,]5%7/XO+4QDE(XD8&V/(_"*W ;$D3_
M.3"O#W+YZ.@4X^(\RLKA+F$4C^RE.=(CY3OOG^()[00\BU%11+5K#E-UIR]!
MP46Q("/BL^_-/\>TU.%MYM^LF= J.D@S)]J,EYP70Y>?9YO#_:*#;85:0*HP
MFV;^UGP!T[*'W0B\XMBYJ+Z6,0FP*RNC,V.6=MJ51G-[D1FZ.&'7*I0W6SRM
MC^& )+:##:53=RIUISX_=7SSU,UVK54^];]2,%-IYD)4SV!AUD@W'H.5DZ Z
M9;0P3-@CPR55!.+7'%3N(O#RU2!0F[5VX4 (F2J6R)N1=:4'(NFS8DF!<+(:
M4CX=Z]S0*Z#;QK93/ N(H9VNO1+;$5DW1P)]$-Q1(;N5HY4<K%E,4?RMF)M5
M4:[LE&%.?E9TPG9A2\>TL[B%B(>IQYXKQ<ZM#BK9O*'ML]3.LTFA$F&TP/YO
M?>]$T2)8GJ +\#Q2(A>+-YN^?."%(J8T-8I&.H=-CCG%PO+CU>9@CKI>.HM*
MV@W[*6Q<H$Y^^+XNK>BK\TBFU@$>QF)&4M)[\^7*PC<KI3F+0R1 $U5F0(C4
MT*HRH8_Q.)]?#5(?)5T8&85;*.V QYKX=%%_7H1O 0;#Q*9"0IW<*0/Q*=+8
M=[E3Y,-%^84<I7>*%/J.!M4HO)I_B#=\,G592>D='C_PE23+K__BI'LD@Z\W
M8N"YWE<!C@X(*3 HO>I1&-)9V2SJL%0AWHM\1_F>G9@::&3Z&IE9B5NL@K;J
M9!XF<.*O*NV*AUXI5X(2L:*/W<1V1XJ9Y&D[/L;\J?H8FLXF9P>KYTY!ZS-)
MY;,9:#R=)A:V/_0ZMBZ(FH2Q3G_I>SNLHUQY'EA-XPG,E6; 8 ('(<=_M<F>
MSZ#R=-+%H#S@U!Y,??LGSOV\_ O!-?:_84HGREU.-YKDYS,IH87*)D6%Y$N5
M3PYNV!=C[.!P?:[+&(M0NGKC%9IYOFP0,^EXDO^.)X)_5861/+/9<LO]1AHJ
MYJXS@T&=>U?9_TLJ*,1[.VA,;+=P70K7-U,M)OM,I2$ B->#R4#=&D=[/4B3
M--(E='&6J+VB"CZ=B>!(GG^E,E(Q05#H+Q&E<D&KKY+:IJND3HC$>X38Y2Z+
M>I9(*[E-R8[8Z"@%!J*QX!CX7= =2>HJ >/_YJ+P ,369)KQ8K'7@E!II_,2
M*UV.LCM(V0JT#YGBR(T)$I :JR\TOQB:=0\_KKAO,(4VV%,[K?Y\/BRPK3X-
M^Z"7K.N=?ZR;\=4'.K_U6GQ]N?0#7<FN[_P$J V%WL=E_HNI8;/6>)1UO:?$
M\D25(=_M9OW"QXNW[_+E8[W)W];9H++8>_EE,#V:B0G02EA)T&1MOU5S'F5I
M>YR-(KR065S_>[/E;'6V:J-DG E#O)*Y"O#B]0@[0O$\]/I@*DZR\B,3]-W;
MX/O?%5$_.QDT'I\,FNWF=F<5,GC9^_O9^^:3V/M.?2414%[L]4(+=Z2%UN/3
M JJ#[6^0 V6)OQ=ZN-/JVD_!/$#9X"Q##R>WE8R]4,.=5H=W*CT-<FBLI"KF
MBIU>Z.!.JVLTGPH=+"46L$Y)US(MJ"1=+]PV9Q6"OGFAE#NM#@/$3X-2FLM0
MRBD%O<]TT%N5:A=C["_T<$<-\CCV93>$5NP4+],X1%"X*NU[SQ/./N"5Q>MB
MW!<>!A0PI:I3L8>!#S*!?7EW=I25?^$'L![\4V@OG_)Y^93/]Z[G*'P ]O#C
M\<'%'V>]\^?UK9[3F:-(.GNO4G1+?DC/KO;3WRCSL$S<Y6E,YXADK LZ]$W_
M=.Z3"BNP"+4O1MP?F&/G5!BH&V">-<6C C0<3Y-1&,'2O-7KC^_[.V(_<LIK
M_F.Z9<F--MB""[002!]86O!VK;%VIRF:337% ^9//O:.3\]Z7RKL\+A;6SD]
MM-RR'*=,?]_E8\<K[L_B837>:^UO[-GHU#:_L>O#8N6A2 K,*9"TYCR.,9A7
M)*G"KCP4Y.^F.W>D_85Y44,E#\;7<G\CWF!G4Q[@"9T!IJOEZIS]DW)O(1/_
MT%M3V)-'V0^&0QF3=V6T%WJOBOE"YX?&?'<DQ8#EE5<G@X%TLUUX*"C63R,9
MX)$^?QZ4-RM11 &9-Q+%4_M2M_;*C@[.+ZJY5UAZVN->3W$8(. /C8Y1,O;W
M_Q]02P$"% ,4    "  M0W188\62D'5"   &FP$ #0              @ $
M    97A?-C,U,S@Y+FAT;5!+ 0(4 Q0    ( "U#=%AYA:0ZUD(  *&; 0 -
M              "  :!"  !E>%\V,S4S.3 N:'1M4$L! A0#%     @ +4-T
M6 %E%O)A"@  VRL   T              ( !H84  &5X7S8S-3,Y,2YH=&U0
M2P$"% ,4    "  M0W18;'F2]2Z>  !TBP, #0              @ $MD
M97A?-C,U,SDR+FAT;5!+ 0(4 Q0    ( "U#=%C<_8I>N@T  (4P   -
M          "  88N 0!E>%\V,S4S.3,N:'1M4$L! A0#%     @ +4-T6,#U
M7-L[/P  TI$!  T              ( !:SP! &5X7S8T,3<Y-RYH=&U02P$"
M% ,4    "  M0W18+QQWEK$'  "A*   #0              @ '1>P$ 97A?
M-C0Q-SDX+FAT;5!+ 0(4 Q0    ( "U#=%A@EQK89P,  &X-   1
M      "  :V# 0!G;G!X+3(P,C0P,S$Y+GAS9%!+ 0(4 Q0    ( "U#=%BC
M?#GGZ00  &8N   5              "  4.' 0!G;G!X+3(P,C0P,S$Y7V1E
M9BYX;6Q02P$"% ,4    "  M0W180.)!5Q &  !K/@  %0
M@ %?C $ 9VYP>"TR,#(T,#,Q.5]L86(N>&UL4$L! A0#%     @ +4-T6'N3
M6Q^"!   -2\  !4              ( !HI(! &=N<'@M,C R-# S,3E?<')E
M+GAM;%!+ 0(4 Q0    ( "U#=%C+5BTU'AT  ,'"   3              "
M 5>7 0!G;G!X,C R-# S,#5?.&LN:'1M4$L%!@     ,  P Y@(  *:T 0
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>gnpx20240305_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="gnpx-20240319.xsd" xlink:type="simple"/>
    <context id="d20248K">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
        </entity>
        <period>
            <startDate>2024-03-19</startDate>
            <endDate>2024-03-19</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="d20248K" id="ixv-442">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="d20248K" id="ixv-443">0001595248</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="d20248K" id="ixv-18">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="d20248K" id="ixv-31">2024-03-19</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="d20248K" id="ixv-37">GENPREX, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="d20248K" id="ixv-49">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="d20248K" id="ixv-54">001-38244</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="d20248K" id="ixv-59">90-0772347</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="d20248K" id="ixv-78">3300 Bee Cave Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="d20248K" id="ixv-87">#650-227</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="d20248K" id="ixv-96">Austin</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="d20248K" id="ixv-103">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="d20248K" id="ixv-115">78746</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="d20248K" id="ixv-128">512</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="d20248K" id="ixv-135">537-7997</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="d20248K" id="ixv-453">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="d20248K" id="ixv-454">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="d20248K" id="ixv-455">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="d20248K" id="ixv-456">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="d20248K" id="ixv-457">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="d20248K" id="ixv-458">GNPX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="d20248K" id="ixv-459">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="d20248K" id="ixv-460">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
